COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF CANNABINOIDS

Description

BACKGROUND

The inhalation of cannabis smoke and vapor is challenging to titrate, which often results in over-consumption and a corresponding undesirable level of intoxication. The oral consumption of cannabis generally displays delayed and variable pharmacokinetics, which results in an unpredictable level of intoxication that also often results in over-consumption. Cannabis formulations that allow users to titrate their dose with predictable pharmacokinetics and predictable levels of intoxication are desirable.

BRIEF DESCRIPTION

Cannabinoids are generally insoluble in glycerol. Various aspects of this disclosure relate to the discovery that cannabinoids will nevertheless dissolve in glycerol in the presence of one or both of ethanol and propylene glycol. Various aspects of this disclosure relate to the discovery that the pharmacokinetics of an orally-administered cannabinoid improve when the cannabinoid is dissolved in glycerol. Without limiting any aspect of this disclosure, an orally-administered cannabinoid dissolved in glycerol rapidly loses solubility as water from the mouth and gastrointestinal tract enter the glycerol, which results in the rapid phase separation of the cannabinoid from the glycerol. This rapid phase separation results in the cannabinoid adhering to the epithelium of the gastrointestinal tract, which improves the pharmacokinetics of the cannabinoid as it enters the blood from the epithelium. This absorption mechanism notably also bypasses liver metabolism.

The oral administration of cannabinoids in glycerol also improves the caloric profile of a cannabinoid formulation. The triglyceride-based cannabinoid formulation EPIDIOLEX® has a high caloric profile. In preferred embodiments, the compositions of this disclosure lack triglycerides and other lipids at high concentrations such as greater than 20 percent because triglycerides interfere with the pharmacokinetic improvement described in the preceding paragraph and because triglycerides are calorie dense. In some embodiments, the compositions of this disclosure lack triglycerides and other lipids at a concentration greater than 10 percent, 5 percent, 2 percent, or 1 percent. In some embodiments, the compositions of this disclosure are essentially free of triglycerides and other lipids except for trace triglycerides and other lipids that cannot be cost-effectively removed during commercial manufacturing and/or any triglycerides and other lipids that an infringer of patent claims that mature from this disclosure might incorporate into a formulation to avoid infringement of a resultant patent.

In commercial embodiments, a composition comprises at least 50 percent glycerol, no greater than 30 percent ethanol, no greater than 30 percent propylene glycol, and water. Such compositions can be delivered as an oral spray, which maximizes the surface area of the liquid to increase the rate at which a cannabinoid loses solubility in the glycerol and partitions out of the glycerol and into the epithelium. A THC spray can contain a volume of about 150 microliters (about 150 milligrams of liquid) that contains 1 milligram of THC, which allows for precise dosing. The rapid pharmacokinetics of the formulation allow consumers to precisely titrate their dose and achieve predictable, desirable levels of intoxication. While this paragraph describes a general formulation for a THC spray, the skilled person will be able to develop other formulations by varying the concentrations of ingredients as set forth in the detailed description that follows using no more than routine experimentation. The skilled person may desire to reduce or remove ethanol or propylene glycol from a formulation, for example, which requires routine experimentation to adjust other ingredients. The skilled person may similarly desire to change the volume of a spray such as within a range of 50 to 250 microliters and/or change the amount of the cannabinoid in the spray such as from 1 milligram to 0.5 milligrams, and the detailed description that follows captures workable ranges for such adjustments. Other cannabinoids are relevant to the formulations of this disclosure including pharmaceutically-relevant cannabinoids for use in treating health conditions.

A guiding principle of this disclosure is the development of formulations in which a cannabinoid is dissolved in a composition at a greater concentration than its solubility in glycerol, which allows for improved pharmacokinetics. An additional consideration is the development of formulations containing low calorie-to-gram ratios and low calorie-to-cannabinoid ratios, which improve consumer interest relative to higher-calorie cannabinoid products, and which was irrelevant during the development of inhaled products such as vape oil and unappreciated during the development of cannabinoid pharmaceuticals such as EPIDIOLEX®.

Various aspects of this disclosure relate to a composition, comprising a liquid phase that consists of chemical species that comprise a solvent and solutes, wherein: each solute of the solutes is dissolved in the solvent of the liquid phase; each chemical species of the liquid phase has a concentration by mass in the liquid phase; the concentration by mass of the solvent in the liquid phase is greater than the concentration by mass of each solute of the liquid phase; the solvent is glycerol; the solutes comprise a cannabinoid; the liquid phase has a pressure and temperature; the cannabinoid has a solubility in glycerol at the pressure and temperature; the concentration by mass of the cannabinoid in the liquid phase is greater than the solubility of the cannabinoid in glycerol at the pressure and temperature; the composition is formulated for oral consumption; and the composition comprises at least 0.1 and no greater than 6 food calories per gram of the composition.

In some embodiments, the concentration of the cannabinoid in the liquid phase is at least 0.1 percent and no greater than 4 percent by mass.

In some embodiments, the concentration of the glycerol in the liquid phase is at least 35 percent and no greater than greater 90 by mass.

In some embodiments, the concentration of the cannabinoid in the liquid phase is at least 100 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature.

In some embodiments, the liquid phase comprises propylene glycol at a concentration of at least 5 percent and no greater than 20 percent by mass; and the propylene glycol is a solute that is dissolved in the glycerol.

In some embodiments, the liquid phase lacks propylene glycol.

In some embodiments, the liquid phase comprises ethanol at a concentration of at least 5 percent and no greater than 35 percent by mass; and the ethanol is a solute that is dissolved in the glycerol.

In some embodiments, the liquid phase lacks ethanol.

In some embodiments, the liquid phase comprises water at a concentration of at least 5 parts per million and no greater than 15 percent by mass; and the water is a solute that is dissolved in the glycerol.

In some embodiments, the liquid phase lacks water.

In some embodiments, the cannabinoid is tetrahydrocannabinol.

In some embodiments, the liquid phase comprises the glycerol at a concentration of at least 45 percent and no greater than 65 percent by mass; the liquid phase comprises propylene glycol at a concentration of at least 5 percent and no greater than 20 percent by mass; the liquid phase comprises ethanol at a concentration of at least 5 percent and no greater than 35 percent by mass; the liquid phase comprises water at a concentration of at least of at least 5 parts per million and no greater than 15 percent by mass; and the liquid phase comprises the cannabinoid at a concentration of at least 0.2 percent and no greater than 2 percent by mass.

In some embodiments, the liquid phase is a dispersed phase; the gas phase is a dispersion medium; the liquid phase is suspended in the gas phase; the composition comprises at least 40 milligrams and no greater than 300 milligrams of the liquid phase; the composition comprises at least 0.16 and no greater than 1.8 food calories; and the composition is a spray.

In some embodiments, the composition comprises at least 0.48 and no greater than 2.1 milligrams of the cannabinoid.

In some embodiments, the composition is an aerosol.

Various aspects of this disclosure relate to a container, comprising a chamber that contains the composition as described anywhere in this disclosure, wherein: the liquid phase of the composition comprises at least 2 milligrams and no greater than 110 milligrams of the cannabinoid; the container is configured to dispense at least 3 and no greater than 110 metered portions of the liquid phase from the container; the metered portions have (a) an average mass of at least 40 milligrams and no greater than 300 milligrams of the liquid phase; (b) an average amount of food calories of at least 0.16 and no greater than 1.8 food calories; and (c) an average dose of the cannabinoid of at least 0.4 milligrams and no greater than 3 milligrams; and the metered portions have (a) a standard deviation of no greater than 20 percent of the average mass of the liquid phase; (b) a standard deviation of no greater than 20 percent of the average amount of food calories; and (c) a standard deviation of no greater than 20 percent of the average dose of the cannabinoid.

In some embodiments, the container is configured to dispense a spray of the liquid phase.

Various aspects of this disclosure relate to a method to administer a cannabinoid to a subject, comprising providing the composition as described anywhere in this disclosure; and spraying a portion of the composition into the mouth of the subject.

In some embodiments, the portion of the composition comprises an administered amount of the cannabinoid; the subject has blood; a bioavailable amount of the cannabinoid enters the blood of the subject following the administering; the composition has an oral bioavailability, which is equal to the bioavailable amount divided by the administered amount; and the oral bioavailability is at least 25 percent.

DETAILED DESCRIPTION

In some embodiments, the concentration by mass of the cannabinoid in the liquid phase is at least 2 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature. In some embodiments, the concentration by mass of the cannabinoid in the liquid phase is at least 4 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature. In some embodiments, the concentration by mass of the cannabinoid in the liquid phase is at least 8 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature. In some embodiments, the concentration by mass of the cannabinoid in the liquid phase is at least 16 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature. In some embodiments, the concentration by mass of the cannabinoid in the liquid phase is at least 32 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature. In some embodiments, the concentration by mass of the cannabinoid in the liquid phase is at least 64 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature. In some embodiments, the concentration by mass of the cannabinoid in the liquid phase is at least 128 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature. In some embodiments, the concentration by mass of the cannabinoid in the liquid phase is at least 256 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature. In some embodiments, the concentration by mass of the cannabinoid in the liquid phase is at least 512 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature. In some embodiments, the concentration by mass of the cannabinoid in the liquid phase is at least 1024 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature.

In some embodiments, the composition comprises at least 0.2 food calories per gram of the composition. In some embodiments, the composition comprises at least 0.4 food calories per gram of the composition. In some embodiments, the composition comprises at least 0.6 food calories per gram of the composition. In some embodiments, the composition comprises at least 0.8 food calories per gram of the composition. In some embodiments, the composition comprises at least 1.0 food calories per gram of the composition. In some embodiments, the composition comprises at least 1.2 food calories per gram of the composition. In some embodiments, the composition comprises at least 1.4 food calories per gram of the composition. In some embodiments, the composition comprises at least 1.6 food calories per gram of the composition. In some embodiments, the composition comprises at least 1.8 food calories per gram of the composition. In some embodiments, the composition comprises at least 2.0 food calories per gram of the composition. In some embodiments, the composition comprises at least 2.2 food calories per gram of the composition. In some embodiments, the composition comprises at least 2.4 food calories per gram of the composition. In some embodiments, the composition comprises at least 2.6 food calories per gram of the composition. In some embodiments, the composition comprises at least 2.8 food calories per gram of the composition. In some embodiments, the composition comprises at least 3.0 food calories per gram of the composition. In some embodiments, the composition comprises at least 3.2 food calories per gram of the composition. In some embodiments, the composition comprises at least 3.4 food calories per gram of the composition. In some embodiments, the composition comprises at least 3.6 food calories per gram of the composition. In some embodiments, the composition comprises at least 3.8 food calories per gram of the composition. In some embodiments, the composition comprises at least 4.0 food calories per gram of the composition. In some embodiments, the composition comprises at least 4.2 food calories per gram of the composition. In some embodiments, the composition comprises at least 4.4 food calories per gram of the composition. In some embodiments, the composition comprises at least 4.6 food calories per gram of the composition. In some embodiments, the composition comprises at least 4.8 food calories per gram of the composition. In some embodiments, the composition comprises at least 5.0 food calories per gram of the composition. In some embodiments, the composition comprises at least 5.2 food calories per gram of the composition. In some embodiments, the composition comprises at least 5.4 food calories per gram of the composition.

“Food calories” refer to calories as reported on a United States food nutrition label.

In some embodiments, the composition comprises no greater than 5.8 food calories per gram of the composition. In some embodiments, the composition comprises no greater than 5.6 food calories per gram of the composition. In some embodiments, the composition comprises no greater than 5.4 food calories per gram of the composition. In some embodiments, the composition comprises no greater than 5.2 food calories per gram of the composition. In some embodiments, the composition comprises no greater than 5.0 food calories per gram of the composition. In some embodiments, the composition comprises no greater than 4.8 food calories per gram of the composition. In some embodiments, the composition comprises no greater than 4.6 food calories per gram of the composition. In some embodiments, the composition comprises no greater than 4.4 food calories per gram of the composition. In some embodiments, the composition comprises no greater than 4.2 food calories per gram of the composition. In some embodiments, the composition comprises no greater than 4.0 food calories per gram of the composition. In some embodiments, the composition comprises no greater than 3.8 food calories per gram of the composition.

In some embodiments, at least 30 percent of the food calories of the composition are derived from the glycerol. In some embodiments, at least 35 percent of the food calories of the composition are derived from the glycerol. In some embodiments, at least 40 percent of the food calories of the composition are derived from the glycerol. In some embodiments, at least 45 percent of the food calories of the composition are derived from the glycerol. In some embodiments, at least 50 percent of the food calories of the composition are derived from the glycerol. In some embodiments, at least 55 percent of the food calories of the composition are derived from the glycerol. In some embodiments, at least 60 percent of the food calories of the composition are derived from the glycerol.

In some embodiments, no greater than 65 percent of the food calories of the composition are derived from the glycerol. In some embodiments, no greater than 60 percent of the food calories of the composition are derived from the glycerol. In some embodiments, no greater than 55 percent of the food calories of the composition are derived from the glycerol. In some embodiments, no greater than 50 percent of the food calories of the composition are derived from the glycerol. In some embodiments, no greater than 45 percent of the food calories of the composition are derived from the glycerol. In some embodiments, no greater than 40 percent of the food calories of the composition are derived from the glycerol. In some embodiments, no greater than 35 percent of the food calories of the composition are derived from the glycerol.

In some embodiments, the concentration of the cannabinoid in the liquid phase is at least 0.1 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is at least 0.2 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is at least 0.4 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is at least 0.6 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is at least 0.8 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is at least 1.0 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is at least 1.2 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is at least 1.4 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is at least 1.6 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is at least 1.8 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is at least 2.0 percent by mass.

In some embodiments, the concentration of the cannabinoid in the liquid phase is no greater than 4.0 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is no greater than 3.8 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is no greater than 3.6 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is no greater than 3.4 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is no greater than 3.2 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is no greater than 3.0 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is no greater than 2.8 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is no greater than 2.6 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is no greater than 2.4 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is no greater than 2.2 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is no greater than 2.0 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is no greater than 1.8 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is no greater than 1.6 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is no greater than 1.4 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is no greater than 1.2 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is no greater than 1.0 percent by mass. In some embodiments, the concentration of the cannabinoid in the liquid phase is no greater than 0.8 percent by mass.

In some embodiments, the concentration of the glycerol in the liquid phase is at least 35 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is at least 40 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is at least 45 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is at least 50 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is at least 55 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is at least 60 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is at least 65 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is at least 70 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is at least 75 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is at least 80 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is at least 85 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is at least 90 percent by mass.

In some embodiments, the concentration of the glycerol in the liquid phase is no greater than 95 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is no greater than 90 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is no greater than 85 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is no greater than 80 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is no greater than 75 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is no greater than 70 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is no greater than 65 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is no greater than 60 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is no greater than 55 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is no greater than 50 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is no greater than 45 percent by mass. In some embodiments, the concentration of the glycerol in the liquid phase is no greater than 40 percent by mass.

In some embodiments, the solutes of the liquid phase comprise one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide, which are dissolved in the glycerol of the liquid phase.

In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 1,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide). In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 5,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 10,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 50,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 100,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 500,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 1,000,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 5,000,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 10,000,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 50,000,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 100,000,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 500,000,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 1,000,000,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 5,000,000,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 10,000,000,000:1.

In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 1,000,000,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide). In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 500,000,000,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 100,000,000,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 50,000,000,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 10,000,000,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 5,000,000,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 1,000,000,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 500,000,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 100,000,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 50,000,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 10,000,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 5,000,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 1,000,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 500,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 100,000:1. In some embodiments, the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 50,000:1.

In some embodiments, the solutes of the liquid phase comprise propylene glycol; and the propylene glycol is dissolved in the glycerol of the liquid phase.

In some embodiments, the concentration of the propylene glycol in the liquid phase is at least 1 percent by mass. In some embodiments, the concentration of the propylene glycol in the liquid phase is at least 5 percent by mass. In some embodiments, the concentration of the propylene glycol in the liquid phase is at least 10 percent by mass. In some embodiments, the concentration of the propylene glycol in the liquid phase is at least 15 percent by mass. In some embodiments, the concentration of the propylene glycol in the liquid phase is at least 20 percent by mass. In some embodiments, the concentration of the propylene glycol in the liquid phase is at least 25 percent by mass. In some embodiments, the concentration of the propylene glycol in the liquid phase is at least 30 percent by mass. In some embodiments, the concentration of the propylene glycol in the liquid phase is at least 35 percent by mass. In some embodiments, the concentration of the propylene glycol in the liquid phase is no greater than 40 percent by mass. In some embodiments, the concentration of the propylene glycol in the liquid phase is no greater than 35 percent by mass. In some embodiments, the concentration of the propylene glycol in the liquid phase is no greater than 30 percent by mass. In some embodiments, the concentration of the propylene glycol in the liquid phase is no greater than 25 percent by mass. In some embodiments, the concentration of the propylene glycol in the liquid phase is no greater than 20 percent by mass. In some embodiments, the concentration of the propylene glycol in the liquid phase is no greater than 15 percent by mass. In some embodiments, the concentration of the propylene glycol in the liquid phase is no greater than 10 percent by mass. In some embodiments, the concentration of the propylene glycol in the liquid phase is no greater than 5 percent by mass.

In some embodiments, the liquid phase lacks propylene glycol at a concentration greater than 500 parts per million by mass. In some embodiments, the liquid phase lacks propylene glycol at a concentration greater than 100 parts per million by mass. In some embodiments, the liquid phase lacks propylene glycol at a concentration greater than 50 parts per million by mass. In some embodiments, the liquid phase lacks propylene glycol at a concentration greater than 10 parts per million by mass. In some embodiments, the liquid phase lacks propylene glycol at a concentration greater than 5 parts per million by mass. In some embodiments, the liquid phase lacks propylene glycol at a concentration greater than 1 part per million by mass.

In some embodiments, the solutes of the liquid phase comprise one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide, which are dissolved in the glycerol of the liquid phase.

In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 1,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide). In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 5,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 10,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 50,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 100,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 500,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 1,000,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 5,000,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 10,000,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 50,000,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 100,000,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 500,000,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 1,000,000,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 5,000,000,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 10,000,000,000:1.

In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 1,000,000,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide). In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 500,000,000,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 100,000,000,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 50,000,000,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 10,000,000,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 5,000,000,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 1,000,000,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 500,000,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 100,000,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 50,000,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 10,000,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 5,000,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 1,000,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 500,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 100,000:1. In some embodiments, the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 50,000:1. In some embodiments, the liquid phase lacks propylene glycol.

In some embodiments, the solutes of the liquid phase comprise ethanol; and the ethanol is dissolved in the glycerol of the liquid phase.

In some embodiments, the concentration of the ethanol in the liquid phase is at least 1 percent by mass. In some embodiments, the concentration of the ethanol in the liquid phase is at least 5 percent by mass. In some embodiments, the concentration of the ethanol in the liquid phase is at least 10 percent by mass. In some embodiments, the concentration of the ethanol in the liquid phase is at least 15 percent by mass. In some embodiments, the concentration of the ethanol in the liquid phase is at least 20 percent by mass. In some embodiments, the concentration of the ethanol in the liquid phase is at least 25 percent by mass. In some embodiments, the concentration of the ethanol in the liquid phase is at least 30 percent by mass. In some embodiments, the concentration of the ethanol in the liquid phase is at least 35 percent by mass.

In some embodiments, the concentration of the ethanol in the liquid phase is no greater than 40 percent by mass. In some embodiments, the concentration of the ethanol in the liquid phase is no greater than 35 percent by mass. In some embodiments, the concentration of the ethanol in the liquid phase is no greater than 30 percent by mass. In some embodiments, the concentration of the ethanol in the liquid phase is no greater than 25 percent by mass. In some embodiments, the concentration of the ethanol in the liquid phase is no greater than 20 percent by mass. In some embodiments, the concentration of the ethanol in the liquid phase is no greater than 15 percent by mass. In some embodiments, the concentration of the ethanol in the liquid phase is no greater than 10 percent by mass. In some embodiments, the concentration of the ethanol in the liquid phase is no greater than 5 percent by mass.

In some embodiments, the liquid phase lacks ethanol at a concentration greater than 500 parts per million by mass. In some embodiments, the liquid phase lacks ethanol at a concentration greater than 100 parts per million by mass. In some embodiments, the liquid phase lacks ethanol at a concentration greater than 50 parts per million by mass. In some embodiments, the liquid phase lacks ethanol at a concentration greater than 10 parts per million by mass. In some embodiments, the liquid phase lacks ethanol at a concentration greater than 5 parts per million by mass. In some embodiments, the liquid phase lacks ethanol at a concentration greater than 1 part per million by mass.

In some embodiments, the solutes of the liquid phase comprise ethyl oxonium and ethoxide, which are dissolved in the glycerol of the liquid phase.

In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:1,000,000. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:500,000. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:100,000. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:50,000. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:10,000. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:5,000. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:1,000. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:500. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:100. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:50. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:10. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:5. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 5:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 10:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 50:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 100:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 500:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1,000:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 5,000:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 10,000:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 50,000:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 100,000:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 500,000:1.

In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1,000,000:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 500,000:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 100,000:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 50,000:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 10,000:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 5,000:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1,000:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 500:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 100:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 50:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 10:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 5:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:1. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:5. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:10. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:50. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:100. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:500. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:1,000. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:5,000. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:10,000. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:50,000. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:100,000. In some embodiments, the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:500,000.

In some embodiments, the liquid phase lacks ethanol.

In some embodiments, the solutes of the liquid phase comprise water; and the water is dissolved in the glycerol of the liquid phase.

In some embodiments, the concentration of the water in the liquid phase is at least 5 parts per million by mass. In some embodiments, the concentration of the water in the liquid phase is at least 10 parts per million by mass. In some embodiments, the concentration of the water in the liquid phase is at least 50 parts per million by mass. In some embodiments, the concentration of the water in the liquid phase is at least 100 parts per million by mass. In some embodiments, the concentration of the water in the liquid phase is at least 500 parts per million by mass. In some embodiments, the concentration of the water in the liquid phase is at least 0.1 percent by mass. In some embodiments, the concentration of the water in the liquid phase is at least 0.5 percent by mass. In some embodiments, the concentration of the water in the liquid phase is at least 1 percent by mass. In some embodiments, the concentration of the water in the liquid phase is at least 5 percent by mass. In some embodiments, the concentration of the water in the liquid phase is at least 10 percent by mass. In some embodiments, the concentration of the water in the liquid phase is at least 15 percent by mass. In some embodiments, the concentration of the water in the liquid phase is at least 20 percent by mass. In some embodiments, the concentration of the water in the liquid phase is at least 25 percent by mass. In some embodiments, the concentration of the water in the liquid phase is at least 30 percent by mass. In some embodiments, the concentration of the water in the liquid phase is at least 35 percent by mass.

In some embodiments, the concentration of the water in the liquid phase is no greater than 40 percent by mass. In some embodiments, the concentration of the water in the liquid phase is no greater than 35 percent by mass. In some embodiments, the concentration of the water in the liquid phase is no greater than 30 percent by mass. In some embodiments, the concentration of the water in the liquid phase is no greater than 25 percent by mass. In some embodiments, the concentration of the water in the liquid phase is no greater than 20 percent by mass. In some embodiments, the concentration of the water in the liquid phase is no greater than 15 percent by mass. In some embodiments, the concentration of the water in the liquid phase is no greater than 10 percent by mass. In some embodiments, the concentration of the water in the liquid phase is no greater than 5 percent by mass.

In some embodiments, the liquid phase lacks water at a concentration greater than 1 percent by mass. In some embodiments, the liquid phase lacks water at a concentration greater than 0.5 percent by mass. In some embodiments, the liquid phase lacks water at a concentration greater than 0.1 percent by mass. In some embodiments, the liquid phase lacks water at a concentration greater than 500 parts per million by mass. In some embodiments, the liquid phase lacks water at a concentration greater than 100 parts per million by mass. In some embodiments, the liquid phase lacks water at a concentration greater than 50 parts per million by mass. In some embodiments, the liquid phase lacks water at a concentration greater than 10 parts per million by mass. In some embodiments, the liquid phase lacks water at a concentration greater than 5 parts per million by mass. In some embodiments, the liquid phase lacks water at a concentration greater than 1 part per million by mass.

In some embodiments, the solutes of the liquid phase comprise hydronium and hydroxide, which are dissolved in the glycerol of the liquid phase.

In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:1,000,000. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:500,000. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:100,000. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:50,000. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:10,000. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:5,000. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:1,000. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:500. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:100. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:50. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:10. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:5. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 5:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 10:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 50:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 100:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 500:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1,000:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 5,000:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 10,000:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 50,000:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 100,000:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 500,000:1.

In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1,000,000:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 500,000:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 100,000:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 50,000:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 10,000:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 5,000:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1,000:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 500:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 100:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 50:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 10:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 5:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:1. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:5. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:10. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:50. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:100. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:500. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:1,000. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:5,000. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:10,000. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:50,000. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:100,000. In some embodiments, the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:500,000.

In some embodiments, the liquid phase lacks water.

In some embodiments, the cannabinoid is 5-alkyl-2-geranylbenzene-1,3-diol.

In some embodiments, the cannabinoid is 5-alkyl-2-(6-isopropenyl-3-methylcyclohex-2-enyl)benzene-1,3-diol.

In some embodiments, the cannabinoid is 5-alkyl-2-(6-isopropenyl-3-methylcyclohex-3-enyl)benzene-1,3-diol.

In some embodiments, the cannabinoid is 3-alkyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene-1-ol.

In some embodiments, the cannabinoid is 3-alkyl-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-1-ol.

In some embodiments, the cannabinoid is 3-alkyl-6,6,9-trimethyl-6H-benzo[c]chromene-1-ol.

In some embodiments, the cannabinoid is (3-alkyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-yl)-O-acetate.

In some embodiments, the cannabinoid is (3-alkyl-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-yl)-O-acetate.

In some embodiments, the cannabinoid is (3-alkyl-6,6,9-trimethyl-6H-benzo[c]chromen-1-yl)-O-acetate.

In some embodiments, the cannabinoid is 3-alkyl-6,6-dimethyl-9-oxo-6,6a,7,8,10,10a-hexahydro-9H-benzo[c]chromene-1-ol.

In some embodiments, the cannabinoid is 3-alkyl-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene-1-ol.

In some embodiments, the cannabinoid is 3-alkyl-9-(hydroxymethyl)-6,6-dimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-1-ol.

In some embodiments, the cannabinoid is 7-alkyl-2-methyl-2-(4-methylpent-3-enyl)-2H-1-benzopyran-5-ol.

In some embodiments, the cannabinoid is 5-alkyl-2-geranyl-3-hydroxyphenolate.

In some embodiments, the cannabinoid is 5-alkyl-3-hydroxy-2-(6-isopropenyl-3-methylcyclohex-2-enyl)phenolate.

In some embodiments, the cannabinoid is 5-alkyl-3-hydroxy-2-(6-isopropenyl-3-methylcyclohex-3-enyl)phenolate.

In some embodiments, the cannabinoid is 3-alkyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene-1-oxide.

In some embodiments, the cannabinoid is 3-alkyl-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-1-oxide.

In some embodiments, the cannabinoid is 3-alkyl-6,6,9-trimethyl-6H-benzo[c]chromene-1-oxide.

In some embodiments, the cannabinoid is 3-alkyl-6,6-dimethyl-9-oxo-6,6a,7,8,10,10a-hexahydro-9H-benzo[c]chromene-1-oxide.

In some embodiments, the cannabinoid is 3-alkyl-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene-1-oxide.

In some embodiments, the cannabinoid is 3-alkyl-9-(hydroxymethyl)-6,6-dimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-1-oxide.

In some embodiments, the cannabinoid is 7-alkyl-2-methyl-2-(4-methylpent-3-enyl)-2H-1-benzopyran-5-oxide.

In some embodiments, the cannabinoid is 3-alkoxy-5-alkyl-2-geranylphenol.

In some embodiments, the cannabinoid is 1,3-dialkoxy-5-alkyl-2-geranylbenzene.

In some embodiments, the cannabinoid is 3-alkoxy-5-alkyl-2-(6-isopropenyl-3-methylcyclohex-2-enyl)phenol.

In some embodiments, the cannabinoid is 1,3-dialkoxy-5-alkyl-2-(6-isopropenyl-3-methylcyclohex-2-enyl)benzene.

In some embodiments, the cannabinoid is 3-alkoxy-5-alkyl-2-(6-isopropenyl-3-methylcyclohex-3-enyl)phenol.

In some embodiments, the cannabinoid is 1,3-dialkoxy-5-alkyl-2-(6-isopropenyl-3-methylcyclohex-3-enyl)phenol.

In some embodiments, the cannabinoid is 1-alkoxy-3-alkyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene.

In some embodiments, the cannabinoid is 1-alkoxy-3-alkyl-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene.

In some embodiments, the cannabinoid is 1-alkoxy-3-alkyl-6,6,9-trimethyl-6H-benzo[c]chromene.

In some embodiments, the cannabinoid is 1-alkoxy-3-alkyl-6,6-dimethyl-9-oxo-6,6a,7,8,10,10a-hexahydro-9H-benzo[c]chromene.

In some embodiments, the cannabinoid is 1-alkoxy-3-alkyl-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene.

In some embodiments, the cannabinoid is 1-alkoxy-3-alkyl-9-(hydroxymethyl)-6,6-dimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene.

In some embodiments, the cannabinoid is 5-alkoxy-7-alkyl-2-methyl-2-(4-methylpent-3-enyl)-2H-1-benzopyran.

In some embodiments, the cannabinoid is N-{3-oxo-3-[(3-alkoxy-5-alkyl-2-geranylphenyl)oxy]propyl}morpholinium.

In some embodiments, the cannabinoid is N-{3-oxo-3-[(3-alkoxy-5-alkyl-2-geranylphenyl)oxy]propyl}morpholine.

In some embodiments, the cannabinoid is N-(3-oxo-3-{[3-alkoxy-5-alkyl-2-(6-isopropenyl-3-methylcyclohex-2-enyl)phenyl]oxy}propyl)morpholinium.

In some embodiments, the cannabinoid is N-(3-oxo-3-{[3-alkoxy-5-alkyl-2-(6-isopropenyl-3-methylcyclohex-2-enyl)phenyl]oxy}propyl)morpholine.

In some embodiments, the cannabinoid is N-(3-oxo-3-{[3-alkoxy-5-alkyl-2-(6-isopropenyl-3-methylcyclohex-3-enyl)phenyl]oxy}propyl)morpholinium.

In some embodiments, the cannabinoid is N-(3-oxo-3-{[3-alkoxy-5-alkyl-2-(6-isopropenyl-3-methylcyclohex-3-enyl)phenyl]oxy}propyl)morpholine.

In some embodiments, alkoxy is methoxy. In some embodiments, alkoxy is ethoxy. In some embodiments, alkoxy is 2-propoxy. In some embodiments, alkoxy is acetyloxy.

In some embodiments, alkyl is methyl. In some embodiments, alkyl is ethyl. In some embodiments, alkyl is propyl. In some embodiments, alkyl is butyl. In some embodiments, alkyl is pentyl. In some embodiments, alkyl is hexyl. In some embodiments, alkyl is heptyl. In some embodiments, alkyl is octyl. In some embodiments, alkyl is nonyl. In some embodiments, alkyl is decyl. In some embodiments, alkyl is undecyl. In some embodiments, alkyl is dodecyl. In some embodiments, alkyl is prop-2-yl. In some embodiments, alkyl is but-2-yl. In some embodiments, alkyl is pent-2-yl. In some embodiments, alkyl is hex-2-yl. In some embodiments, alkyl is hept-2-yl. In some embodiments, alkyl is octan-2-yl. In some embodiments, alkyl is nonan-2-yl. In some embodiments, alkyl is dec-2-yl. In some embodiments, alkyl is undec-2-yl. In some embodiments, alkyl is dodec-2-yl. In some embodiments, alkyl is 2-methylpropyl. In some embodiments, alkyl is 2-methylbutyl. In some embodiments, alkyl is 2-methylpentyl. In some embodiments, alkyl is 2-methylhexyl. In some embodiments, alkyl is 2-methylheptyl. In some embodiments, alkyl is 2-methyloctyl. In some embodiments, alkyl is 2-methylnonyl. In some embodiments, alkyl is 2-methyldecyl. In some embodiments, alkyl is 2-methylundecyl. In some embodiments, alkyl is 2-methylprop-2-yl. In some embodiments, alkyl is 2-methylbut-2-yl. In some embodiments, alkyl is 2-methylpent-2-yl. In some embodiments, alkyl is 2-methylhex-2-yl. In some embodiments, alkyl is 2-methylhept-2-yl. In some embodiments, alkyl is 2-methyloct-2-yl. In some embodiments, alkyl is 2-methylnonan-2-yl. In some embodiments, alkyl is 2-methyldec-2-yl. In some embodiments, alkyl is 2-methylundec-2-yl. In some embodiments, alkyl is 3-methylbut-2-yl. In some embodiments, alkyl is 3-methylpent-2-yl. In some embodiments, alkyl is 3-methylhex-2-yl. In some embodiments, alkyl is 3-methylhept-2-yl. In some embodiments, alkyl is 3-methyloct-2-yl. In some embodiments, alkyl is 3-methylnonan-2-yl. In some embodiments, alkyl is 3-methyldec-2-yl. In some embodiments, alkyl is 3-methylundec-2-yl. In some embodiments, alkyl is 2,3-dimethylbut-2-yl. In some embodiments, alkyl is 2,3-dimethylpent-2-yl. In some embodiments, alkyl is 2,3-dimethylhex-2-yl. In some embodiments, alkyl is 2,3-dimethylhept-2-yl. In some embodiments, alkyl is 2,3-dimethyloct-2-yl. In some embodiments, alkyl is 2,3-dimethylnonan-2-yl. In some embodiments, alkyl is 2,3-dimethyldec-2-yl. In some embodiments, alkyl is cyclopropyl. In some embodiments, alkyl is 1-methylcyclopropyl. In some embodiments, alkyl is 1-ethylcyclopropyl. In some embodiments, alkyl is 1-propylcyclopropyl. In some embodiments, alkyl is 1-butylcyclopropyl. In some embodiments, alkyl is 1-pentylcyclopropyl. In some embodiments, alkyl is 1-hexylcyclopropyl. In some embodiments, alkyl is 1-heptylcyclopropyl. In some embodiments, alkyl is 1-octylcyclopropyl. In some embodiments, alkyl is 1-nonylcyclopropyl. In some embodiments, alkyl is cyclobutyl. In some embodiments, alkyl is 1-methylcyclobutyl. In some embodiments, alkyl is 1-ethylcyclobutyl. In some embodiments, alkyl is 1-propylcyclobutyl. In some embodiments, alkyl is 1-butylcyclobutyl. In some embodiments, alkyl is 1-pentylcyclobutyl. In some embodiments, alkyl is 1-hexylcyclobutyl. In some embodiments, alkyl is 1-heptylcyclobutyl. In some embodiments, alkyl is 1-octylcyclobutyl. In some embodiments, alkyl is cyclopentyl. In some embodiments, alkyl is 1-methylcyclopentyl. In some embodiments, alkyl is 1-ethylcyclopentyl. In some embodiments, alkyl is 1-propylcyclopentyl. In some embodiments, alkyl is 1-butylcyclopentyl. In some embodiments, alkyl is 1-pentylcyclopentyl. In some embodiments, alkyl is 1-hexylcyclopentyl. In some embodiments, alkyl is 1-heptylcyclopentyl. In some embodiments, alkyl is cyclohexyl. In some embodiments, alkyl is 1-methylcyclohexyl. In some embodiments, alkyl is 1-ethylcyclohexyl. In some embodiments, alkyl is 1-propylcyclohexyl. In some embodiments, alkyl is 1-butylcyclohexyl. In some embodiments, alkyl is 1-pentylcyclohexyl. In some embodiments, alkyl is 1-hexylcyclohexyl. In some embodiments, alkyl is ethenyl. In some embodiments, alkyl is prop-1-enyl. In some embodiments, alkyl is but-1-enyl. In some embodiments, alkyl is pent-1-enyl. In some embodiments, alkyl is hex-1-enyl. In some embodiments, alkyl is hept-1-enyl. In some embodiments, alkyl is oct-1-enyl. In some embodiments, alkyl is nonan-1-enyl. In some embodiments, alkyl is dec-1-enyl. In some embodiments, alkyl is undec-1-enyl. In some embodiments, alkyl is dodec-1-enyl. In some embodiments, alkyl is ethynyl. In some embodiments, alkyl is prop-1-ynyl. In some embodiments, alkyl is but-1-ynyl. In some embodiments, alkyl is pent-1-ynyl. In some embodiments, alkyl is hex-1-ynyl. In some embodiments, alkyl is hept-1-ynyl. In some embodiments, alkyl is oct-1-ynyl. In some embodiments, alkyl is nonan-1-ynyl. In some embodiments, alkyl is dec-1-ynyl. In some embodiments, alkyl is undec-1-ynyl. In some embodiments, alkyl is dodec-1-ynyl. In some embodiments, alkyl is 2-phenylethyl. In some embodiments, alkyl is 2-phenylprop-2-yl. In some embodiments, alkyl is adamant-1-yl. In some embodiments, alkyl is adamant-2-yl. In some embodiments, alkyl is 6-fluorohex-2-enyl. In some embodiments, alkyl is 6-fluorohex-2-ynyl. In some embodiments, alkyl is 2-methyl-6-fluorohex-2-yl. In some embodiments, alkyl is 6-chlorohex-2-enyl. In some embodiments, alkyl is 6-chlorohex-2-ynyl. In some embodiments, alkyl is 2-methyl-6-chlorohex-2-yl. In some embodiments, alkyl is 6-bromohex-2-enyl. In some embodiments, alkyl is 6-bromohex-2-ynyl. In some embodiments, alkyl is 2-methyl-6-bromohex-2-yl. In some embodiments, alkyl is 6-iodohex-2-enyl. In some embodiments, alkyl is 6-iodohex-2-ynyl. In some embodiments, alkyl is 2-methyl-6-iodohex-2-yl.

In some embodiments, the cannabinoid is cannabidiol.

In some embodiments, the cannabinoid is tetrahydrocannabinol.

In some embodiments, the cannabinoid is delta8-tetrahydrocannabinol.

In some embodiments, the cannabinoid is cannabigerol.

In some embodiments, the cannabinoid is cannabidivarin.

In some embodiments, the cannabinoid is tetrahydrocannabivarin.

In some embodiments, the cannabinoid is delta8-tetrahydrocannabivarin.

In some embodiments, the cannabinoid is cannabigerovarin.

In some embodiments, the cannabinoid is cannabichromene.

In some embodiments, the cannabinoid is cannabinol.

In some embodiments, the cannabinoid is cannabivarin.

In some embodiments, the cannabinoid is tetrahydrocannabiphorol.

In some embodiments, the cannabinoid is perrottetinene.

In some embodiments, the cannabinoid is nabilone.

In some embodiments, the cannabinoid is parahexyl.

In some embodiments, the cannabinoid is HUM-217.

In some embodiments, the cannabinoid is HU-331.

Various aspects of the disclosure relate to a composition, comprising a liquid phase that comprises a cannabinoid.

In some embodiments, the liquid phase comprises no greater than 2.0 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 1.9 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 1.8 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 1.7 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 1.6 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 1.5 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 1.4 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 1.3 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 1.2 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 1.1 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 1.0 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 0.9 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 0.8 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 0.7 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 0.6 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 0.5 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 0.4 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 0.3 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 0.2 food calories per milligram of the cannabinoid.

In some embodiments, the liquid phase comprises at least 0.1 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises at least 0.2 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises at least 0.3 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises at least 0.4 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises at least 0.5 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises at least 0.6 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises at least 0.7 food calories per milligram of the cannabinoid. In some embodiments, the liquid phase comprises at least 0.8 food calories per milligram of the cannabinoid.

In some embodiments, the composition comprises at least 10 milligrams of the liquid phase. In some embodiments, the composition comprises at least 20 milligrams of the liquid phase. In some embodiments, the composition comprises at least 40 milligrams of the liquid phase. In some embodiments, the composition comprises at least 60 milligrams of the liquid phase. In some embodiments, the composition comprises at least 80 milligrams of the liquid phase. In some embodiments, the composition comprises at least 100 milligrams of the liquid phase. In some embodiments, the composition comprises at least 120 milligrams of the liquid phase. In some embodiments, the composition comprises at least 140 milligrams of the liquid phase. In some embodiments, the composition comprises at least 160 milligrams of the liquid phase. In some embodiments, the composition comprises at least 180 milligrams of the liquid phase.

In some embodiments, the composition comprises no greater than 300 milligrams of the liquid phase. In some embodiments, the composition comprises no greater than 280 milligrams of the liquid phase. In some embodiments, the composition comprises no greater than 260 milligrams of the liquid phase. In some embodiments, the composition comprises no greater than 240 milligrams of the liquid phase. In some embodiments, the composition comprises no greater than 220 milligrams of the liquid phase. In some embodiments, the composition comprises no greater than 200 milligrams of the liquid phase. In some embodiments, the composition comprises no greater than 180 milligrams of the liquid phase. In some embodiments, the composition comprises no greater than 160 milligrams of the liquid phase. In some embodiments, the composition comprises no greater than 140 milligrams of the liquid phase. In some embodiments, the composition comprises no greater than 120 milligrams of the liquid phase.

In some embodiments, the composition comprises at least 0.12 food calories. In some embodiments, the composition comprises at least 0.16 food calories. In some embodiments, the composition comprises at least 0.20 food calories. In some embodiments, the composition comprises at least 0.24 food calories. In some embodiments, the composition comprises at least 0.28 food calories. In some embodiments, the composition comprises at least 0.32 food calories. In some embodiments, the composition comprises at least 0.36 food calories. In some embodiments, the composition comprises at least 0.40 food calories. In some embodiments, the composition comprises at least 0.44 food calories. In some embodiments, the composition comprises at least 0.48 food calories. In some embodiments, the composition comprises at least 0.52 food calories. In some embodiments, the composition comprises at least 0.56 food calories. In some embodiments, the composition comprises at least 0.60 food calories. In some embodiments, the composition comprises at least 0.64 food calories. In some embodiments, the composition comprises at least 0.68 food calories. In some embodiments, the composition comprises at least 0.72 food calories. In some embodiments, the composition comprises at least 0.76 food calories. In some embodiments, the composition comprises at least 0.80 food calories. In some embodiments, the composition comprises at least 0.84 food calories.

In some embodiments, the composition comprises no greater than 2.00 food calories. In some embodiments, the composition comprises no greater than 1.90 food calories. In some embodiments, the composition comprises no greater than 1.80 food calories. In some embodiments, the composition comprises no greater than 1.70 food calories. In some embodiments, the composition comprises no greater than 1.60 food calories. In some embodiments, the composition comprises no greater than 1.50 food calories. In some embodiments, the composition comprises no greater than 1.40 food calories. In some embodiments, the composition comprises no greater than 1.30 food calories. In some embodiments, the composition comprises no greater than 1.20 food calories. In some embodiments, the composition comprises no greater than 1.10 food calories. In some embodiments, the composition comprises no greater than 1.00 food calories. In some embodiments, the composition comprises no greater than 0.90 food calories. In some embodiments, the composition comprises no greater than 0.86 food calories. In some embodiments, the composition comprises no greater than 0.82 food calories. In some embodiments, the composition comprises no greater than 0.78 food calories. In some embodiments, the composition comprises no greater than 0.74 food calories. In some embodiments, the composition comprises no greater than 0.70 food calories. In some embodiments, the composition comprises no greater than 0.66 food calories. In some embodiments, the composition comprises no greater than 0.62 food calories.

In some embodiments, the composition comprises at least 1 microgram of the cannabinoid. In some embodiments, the composition comprises at least 2 micrograms of the cannabinoid. In some embodiments, the composition comprises at least 4 micrograms of the cannabinoid. In some embodiments, the composition comprises at least 8 micrograms of the cannabinoid. In some embodiments, the composition comprises at least 16 micrograms of the cannabinoid. In some embodiments, the composition comprises at least 32 micrograms of the cannabinoid. In some embodiments, the composition comprises at least 64 micrograms of the cannabinoid. In some embodiments, the composition comprises at least 128 micrograms of the cannabinoid. In some embodiments, the composition comprises at least 256 micrograms of the cannabinoid. In some embodiments, the composition comprises at least 0.48 milligrams of the cannabinoid. In some embodiments, the composition comprises at least 0.6 milligrams of the cannabinoid. In some embodiments, the composition comprises at least 0.7 milligrams of the cannabinoid. In some embodiments, the composition comprises at least 0.8 milligrams of the cannabinoid. In some embodiments, the composition comprises at least 0.9 milligrams of the cannabinoid.

In some embodiments, the composition comprises no greater than 2.1 milligrams of the cannabinoid. In some embodiments, the composition comprises no greater than 2.0 milligrams of the cannabinoid. In some embodiments, the composition comprises no greater than 1.9 milligrams of the cannabinoid. In some embodiments, the composition comprises no greater than 1.8 milligrams of the cannabinoid. In some embodiments, the composition comprises no greater than 1.7 milligrams of the cannabinoid. In some embodiments, the composition comprises no greater than 1.6 milligrams of the cannabinoid. In some embodiments, the composition comprises no greater than 1.5 milligrams of the cannabinoid. In some embodiments, the composition comprises no greater than 1.4 milligrams of the cannabinoid. In some embodiments, the composition comprises no greater than 1.3 milligrams of the cannabinoid. In some embodiments, the composition comprises no greater than 1.2 milligrams of the cannabinoid. In some embodiments, the composition comprises no greater than 1.1 milligrams of the cannabinoid.

In some embodiments, the composition is a spray.

In some embodiments, the composition is an aerosol.

In some embodiments, the composition is an aerosol spray.

In some embodiments, the composition comprises a gas phase, wherein the liquid phase is a dispersed phase; the gas phase is a dispersion medium; and the liquid phase is suspended in the gas phase.

In some embodiments, the gas phase comprises air. In some embodiments, the gas phase consists essentially of air.

In some embodiments, the gas phase comprises a propellant. In some embodiments, the gas phase consists essentially of the propellant.

In some embodiments, the propellant is nitrous oxide.

In some embodiments, the propellant is carbon dioxide.

In some embodiments, the propellant is 1,1,1,2-tetrafluorethane.

In some embodiments, the propellant is 1,1,1,2,3,3,3-heptafluoropropane.

In some embodiments, the propellant is hydrofluoroolefin.

In some embodiments, the propellant is dimethyl ether.

In some embodiments, the propellant is methyl ethyl ether.

Various aspects of the disclosure relate to a container configured to dispense a composition as described anywhere in the disclosure.

Various aspects of the disclosure relate to a container, comprising a chamber that contains a composition as described anywhere in the disclosure.

In some embodiments, the liquid phase of a composition of a container comprises at least 10 micrograms of the cannabinoid. In some embodiments, the liquid phase comprises at least 20 micrograms of the cannabinoid. In some embodiments, the liquid phase comprises at least 40 micrograms of the cannabinoid. In some embodiments, the liquid phase comprises at least 80 micrograms of the cannabinoid. In some embodiments, the liquid phase comprises at least 160 micrograms of the cannabinoid. In some embodiments, the liquid phase comprises at least 320 micrograms of the cannabinoid. In some embodiments, the liquid phase comprises at least 640 micrograms of the cannabinoid. In some embodiments, the liquid phase comprises at least 1 milligram of the cannabinoid In some embodiments, the liquid phase comprises at least 2 milligrams of the cannabinoid. In some embodiments, the liquid phase comprises at least 4 milligrams of the cannabinoid. In some embodiments, the liquid phase comprises at least 8 milligrams of the cannabinoid. In some embodiments, the liquid phase comprises at least 16 milligrams of the cannabinoid. In some embodiments, the liquid phase comprises at least 32 milligrams of the cannabinoid. In some embodiments, the liquid phase comprises at least 64 milligrams of the cannabinoid. In some embodiments, the liquid phase comprises at least 80 milligrams of the cannabinoid. In some embodiments, the liquid phase comprises at least 90 milligrams of the cannabinoid. In some embodiments, the liquid phase comprises at least 99 milligrams of the cannabinoid.

In some embodiments, the liquid phase of a composition of a container comprises no greater than 120 milligrams of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 110 milligrams of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 101 milligrams of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 90 milligrams of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 80 milligrams of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 64 milligrams of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 32 milligrams of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 16 milligrams of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 8 milligrams of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 4 milligrams of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 2 milligrams of the cannabinoid. In some embodiments, the liquid phase comprises no greater than 1 milligram of the cannabinoid.

In some embodiments, the container is configured to dispense at least 1 metered portion of the composition. In some embodiments, the container is configured to dispense at least 2 metered portions of the composition. In some embodiments, the container is configured to dispense at least 3 metered portions of the composition. In some embodiments, the container is configured to dispense at least 4 metered portions of the composition. In some embodiments, the container is configured to dispense at least 6 metered portions of the composition. In some embodiments, the container is configured to dispense at least 8 metered portions of the composition. In some embodiments, the container is configured to dispense at least 12 metered portions of the composition. In some embodiments, the container is configured to dispense at least 16 metered portions of the composition. In some embodiments, the container is configured to dispense at least 24 metered portions of the composition. In some embodiments, the container is configured to dispense at least 32 metered portions of the composition. In some embodiments, the container is configured to dispense at least 48 metered portions of the composition. In some embodiments, the container is configured to dispense at least 64 metered portions of the composition. In some embodiments, the container is configured to dispense at least 96 metered portions of the composition.

In some embodiments, the container is configured to dispense no greater than 110 metered portions of the composition. In some embodiments, the container is configured to dispense no greater than 96 metered portions of the composition. In some embodiments, the container is configured to dispense no greater than 48 metered portions of the composition. In some embodiments, the container is configured to dispense no greater than 24 metered portions of the composition. In some embodiments, the container is configured to dispense no greater than 12 metered portions of the composition.

In some embodiments, the metered portions have an average mass of at least 10 milligrams of the liquid phase. In some embodiments, the metered portions have an average mass of at least 20 milligrams of the liquid phase. In some embodiments, the metered portions have an average mass of at least 40 milligrams of the liquid phase. In some embodiments, the metered portions have an average mass of at least 60 milligrams of the liquid phase. In some embodiments, the metered portions have an average mass of at least 80 milligrams of the liquid phase. In some embodiments, the metered portions have an average mass of at least 100 milligrams of the liquid phase. In some embodiments, the metered portions have an average mass of at least 120 milligrams of the liquid phase. In some embodiments, the metered portions have an average mass of at least 140 milligrams of the liquid phase. In some embodiments, the metered portions have an average mass of at least 160 milligrams of the liquid phase. In some embodiments, the metered portions have an average mass of at least 180 milligrams of the liquid phase.

In some embodiments, the metered portions have an average mass of no greater than 300 milligrams of the liquid phase. In some embodiments, the metered portions have an average mass of no greater than 280 milligrams of the liquid phase. In some embodiments, the metered portions have an average mass of no greater than 260 milligrams of the liquid phase. In some embodiments, the metered portions have an average mass of no greater than 240 milligrams of the liquid phase. In some embodiments, the metered portions have an average mass of no greater than 220 milligrams of the liquid phase. In some embodiments, the metered portions have an average mass of no greater than 200 milligrams of the liquid phase. In some embodiments, the metered portions have an average mass of no greater than 180 milligrams of the liquid phase. In some embodiments, the metered portions have an average mass of no greater than 160 milligrams of the liquid phase. In some embodiments, the metered portions have an average mass of no greater than 140 milligrams of the liquid phase. In some embodiments, the metered portions have an average mass of no greater than 120 milligrams of the liquid phase.

In some embodiments, the metered portions have an average amount of food calories of at least 0.12 food calories. In some embodiments, the metered portions have an average amount of food calories of at least 0.16 food calories. In some embodiments, the metered portions have an average amount of food calories of at least 0.20 food calories. In some embodiments, the metered portions have an average amount of food calories of at least 0.24 food calories. In some embodiments, the metered portions have an average amount of food calories of at least 0.28 food calories. In some embodiments, the metered portions have an average amount of food calories of at least 0.32 food calories. In some embodiments, the metered portions have an average amount of food calories of at least 0.36 food calories. In some embodiments, the metered portions have an average amount of food calories of at least 0.40 food calories. In some embodiments, the metered portions have an average amount of food calories of at least 0.44 food calories. In some embodiments, the metered portions have an average amount of food calories of at least 0.48 food calories. In some embodiments, the metered portions have an average amount of food calories of at least 0.52 food calories. In some embodiments, the metered portions have an average amount of food calories of at least 0.56 food calories. In some embodiments, the metered portions have an average amount of food calories of at least 0.60 food calories. In some embodiments, the metered portions have an average amount of food calories of at least 0.64 food calories. In some embodiments, the metered portions have an average amount of food calories of at least 0.68 food calories. In some embodiments, the metered portions have an average amount of food calories of at least 0.72 food calories. In some embodiments, the metered portions have an average amount of food calories of at least 0.76 food calories. In some embodiments, the metered portions have an average amount of food calories of at least 0.80 food calories. In some embodiments, the metered portions have an average amount of food calories of at least 0.84 food calories.

In some embodiments, the metered portions have an average amount of food calories of no greater than 2.00 food calories. In some embodiments, the metered portions have an average amount of food calories of no greater than 1.90 food calories. In some embodiments, the metered portions have an average amount of food calories of no greater than 1.80 food calories. In some embodiments, the metered portions have an average amount of food calories of no greater than 1.70 food calories. In some embodiments, the metered portions have an average amount of food calories of no greater than 1.60 food calories. In some embodiments, the metered portions have an average amount of food calories of no greater than 1.50 food calories. In some embodiments, the metered portions have an average amount of food calories of no greater than 1.40 food calories. In some embodiments, the metered portions have an average amount of food calories of no greater than 1.30 food calories. In some embodiments, the metered portions have an average amount of food calories of no greater than 1.20 food calories. In some embodiments, the metered portions have an average amount of food calories of no greater than 1.10 food calories. In some embodiments, the metered portions have an average amount of food calories of no greater than 1.00 food calories. In some embodiments, the metered portions have an average amount of food calories of no greater than 0.90 food calories. In some embodiments, the metered portions have an average amount of food calories of no greater than 0.86 food calories. In some embodiments, the metered portions have an average amount of food calories of no greater than 0.82 food calories. In some embodiments, the metered portions have an average amount of food calories of no greater than 0.78 food calories. In some embodiments, the metered portions have an average amount of food calories of no greater than 0.74 food calories. In some embodiments, the metered portions have an average amount of food calories of no greater than 0.70 food calories. In some embodiments, the metered portions have an average amount of food calories of no greater than 0.66 food calories. In some embodiments, the metered portions have an average amount of food calories of no greater than 0.62 food calories.

In some embodiments, the metered portions have an average dose of the cannabinoid of at least 1 microgram. In some embodiments, the metered portions have an average dose of the cannabinoid of at least 2 micrograms. In some embodiments, the metered portions have an average dose of the cannabinoid of at least 4 micrograms. In some embodiments, the metered portions have an average dose of the cannabinoid of at least 8 micrograms. In some embodiments, the metered portions have an average dose of the cannabinoid of at least 16 micrograms. In some embodiments, the metered portions have an average dose of the cannabinoid of at least 32 micrograms. In some embodiments, the metered portions have an average dose of the cannabinoid of at least 64 micrograms. In some embodiments, the metered portions have an average dose of the cannabinoid of at least 128 micrograms. In some embodiments, the metered portions have an average dose of the cannabinoid of at least 256 micrograms. In some embodiments, the metered portions have an average dose of the cannabinoid of at least 0.48 milligrams. In some embodiments, the metered portions have an average dose of the cannabinoid of at least 0.6 milligrams. In some embodiments, the metered portions have an average dose of the cannabinoid of at least 0.7 milligrams. In some embodiments, the metered portions have an average dose of the cannabinoid of at least 0.8 milligrams. In some embodiments, the metered portions have an average dose of the cannabinoid of at least 0.9 milligrams.

In some embodiments, the metered portions have an average dose of the cannabinoid of no greater than 2.1 milligrams. In some embodiments, the metered portions have an average dose of the cannabinoid of no greater than 2.0 milligrams. In some embodiments, the metered portions have an average dose of the cannabinoid of no greater than 1.9 milligrams. In some embodiments, the metered portions have an average dose of the cannabinoid of no greater than 1.8 milligrams. In some embodiments, the metered portions have an average dose of the cannabinoid of no greater than 1.7 milligrams. In some embodiments, the metered portions have an average dose of the cannabinoid of no greater than 1.6 milligrams. In some embodiments, the metered portions have an average dose of the cannabinoid of no greater than 1.5 milligrams. In some embodiments, the metered portions have an average dose of the cannabinoid of no greater than 1.4 milligrams. In some embodiments, the metered portions have an average dose of the cannabinoid of no greater than 1.3 milligrams. In some embodiments, the metered portions have an average dose of the cannabinoid of no greater than 1.2 milligrams. In some embodiments, the metered portions have an average dose of the cannabinoid of no greater than 1.1 milligrams.

In some embodiments, the metered portions have a standard deviation of no greater than 30 percent of the average mass of the liquid phase. In some embodiments, the metered portions have a standard deviation of no greater than 25 percent of the average mass of the liquid phase. In some embodiments, the metered portions have a standard deviation of no greater than 20 percent of the average mass of the liquid phase. In some embodiments, the metered portions have a standard deviation of no greater than 15 percent of the average mass of the liquid phase. In some embodiments, the metered portions have a standard deviation of no greater than 10 percent of the average mass of the liquid phase. In some embodiments, the metered portions have a standard deviation of no greater than 5 percent of the average mass of the liquid phase.

In some embodiments, the metered portions have a standard deviation of no greater than 30 percent of the average amount of food calories. In some embodiments, the metered portions have a standard deviation of no greater than 25 percent of the average amount of food calories. In some embodiments, the metered portions have a standard deviation of no greater than 20 percent of the average amount of food calories. In some embodiments, the metered portions have a standard deviation of no greater than 15 percent of the average amount of food calories. In some embodiments, the metered portions have a standard deviation of no greater than 10 percent of the average amount of food calories. In some embodiments, the metered portions have a standard deviation of no greater than 5 percent of the average amount of food calories.

In some embodiments, the metered portions have a standard deviation of no greater than 30 percent of the average dose of the cannabinoid. In some embodiments, the metered portions have a standard deviation of no greater than 25 percent of the average dose of the cannabinoid. In some embodiments, the metered portions have a standard deviation of no greater than 20 percent of the average dose of the cannabinoid. In some embodiments, the metered portions have a standard deviation of no greater than 15 percent of the average dose of the cannabinoid. In some embodiments, the metered portions have a standard deviation of no greater than 10 percent of the average dose of the cannabinoid. In some embodiments, the metered portions have a standard deviation of no greater than 5 percent of the average dose of the cannabinoid.

In some embodiments, the container is configured to dispense a spray of the liquid phase.

In some embodiments, the container is configured to dispense an aerosol spray of the liquid phase.

Various aspects of the disclosure relate to a method to administer a cannabinoid to a subject, comprising providing a container as described anywhere in the disclosure; spraying a portion of the composition of the container; and then orally consuming the portion of the composition, wherein the subject orally consumes the portion of the composition.

Various aspects of the disclosure relate to a method to administer a cannabinoid to a subject, comprising providing a container as described anywhere in the disclosure; spraying the composition of the container; and then orally consuming the composition, wherein the subject orally consumes the composition.

Various aspects of the disclosure relate to a method to administer a cannabinoid to a subject, comprising providing a container as described anywhere in the disclosure; and spraying a portion of the composition of the container into the mouth of the subject.

Various aspects of the disclosure relate to a method to administer a cannabinoid to a subject, comprising providing a container as described anywhere in the disclosure; and spraying the composition of the container into the mouth of the subject.

Various aspects of the disclosure relate to a method to administer a cannabinoid to a subject, comprising providing a container as described anywhere in the disclosure; and orally administering a portion of the composition of the container to the subject.

Various aspects of the disclosure relate to a method to administer a cannabinoid to a subject, comprising providing a composition as described anywhere in the disclosure; spraying a portion of the composition; and then orally consuming the portion of the composition, wherein the subject orally consumes the portion of the composition.

Various aspects of the disclosure relate to a method to administer a cannabinoid to a subject, comprising providing a composition as described anywhere in the disclosure; spraying the composition; and then orally consuming the composition, wherein the subject orally consumes the composition.

Various aspects of the disclosure relate to a method to administer a cannabinoid to a subject, comprising providing a composition as described anywhere in the disclosure; and spraying a portion of the composition into the mouth of the subject.

Various aspects of the disclosure relate to a method to administer a cannabinoid to a subject, comprising providing a composition as described anywhere in the disclosure; and orally administering a portion of the composition to the subject.

Various aspects of the disclosure relate to a method to treat a health condition in a subject, comprising providing a container as described anywhere in the disclosure; spraying a portion of the composition of the container; and then orally consuming the portion of the composition, wherein the subject orally consumes the portion of the composition.

“Treat” refers to at least one of: to cure a health condition; to increase the probability that a health condition will be cured; to shorten the time over which a health condition is cured; to increase the probability that the time necessary to cure a health condition will be shortened; to decrease the severity of a health condition; to increase the probability that the severity of a health condition will decrease; to shorten the time over which the severity of a health condition is decreased; to increase the probability that the time necessary to decrease the severity of a health condition will be shortened; to inhibit a health condition from worsening; to increase the probability that a health condition will not worsen; to delay the worsening of a health condition; to increase the probability that the worsening of a health condition will be delayed; to inhibit the occurrence or recurrence of a health condition; to decrease the probability that a health condition will occur or reoccur; to delay the onset of a health condition; to increase the probability that the onset of a health condition will be delayed; to alleviate at least one symptom of a health condition; to increase the probability that at least one symptom of a health condition will be alleviated; to shorten the time over which at least one symptom of a health condition is alleviated; to increase the probability that the time necessary to alleviate at least one symptom of a health condition will be shortened; to decrease the severity of at least one symptom of a health condition; to increase the probability that the severity of at least one symptom of a health condition will be decreased; to shorten the time over which the severity of at least one symptom of a health condition is decreased; to increase the probability that the time necessary to decrease the severity of at least one symptom of a health condition will be shortened; to inhibit at least one symptom of a health condition from worsening; to increase the probability that at least one symptom of a health condition will not worsen; to delay the worsening of at least one symptom of a health condition; to increase the probability that the worsening of at least one symptom of a health condition will be delayed; to inhibit at least one symptom of a health condition from occurring or reoccurring; to decrease the probability that at least one symptom of a health condition will occur or reoccur; to delay the onset of at least one symptom of a health condition; and to increase the probability that the onset of at least one symptom of a health condition will be delayed.

Various aspects of the disclosure relate to a method to treat a health condition in a subject, comprising providing a container as described anywhere in the disclosure; spraying the composition of the container; and then orally consuming the composition, wherein the subject orally consumes the composition.

Various aspects of the disclosure relate to a method to treat a health condition in a subject, comprising providing a container as described anywhere in the disclosure; and spraying a portion of the composition of the container into the mouth of the subject.

Various aspects of the disclosure relate to a method to treat a health condition in a subject, comprising providing a container as described anywhere in the disclosure; and spraying the composition of the container into the mouth of the subject.

Various aspects of the disclosure relate to a method to treat a health condition in a subject, comprising providing a container as described anywhere in the disclosure; and orally administering a portion of the composition of the container to the subject.

Various aspects of the disclosure relate to a method to treat a health condition in a subject, comprising providing a composition as described anywhere in the disclosure; spraying a portion of the composition; and then orally consuming the portion of the composition, wherein the subject orally consumes the portion of the composition.

Various aspects of the disclosure relate to a method to treat a health condition in a subject, comprising providing a composition as described anywhere in the disclosure; spraying the composition; and then orally consuming the composition, wherein the subject orally consumes the composition.

Various aspects of the disclosure relate to a method to treat a health condition in a subject, comprising providing a composition as described anywhere in the disclosure; and spraying a portion of the composition into the mouth of the subject.

Various aspects of the disclosure relate to a method to treat a health condition in a subject, comprising providing a composition as described anywhere in the disclosure; and orally administering a portion of the composition to the subject.

In some embodiments, the health condition is type 2 diabetes mellitus; metabolic syndrome; dyslipidemias; cardiovascular disease; hypertension; pre-hypertension; a neurodegenerative disease or neuropathy; mild cognitive impairment; Alzheimer's Disease; Parkinson's Disease; amyotrophic lateral sclerosis (“ALS”); a motor neuron disease; Huntington's disease; an autoimmune disorder; arthritis; ankylosing spondylitis; an inflammatory autoimmune-mediated arthritis; rheumatoid arthritis; osteoarthritis; psoriatic arthritis; psoriasis; plaque psoriasis; lupus; Sjogren's syndrome; inflammatory bowel disease; Crohn's disease; steroid dependent Crohn's disease; ulcerative colitis; graft-versus-host disease; fibrosis; a localized fibrotic disorder; a fibroproliferative disorder; a systemic fibrotic disorder; frozen shoulder; ocular fibrosis; a headache; a migraine headache; an episodic migraine; pain; nociceptive pain; allodynia; chronic pain; intractable pain; back pain; lower back pain; chronic back pain; sciatica; spinal stenosis; acute radicular back pain; chronic radiculopathy; post laminectomy syndrome; post-operative pain; post-operative cognitive dysfunction; post-operative cognitive deficit; post-operative delerium; stomach pain; endometriosis; dysmenorrhea; pelvic pain; visceral pain; musculoskeletal pain; musculoskeletal joint pain; temporomandibular joint pain; myofascial pain; interstitial cystitis; postherpetic neuralgia; sickle cell anemia; sickle cell disease; cancer pain; intractable cancer pain; fibromyalgia; neurogenic pain; neuropathic pain; peripheral neuropathy; diabetic peripheral neuropathy; chemotherapy-induced peripheral neuropathy; inflammatory demyelinating polyneuropathy; allodynia; peripheral pain; hyperalgesia; opioid-induced hyperalgesia; reflex sympathetic dystrophy; residual limb pain; idiopathic pain; psychogenic pain; causalgia; complex regional pain syndrome; complex regional pain syndrome type I; complex regional pain syndrome type II; arthralgia; fatigue; odontalgia; toothache; Dupuytren's contracture; early stage Dupuytren's contracture; gout; hallux valgus; hallux rigidus; epidermolysis bullosa; hemorrhoids; constipation; a urinary stone; bladder pain syndrome; detrusor overactivity; elevated intraocular pressure; glaucoma; retinitis pigmentosa; retinal degeneration; Sturge-Weber syndrome; heart failure; liver disease; fatty liver; non-alcoholic fatty liver disease (“NAFLD”); non-alcoholic steatohepatitis (“NASH”); liver cirrhosis; decompensated cirrhosis; hepatic encephalopathy; hepatitis; hepatitis C; autoimmune hepatitis; nausea; gastroparesis; dyspepsia; Prader-Willi syndrome; cachexia; anorexia; anorexia nervosa; bulimia; vomiting; motion sickness; cancer chemotherapy-induced anorexia; human deficiency virus (“HIV”) infection related nausea or cachexia; human deficiency virus (“HIV”); acquired immune deficiency syndrome (“AIDS”) related nausea or cachexia; acquired immune deficiency syndrome (“AIDS”); anxiety; generalized anxiety disorder; a specific phobia; agoraphobia; social anxiety disorder; separation anxiety disorder; panic disorder; a panic attack; selective mutism; obsessive-compulsive disorder; depression; treatment resistant depression; a major depressive disorder with psychotic feature(s); psychotic depression; paranoia; psychosis; early psychosis; an unspecified psychosis; an unspecified reactive psychosis; a psychotic disorder; a brief psychotic disorder; a debilitating psychiatric disorder; schizophrenia; schizophreniform disorder; schizoaffective disorder; schizophrenia-related psychotic disorder; dementia; a major neurocognitive disorder with aggressive behavior; paranoid personality disorder; schizoid personality disorder; schizotypal personality disorder; a shared psychotic disorder; a shared paranoia disorder; a delusional disorder; bipolar disorder; bipolar I disorder; bipolar I disorder; bipolar depression; bipolar affective disorder; mania; manic disorder; manic-depressive psychosis; an addiction; an addiction to alcohol or an alcohol use disorder; an addiction to tobacco or a tobacco use disorder; an addiction to nicotine or a nicotine use disorder; an addiction to an opioid or an opioid use disorder; an addiction to a stimulant or a stimulant use disorder; an addiction to cocaine or a cocaine use disorder; an addiction to a prescription drug or a prescription drug use disorder; an addiction to gambling; an addiction to food; an addiction to shopping; an addiction to the internet; an addiction to sex; drug withdrawal or a drug use disorder; alcohol withdrawal syndrome; nicotine withdrawal; opioid withdrawal; cannabis withdrawal; benzodiazepine withdrawal syndrome; antidepressant discontinuation syndrome; antipsychotic withdrawal syndrome; addictive behavior; cannabis use disorder; attention deficit hyperactivity disorder (“ADHD”); autism or an autism spectrum disorder; Asperger syndrome; fragile X syndrome; a pervasive developmental disorder not otherwise specified (“PDD-NOS”); a childhood disintegrative disorder; Tourette's syndrome; Down syndrome; post-traumatic stress disorder (“PTSD”); asthma; respiratory disease; chronic lower respiratory disease; chronic obstructive pulmonary disease (“COPD”); insomnia; sleep apnea; obstructive sleep apnea; or restless legs syndrome; cramping; muscle spasms; spasticity; spasmodic torticollis; a dyskinetic movement disorder; dystonia; intractable spasticity; intractable skeletal muscular spasticity; inclusion body myositis; myasthenia gravis; muscular dystrophy; Duchenne muscular dystrophy; muscle tremor; cerebellar tremor; dystonic tremor; essential tremor; orthostatic tremor; Parkinsonian tremor; physiological tremor; psychogenic tremor; rubral tremor; nystagmus; blepharospasm; a seizure disorder; recurrent focal seizures; recurrent generalized seizures; recurrent absence seizures; recurrent myoclonic-absence seizures; recurrent myoclonus; recurrent myoclonic seizures; recurrent tonic seizures; recurrent tonic-clonic seizures; recurrent atonic seizures; recurrent chronic seizures; epilepsy; recurrent epileptic spasms; recurrent infantile spasms; refractory epilepsy; refractory childhood epilepsy; intractable epilepsy; treatment-resistant epilepsy; drug resistant epilepsy; electrical status epilepticus of sleep; Lennox-Gastaut syndrome; Dravet syndrome; febrile infection related epilepsy syndrome (“FIRES”); juvenile myoclonic epilepsy; childhood absence epilepsy; myoclonic absence seizures (“MAS”); myoclonic astatic epilepsy (“MAE”); tuberous sclerosis complex (“TSC”); Rett syndrome; Angelman syndrome; a neurological condition; stroke; hemorrhagic stroke; ischemic stroke; an ischemic reperfusion injury; epilpetic encephalopathy; neonatal hypoxic-ischemic encephalopathy (“NHIE”); hydrocephalus; hydromyelia; traumatic brain injury (“TBI”); post-concussion syndrome; chronic traumatic encephalopathy; a spinal cord injury; a spinal cord disease; syringomyelia; Tarlov cysts; cystic fibrosis; cerebral palsy; spinocerebellar ataxia; a neural-tube defect; neuropathy; a brain tumor; glioblastoma multiforme; glioblastoma astrocytoma; neurofibromatosis; Arnold-Chiari malformation; multiple sclerosis; a connective tissue disorder; Ehlers-Danlos syndrome; fibrous dysplasia; osteogenesis imperfecta; nail-patella syndrome; idiopathic pulmonary fibrosis; bone loss; a bone fracture; bone loss caused by a bone fracture; bone loss caused by a surgical procedure; a periodontal defect; periodontal disease; osteopenia; an osteolytic bone disease; osteoporosis; age-related osteoporosis; hormone-related osteoporosis; hypogonadism-related osteoporosis; diabetes-related osteoporosis; glucocorticoid-related osteoporosis; or disuse osteoporosis; a carcinoma; sarcoma; lymphoma; leukemia; germ cell tumor; or blastoma; condition is brain cancer; ovarian cancer; breast cancer; vaginal cancer; vulvar cancer; uterine cancer; cervical cancer; endometrial cancer; prostate cancer; testicular cancer; penile cancer; liver cancer; intrahepatic bile duct cancer; lung cancer; small cell lung cancer; non-small cell lung cancer; bronchial cancer; mesothelioma; pancreatic cancer; gall bladder cancer; non-melanoma skin cancer; melanoma; Kaposi sarcoma; thyroid cancer; head and neck cancer; nasopharyngeal cancer; oropharyngeal cancer; hypopharyngeal cancer; laryngeal cancer; oral cavity cancer; tongue cancer; mouth cancer; salivary gland cancer; esophageal cancer; gastric cancer; colorectal cancer; colon cancer; rectal cancer; anal cancer; kidney cancer; renal cell cancer; renal pelvis cancer; bladder cancer; urethral cancer; Hodgkin lymphoma; non-Hodgkin's lymphoma; myeloma; multiple myeloma; acute lymphocytic leukemia; chronic lymphocytic leukemia; acute myeloid leukemia; chronic myeloid leukemia; osteosarcoma; soft tissue cancer; a severe acute respiratory syndrome coronavirus 2 infection; long COVID; hidradenitis suppurativa; chronic spontaneous urticaria; atopic dermatitis; eczema; acne; male pattern baldness; alpoecia; androgenetic alopecia.

In some embodiments, at least one symptom of the health condition is pain; and the composition is administered to treat pain.

In some embodiments, at least one symptom of the health condition is inflammation; and the composition is administered to treat inflammation.

In some embodiments, at least one symptom of the health condition is anxiety; and the composition is administered to treat anxiety.

In some embodiments, the subject presents with both the health condition and hypertension; hypertension exacerbates the health condition; and the composition is administered to treat the hypertension.

In some embodiments, the subject presents with both the health condition and pre-hypertension; either pre-hypertension or hypertension exacerbates the health condition; and the composition is administered to either treat the pre-hypertension or reduce the risk that the subject will develop hypertension.

In some embodiments, diuretic properties of the cannabinoid treat the health condition.

In some embodiments, the health condition is an autoimmune disease; and the composition is administered to inhibit aberrant immune response in the subject.

In some embodiments, aberrant tumor necrosis factor alpha (“TNF-alpha”) signaling either causes or exacerbates the health condition; and the composition is administered to inhibit TNF-alpha-mediated signaling pathways.

In some embodiments, aberrant interferon gamma (“INF-gamma”) signaling either causes or exacerbates the health condition; and the composition is administered to inhibit INF-gamma-mediated signaling pathways.

In some embodiments, at least one symptom of the health condition is muscle cramping, spasticity, tremor, or muscle spasms; and the composition is administered to treat the muscle cramping, spasticity, tremor, or muscle spasms.

In some embodiments, at least one symptom of the health condition is seizures; and the composition is administered to treat seizures.

In some embodiments, at least one symptom of the health condition is appetite suppression, nausea, or vomiting; and the composition is administered to treat the appetite suppression, nausea, or vomiting.

In some embodiments, the subject is receiving a primary pharmaceutical agent to treat the health condition; the primary pharmaceutical agent causes appetite suppression, nausea, or vomiting; and the composition is administered to treat the appetite suppression, nausea, or vomiting.

In some embodiments, at least one symptom of the health condition is decreased bone density; and the composition is administered to treat bone loss.

In some embodiments, the health condition is a terminal illness; and the composition is administered to provide palliative care.

In some embodiments, at least 10 milligrams of the liquid phase are administered to the subject. In some embodiments, at least 20 milligrams of the liquid phase are administered to the subject. In some embodiments, at least 40 milligrams of the liquid phase are administered to the subject. In some embodiments, at least 60 milligrams of the liquid phase are administered to the subject. In some embodiments, at least 80 milligrams of the liquid phase are administered to the subject. In some embodiments, at least 100 milligrams of the liquid phase are administered to the subject. In some embodiments, at least 120 milligrams of the liquid phase are administered to the subject. In some embodiments, at least 140 milligrams of the liquid phase are administered to the subject. In some embodiments, at least 160 milligrams of the liquid phase are administered to the subject. In some embodiments, at least 180 milligrams of the liquid phase are administered to the subject. In some embodiments, at least 200 milligrams of the liquid phase are administered to the subject. In some embodiments, at least 300 milligrams of the liquid phase are administered to the subject. In some embodiments, at least 400 milligrams of the liquid phase are administered to the subject. In some embodiments, at least 500 milligrams of the liquid phase are administered to the subject. In some embodiments, at least 600 milligrams of the liquid phase are administered to the subject. In some embodiments, at least 700 milligrams of the liquid phase are administered to the subject. In some embodiments, at least 800 milligrams of the liquid phase are administered to the subject. In some embodiments, at least 900 milligrams of the liquid phase are administered to the subject. In some embodiments, at least 1.0 gram of the liquid phase are administered to the subject. In some embodiments, at least 1.2 grams of the liquid phase are administered to the subject. In some embodiments, at least 1.4 grams of the liquid phase are administered to the subject. In some embodiments, at least 1.6 grams of the liquid phase are administered to the subject. In some embodiments, at least 1.8 grams of the liquid phase are administered to the subject.

In some embodiments, no greater than 5.0 grams of the liquid phase are administered to the subject. In some embodiments, no greater than 4.0 grams of the liquid phase are administered to the subject. In some embodiments, no greater than 3.0 grams of the liquid phase are administered to the subject. In some embodiments, no greater than 2.0 grams of the liquid phase are administered to the subject. In some embodiments, no greater than 1.8 grams of the liquid phase are administered to the subject. In some embodiments, no greater than 1.6 grams of the liquid phase are administered to the subject. In some embodiments, no greater than 1.4 grams of the liquid phase are administered to the subject. In some embodiments, no greater than 1.2 grams of the liquid phase are administered to the subject. In some embodiments, no greater than 1.0 grams of the liquid phase are administered to the subject. In some embodiments, no greater than 900 milligrams of the liquid phase are administered to the subject. In some embodiments, no greater than 800 milligrams of the liquid phase are administered to the subject. In some embodiments, no greater than 700 milligrams of the liquid phase are administered to the subject. In some embodiments, no greater than 600 milligrams of the liquid phase are administered to the subject. In some embodiments, no greater than 500 milligrams of the liquid phase are administered to the subject. In some embodiments, no greater than 400 milligrams of the liquid phase are administered to the subject. In some embodiments, no greater than 300 milligrams of the liquid phase are administered to the subject. In some embodiments, no greater than 200 milligrams of the liquid phase are administered to the subject.

In some embodiments, at least 1 micrograms of the cannabinoid are administered to the subject. In some embodiments, at least 2 micrograms of the cannabinoid are administered to the subject. In some embodiments, at least 4 micrograms of the cannabinoid are administered to the subject. In some embodiments, at least 8 micrograms of the cannabinoid are administered to the subject. In some embodiments, at least 16 micrograms of the cannabinoid are administered to the subject. In some embodiments, at least 32 micrograms of the cannabinoid are administered to the subject. In some embodiments, at least 64 micrograms of the cannabinoid are administered to the subject. In some embodiments, at least 128 micrograms of the cannabinoid are administered to the subject. In some embodiments, at least 256 micrograms of the cannabinoid are administered to the subject. In some embodiments, at least 0.48 milligrams of the cannabinoid are administered to the subject. In some embodiments, at least 0.6 milligrams of the cannabinoid are administered to the subject. In some embodiments, at least 0.7 milligrams of the cannabinoid are administered to the subject. In some embodiments, at least 0.8 milligrams of the cannabinoid are administered to the subject. In some embodiments, at least 0.9 milligrams of the cannabinoid are administered to the subject. In some embodiments, at least 1 milligrams of the cannabinoid are administered to the subject. In some embodiments, at least 2 milligrams of the cannabinoid are administered to the subject. In some embodiments, at least 3 milligrams of the cannabinoid are administered to the subject. In some embodiments, at least 4 milligrams of the cannabinoid are administered to the subject. In some embodiments, at least 5 milligrams of the cannabinoid are administered to the subject. In some embodiments, at least 6 milligrams of the cannabinoid are administered to the subject. In some embodiments, at least 7 milligrams of the cannabinoid are administered to the subject. In some embodiments, at least 8 milligrams of the cannabinoid are administered to the subject. In some embodiments, at least 9 milligrams of the cannabinoid are administered to the subject. In some embodiments, no greater than 100 milligrams of the cannabinoid are administered to the subject. In some embodiments, no greater than 80 milligrams of the cannabinoid are administered to the subject. In some embodiments, no greater than 60 milligrams of the cannabinoid are administered to the subject. In some embodiments, no greater than 40 milligrams of the cannabinoid are administered to the subject. In some embodiments, no greater than 20 milligrams of the cannabinoid are administered to the subject. In some embodiments, no greater than 11 milligrams of the cannabinoid are administered to the subject. In some embodiments, no greater than 9 milligrams of the cannabinoid are administered to the subject. In some embodiments, no greater than 8 milligrams of the cannabinoid are administered to the subject. In some embodiments, no greater than 7 milligrams of the cannabinoid are administered to the subject. In some embodiments, no greater than 6 milligrams of the cannabinoid are administered to the subject. In some embodiments, no greater than 5 milligrams of the cannabinoid are administered to the subject. In some embodiments, no greater than 4 milligrams of the cannabinoid are administered to the subject. In some embodiments, no greater than 3 milligrams of the cannabinoid are administered to the subject. In some embodiments, no greater than 2 milligrams of the cannabinoid are administered to the subject. In some embodiments, no greater than 1.2 milligrams of the cannabinoid are administered to the subject.

In preferred embodiments related to health conditions, a therapeutically effective amount of the cannabinoid is administered to the subject.

In some embodiments, the subject is a mammal.

In some embodiments, the subject is a rodent. In some embodiments, the subject is a lagomorph. In some embodiments, the subject is a feline. In some embodiments, the subject is a canine. In some embodiments, the subject is a porcine. In some embodiments, the subject is an ovine. In some embodiments, the subject is a caprine. In some embodiments, the subject is a vicugna. In some embodiments, the subject is a bovine. In some embodiments, the subject is an equine. In some embodiments, the subject is a primate.

In some embodiments, the subject is a human.

In some embodiments, the administering produces a Tmax, which is the time it takes to achieve a maximum blood concentration of the cannabinoid in the subject following the administering; and the Tmax is no greater than 30 minutes. In some embodiments, the Tmax is no greater than 25 minutes. In some embodiments, the Tmax is no greater than 20 minutes. In some embodiments, the Tmax is no greater than 15 minutes. In some embodiments, the Tmax is no greater than 10 minutes. In some embodiments, the Tmax is no greater than 5 minutes.

In some embodiments, an administered amount of the cannabinoid is administered to the subject during the administering; the subject has blood; a bioavailable amount of the cannabinoid enters the blood of the subject following the administering; the composition has an oral bioavailability, which is equal to the bioavailable amount divided by the administered amount; and the oral bioavailability is at least 5 percent. In some embodiments, the oral bioavailability is at least 10 percent. In some embodiments, the oral bioavailability is at least 15 percent. In some embodiments, the oral bioavailability is at least 20 percent. In some embodiments, the oral bioavailability is at least 25 percent. In some embodiments, the oral bioavailability is at least 30 percent. In some embodiments, the oral bioavailability is at least 35 percent. In some embodiments, the oral bioavailability is at least 40 percent. In some embodiments, the oral bioavailability is at least 45 percent. In some embodiments, the oral bioavailability is at least 50 percent.

Any of the features of the specification can be combined as grammar, mathematics, and logic allow, and specific combinations are set forth by the multiple dependency of the original claims. The fact that some combinations of features of the specification and/or original claims might create grammatical, mathematical, or logical inconsistencies (such as the combination of ingredients at percentages that sum to greater than 100 percent) shall not be used to discount other combinations of features of the specification and/or original claims that maintain grammatical, mathematical, and logical consistency.

Claims

1. A composition, comprising a liquid phase that consists of chemical species that comprise a solvent and solutes, wherein: each solute of the solutes is dissolved in the solvent of the liquid phase;each chemical species of the liquid phase has a concentration by mass in the liquid phase;the concentration by mass of the solvent in the liquid phase is greater than the concentration by mass of each solute of the liquid phase;the solvent is glycerol;the solutes comprise a cannabinoid;the liquid phase has a pressure and temperature;the cannabinoid has a solubility in glycerol at the pressure and temperature;the concentration by mass of the cannabinoid in the liquid phase is greater than the solubility of the cannabinoid in glycerol at the pressure and temperature;the composition is formulated for oral consumption; andthe composition comprises at least 0.1 and no greater than 6 food calories per gram of the composition.
2. The composition of claim 1, wherein the concentration of the cannabinoid in the liquid phase is at least 0.1 percent and no greater than 4 percent by mass.
3. The composition of claim 1, wherein the concentration of the glycerol in the liquid phase is at least 35 percent and no greater than greater 90 by mass.
4. The composition of claim 1, wherein the concentration of the cannabinoid in the liquid phase is at least 100 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature.
5. The composition of claim 1, wherein: the liquid phase comprises propylene glycol at a concentration of at least 5 percent and no greater than 20 percent by mass; andthe propylene glycol is a solute that is dissolved in the glycerol.
6. The composition of claim 1, wherein the liquid phase lacks propylene glycol.
7. The composition of claim 1, wherein: the liquid phase comprises ethanol at a concentration of at least 5 percent and no greater than 35 percent by mass; andthe ethanol is a solute that is dissolved in the glycerol.
8. The composition of claim 1, wherein the liquid phase lacks ethanol.
9. The composition of claim 1, wherein: the liquid phase comprises water at a concentration of at least 5 parts per million and no greater than 15 percent by mass; andthe water is a solute that is dissolved in the glycerol.
10. The composition of claim 1, wherein the liquid phase lacks water.
11. The composition of claim 1, wherein the cannabinoid is tetrahydrocannabinol.
12. The composition of claim 1, wherein: the liquid phase comprises the glycerol at a concentration of at least 45 percent and no greater than 65 percent by mass;the liquid phase comprises propylene glycol at a concentration of at least 5 percent and no greater than 20 percent by mass;the liquid phase comprises ethanol at a concentration of at least 5 percent and no greater than 35 percent by mass;the liquid phase comprises water at a concentration of at least of at least 5 parts per million and no greater than 15 percent by mass; andthe liquid phase comprises the cannabinoid at a concentration of at least 0.2 percent and no greater than 2 percent by mass.
13. The composition of claim 1, comprising a gas phase, wherein: the liquid phase is a dispersed phase;the gas phase is a dispersion medium;the liquid phase is suspended in the gas phase;the composition comprises at least 40 milligrams and no greater than 300 milligrams of the liquid phase;the composition comprises at least 0.16 and no greater than 1.8 food calories; andthe composition is a spray.
14. The composition of claim 13, comprising at least 0.48 and no greater than 2.1 milligrams of the cannabinoid.
15. The composition of claim 13, wherein the composition is an aerosol.
16. A container, comprising a chamber that contains the composition of claim 1, wherein: the liquid phase of the composition comprises at least 2 milligrams and no greater than 110 milligrams of the cannabinoid;the container is configured to dispense at least 3 and no greater than 110 metered portions of the liquid phase from the container;the metered portions have (a) an average mass of at least 40 milligrams and no greater than 300 milligrams of the liquid phase; (b) an average amount of food calories of at least 0.16 and no greater than 1.8 food calories; and (c) an average dose of the cannabinoid of at least 0.4 milligrams and no greater than 3 milligrams; andthe metered portions have (a) a standard deviation of no greater than 20 percent of the average mass of the liquid phase; (b) a standard deviation of no greater than 20 percent of the average amount of food calories; and (c) a standard deviation of no greater than 20 percent of the average dose of the cannabinoid.
17. The container of claim 16, wherein the container is configured to dispense a spray of the liquid phase.
18. A method to administer a cannabinoid to a subject, comprising providing the composition according to claim 1; and spraying a portion of the composition into the mouth of the subject.
19. The method of claim 18, wherein the administering produces a Tmax, which is the time it takes to achieve a maximum blood concentration of the cannabinoid in the subject following the administering; and the Tmax is no greater than 10 minutes.
20. The method of claim 18, wherein the portion of the composition comprises an administered amount of the cannabinoid; the subject has blood; a bioavailable amount of the cannabinoid enters the blood of the subject following the administering; the composition has an oral bioavailability, which is equal to the bioavailable amount divided by the administered amount; and the oral bioavailability is at least 25 percent.
21. The composition of any one of claim 1, wherein the concentration by mass of the cannabinoid in the liquid phase is at least 2 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature.
22. The composition of any one of claims 1 and 21, wherein the concentration by mass of the cannabinoid in the liquid phase is at least 4 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature.
23. The composition of any one of claims 1, 21, and 22, wherein the concentration by mass of the cannabinoid in the liquid phase is at least 8 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature.
24. The composition of any one of claims 1 and 21-23, wherein the concentration by mass of the cannabinoid in the liquid phase is at least 16 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature.
25. The composition of any one of claims 1 and 21-24, wherein the concentration by mass of the cannabinoid in the liquid phase is at least 32 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature.
26. The composition of any one of claims 1 and 21-25, wherein the concentration by mass of the cannabinoid in the liquid phase is at least 64 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature.
27. The composition of any one of claims 1 and 21-26, wherein the concentration by mass of the cannabinoid in the liquid phase is at least 128 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature.
28. The composition of any one of claims 1 and 21-27, wherein the concentration by mass of the cannabinoid in the liquid phase is at least 256 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature.
29. The composition of any one of claims 1 and 21-28, wherein the concentration by mass of the cannabinoid in the liquid phase is at least 512 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature.
30. The composition of any one of claims 1 and 21-29, wherein the concentration by mass of the cannabinoid in the liquid phase is at least 1024 times greater than the solubility of the cannabinoid in glycerol at the pressure and temperature.
31. The composition of any one of claims 1 and 21-30, wherein the composition comprises at least 0.2 food calories per gram of the composition.
32. The composition of any one of claims 1 and 21-31, wherein the composition comprises at least 0.4 food calories per gram of the composition.
33. The composition of any one of claims 1 and 21-32, wherein the composition comprises at least 0.6 food calories per gram of the composition.
34. The composition of any one of claims 1 and 21-33, wherein the composition comprises at least 0.8 food calories per gram of the composition.
35. The composition of any one of claims 1 and 21-34, wherein the composition comprises at least 1.0 food calories per gram of the composition.
36. The composition of any one of claims 1 and 21-35, wherein the composition comprises at least 1.2 food calories per gram of the composition.
37. The composition of any one of claims 1 and 21-36, wherein the composition comprises at least 1.4 food calories per gram of the composition.
38. The composition of any one of claims 1 and 21-37, wherein the composition comprises at least 1.6 food calories per gram of the composition.
39. The composition of any one of claims 1 and 21-38, wherein the composition comprises at least 1.8 food calories per gram of the composition.
40. The composition of any one of claims 1 and 21-39, wherein the composition comprises at least 2.0 food calories per gram of the composition.
41. The composition of any one of claims 1 and 21-40, wherein the composition comprises at least 2.2 food calories per gram of the composition.
42. The composition of any one of claims 1 and 21-41, wherein the composition comprises at least 2.4 food calories per gram of the composition.
43. The composition of any one of claims 1 and 21-42, wherein the composition comprises at least 2.6 food calories per gram of the composition.
44. The composition of any one of claims 1 and 21-43, wherein the composition comprises at least 2.8 food calories per gram of the composition.
45. The composition of any one of claims 1 and 21-44, wherein the composition comprises at least 3.0 food calories per gram of the composition.
46. The composition of any one of claims 1 and 21-45, wherein the composition comprises at least 3.2 food calories per gram of the composition.
47. The composition of any one of claims 1 and 21-46, wherein the composition comprises at least 3.4 food calories per gram of the composition.
48. The composition of any one of claims 1 and 21-47, wherein the composition comprises at least 3.6 food calories per gram of the composition.
49. The composition of any one of claims 1 and 21-48, wherein the composition comprises at least 3.8 food calories per gram of the composition.
50. The composition of any one of claims 1 and 21-49, wherein the composition comprises at least 4.0 food calories per gram of the composition.
51. The composition of any one of claims 1 and 21-50, wherein the composition comprises at least 4.2 food calories per gram of the composition.
52. The composition of any one of claims 1 and 21-51, wherein the composition comprises at least 4.4 food calories per gram of the composition.
53. The composition of any one of claims 1 and 21-52, wherein the composition comprises at least 4.6 food calories per gram of the composition.
54. The composition of any one of claims 1 and 21-53, wherein the composition comprises at least 4.8 food calories per gram of the composition.
55. The composition of any one of claims 1 and 21-54, wherein the composition comprises at least 5.0 food calories per gram of the composition.
56. The composition of any one of claims 1 and 21-55, wherein the composition comprises at least 5.2 food calories per gram of the composition.
57. The composition of any one of claims 1 and 21-56, wherein the composition comprises at least 5.4 food calories per gram of the composition.
58. The composition of any one of claims 1 and 21-57, wherein the composition comprises no greater than 5.8 food calories per gram of the composition.
59. The composition of any one of claims 1 and 21-58, wherein the composition comprises no greater than 5.6 food calories per gram of the composition.
60. The composition of any one of claims 1 and 21-56, wherein the composition comprises no greater than 5.4 food calories per gram of the composition.
61. The composition of any one of claims 1 and 21-55, wherein the composition comprises no greater than 5.2 food calories per gram of the composition.
62. The composition of any one of claims 1 and 21-54, wherein the composition comprises no greater than 5.0 food calories per gram of the composition.
63. The composition of any one of claims 1 and 21-53, wherein the composition comprises no greater than 4.8 food calories per gram of the composition.
64. The composition of any one of claims 1 and 21-52, wherein the composition comprises no greater than 4.6 food calories per gram of the composition.
65. The composition of any one of claims 1 and 21-51, wherein the composition comprises no greater than 4.4 food calories per gram of the composition.
66. The composition of any one of claims 1 and 21-50, wherein the composition comprises no greater than 4.2 food calories per gram of the composition.
67. The composition of any one of claims 1 and 21-49, wherein the composition comprises no greater than 4.0 food calories per gram of the composition.
68. The composition of any one of claims 1 and 21-48, wherein the composition comprises no greater than 3.8 food calories per gram of the composition.
69. The composition of any one of claims 1 and 21-68, wherein at least 30 percent of the food calories of the composition are derived from the glycerol.
70. The composition of any one of claims 1 and 21-69, wherein at least 35 percent of the food calories of the composition are derived from the glycerol.
71. The composition of any one of claims 1 and 21-70, wherein at least 40 percent of the food calories of the composition are derived from the glycerol.
72. The composition of any one of claims 1 and 21-71, wherein at least 45 percent of the food calories of the composition are derived from the glycerol.
73. The composition of any one of claims 1 and 21-72, wherein at least 50 percent of the food calories of the composition are derived from the glycerol.
74. The composition of any one of claims 1 and 21-73, wherein at least 55 percent of the food calories of the composition are derived from the glycerol.
75. The composition of any one of claims 1 and 21-74, wherein at least 60 percent of the food calories of the composition are derived from the glycerol.
76. The composition of any one of claims 1 and 21-75, wherein no greater than 65 percent of the food calories of the composition are derived from the glycerol.
77. The composition of any one of claims 1 and 21-74, wherein no greater than 60 percent of the food calories of the composition are derived from the glycerol.
78. The composition of any one of claims 1 and 21-73, wherein no greater than 55 percent of the food calories of the composition are derived from the glycerol.
79. The composition of any one of claims 1 and 21-72, wherein no greater than 50 percent of the food calories of the composition are derived from the glycerol.
80. The composition of any one of claims 1 and 21-71, wherein no greater than 45 percent of the food calories of the composition are derived from the glycerol.
81. The composition of any one of claims 1 and 21-70, wherein no greater than 40 percent of the food calories of the composition are derived from the glycerol.
82. The composition of any one of claims 1 and 21-69, wherein no greater than 35 percent of the food calories of the composition are derived from the glycerol.
83. The composition of any one of claims 1 and 21-82, wherein the concentration of the cannabinoid in the liquid phase is at least 0.1 percent by mass.
84. The composition of any one of claims 1 and 21-83, wherein the concentration of the cannabinoid in the liquid phase is at least 0.2 percent by mass.
85. The composition of any one of claims 1 and 21-84, wherein the concentration of the cannabinoid in the liquid phase is at least 0.4 percent by mass.
86. The composition of any one of claims 1 and 21-85, wherein the concentration of the cannabinoid in the liquid phase is at least 0.6 percent by mass.
87. The composition of any one of claims 1 and 21-86, wherein the concentration of the cannabinoid in the liquid phase is at least 0.8 percent by mass.
88. The composition of any one of claims 1 and 21-87, wherein the concentration of the cannabinoid in the liquid phase is at least 1.0 percent by mass.
89. The composition of any one of claims 1 and 21-88, wherein the concentration of the cannabinoid in the liquid phase is at least 1.2 percent by mass.
90. The composition of any one of claims 1 and 21-89, wherein the concentration of the cannabinoid in the liquid phase is at least 1.4 percent by mass.
91. The composition of any one of claims 1 and 21-90, wherein the concentration of the cannabinoid in the liquid phase is at least 1.6 percent by mass.
92. The composition of any one of claims 1 and 21-91, wherein the concentration of the cannabinoid in the liquid phase is at least 1.8 percent by mass.
93. The composition of any one of claims 1 and 21-92, wherein the concentration of the cannabinoid in the liquid phase is at least 2.0 percent by mass.
94. The composition of any one of claims 1 and 21-93, wherein the concentration of the cannabinoid in the liquid phase is no greater than 4.0 percent by mass.
95. The composition of any one of claims 1 and 21-94, wherein the concentration of the cannabinoid in the liquid phase is no greater than 3.8 percent by mass.
96. The composition of any one of claims 1 and 21-95, wherein the concentration of the cannabinoid in the liquid phase is no greater than 3.6 percent by mass.
97. The composition of any one of claims 1 and 21-96, wherein the concentration of the cannabinoid in the liquid phase is no greater than 3.4 percent by mass.
98. The composition of any one of claims 1 and 21-97, wherein the concentration of the cannabinoid in the liquid phase is no greater than 3.2 percent by mass.
99. The composition of any one of claims 1 and 21-98, wherein the concentration of the cannabinoid in the liquid phase is no greater than 3.0 percent by mass.
100. The composition of any one of claims 1 and 21-99, wherein the concentration of the cannabinoid in the liquid phase is no greater than 2.8 percent by mass.
101. The composition of any one of claims 1 and 21-100, wherein the concentration of the cannabinoid in the liquid phase is no greater than 2.6 percent by mass.
102. The composition of any one of claims 1 and 21-101, wherein the concentration of the cannabinoid in the liquid phase is no greater than 2.4 percent by mass.
103. The composition of any one of claims 1 and 21-102, wherein the concentration of the cannabinoid in the liquid phase is no greater than 2.2 percent by mass.
104. The composition of any one of claims 1 and 21-92, wherein the concentration of the cannabinoid in the liquid phase is no greater than 2.0 percent by mass.
105. The composition of any one of claims 1 and 21-91, wherein the concentration of the cannabinoid in the liquid phase is no greater than 1.8 percent by mass.
106. The composition of any one of claims 1 and 21-90, wherein the concentration of the cannabinoid in the liquid phase is no greater than 1.6 percent by mass.
107. The composition of any one of claims 1 and 21-89, wherein the concentration of the cannabinoid in the liquid phase is no greater than 1.4 percent by mass.
108. The composition of any one of claims 1 and 21-88, wherein the concentration of the cannabinoid in the liquid phase is no greater than 1.2 percent by mass.
109. The composition of any one of claims 1 and 21-87, wherein the concentration of the cannabinoid in the liquid phase is no greater than 1.0 percent by mass.
110. The composition of any one of claims 1 and 21-86, wherein the concentration of the cannabinoid in the liquid phase is no greater than 0.8 percent by mass.
111. The composition of any one of claims 1 and 21-110, wherein the concentration of the glycerol in the liquid phase is at least 35 percent by mass.
112. The composition of any one of claims 1 and 21-111, wherein the concentration of the glycerol in the liquid phase is at least 40 percent by mass.
113. The composition of any one of claims 1 and 21-112, wherein the concentration of the glycerol in the liquid phase is at least 45 percent by mass.
114. The composition of any one of claims 1 and 21-113, wherein the concentration of the glycerol in the liquid phase is at least 50 percent by mass.
115. The composition of any one of claims 1 and 21-114, wherein the concentration of the glycerol in the liquid phase is at least 55 percent by mass.
116. The composition of any one of claims 1 and 21-115, wherein the concentration of the glycerol in the liquid phase is at least 60 percent by mass.
117. The composition of any one of claims 1 and 21-116, wherein the concentration of the glycerol in the liquid phase is at least 65 percent by mass.
118. The composition of any one of claims 1 and 21-117, wherein the concentration of the glycerol in the liquid phase is at least 70 percent by mass.
119. The composition of any one of claims 1 and 21-118, wherein the concentration of the glycerol in the liquid phase is at least 75 percent by mass.
120. The composition of any one of claims 1 and 21-119, wherein the concentration of the glycerol in the liquid phase is at least 80 percent by mass.
121. The composition of any one of claims 1 and 21-120, wherein the concentration of the glycerol in the liquid phase is at least 85 percent by mass.
122. The composition of any one of claims 1 and 21-121, wherein the concentration of the glycerol in the liquid phase is at least 90 percent by mass.
123. The composition of any one of claims 1 and 21-122, wherein the concentration of the glycerol in the liquid phase is no greater than 95 percent by mass.
124. The composition of any one of claims 1 and 21-121, wherein the concentration of the glycerol in the liquid phase is no greater than 90 percent by mass.
125. The composition of any one of claims 1 and 21-120, wherein the concentration of the glycerol in the liquid phase is no greater than 85 percent by mass.
126. The composition of any one of claims 1 and 21-119, wherein the concentration of the glycerol in the liquid phase is no greater than 80 percent by mass.
127. The composition of any one of claims 1 and 21-118, wherein the concentration of the glycerol in the liquid phase is no greater than 75 percent by mass.
128. The composition of any one of claims 1 and 21-117, wherein the concentration of the glycerol in the liquid phase is no greater than 70 percent by mass.
129. The composition of any one of claims 1 and 21-116, wherein the concentration of the glycerol in the liquid phase is no greater than 65 percent by mass.
130. The composition of any one of claims 1 and 21-115, wherein the concentration of the glycerol in the liquid phase is no greater than 60 percent by mass.
131. The composition of any one of claims 1 and 21-114, wherein the concentration of the glycerol in the liquid phase is no greater than 55 percent by mass.
132. The composition of any one of claims 1 and 21-113, wherein the concentration of the glycerol in the liquid phase is no greater than 50 percent by mass.
133. The composition of any one of claims 1 and 21-112, wherein the concentration of the glycerol in the liquid phase is no greater than 45 percent by mass.
134. The composition of any one of claims 1 and 21-111, wherein the concentration of the glycerol in the liquid phase is no greater than 40 percent by mass.
135. The composition of any one of claims 1 and 21-134, wherein the solutes of the liquid phase comprise one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide, which are dissolved in the glycerol of the liquid phase.
136. The composition of claim 135, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 1,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
137. The composition of claim 135, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 5,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
138. The composition of claim 135, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 10,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
139. The composition of claim 135, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 50,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
140. The composition of claim 135, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 100,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
141. The composition of claim 135, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 500,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
142. The composition of claim 135, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 1,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
143. The composition of claim 135, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 5,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
144. The composition of claim 135, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 10,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
145. The composition of claim 135, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 50,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
146. The composition of claim 135, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 100,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
147. The composition of claim 135, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 500,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
148. The composition of claim 135, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 1,000,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
149. The composition of claim 135, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 5,000,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
150. The composition of claim 135, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of at least 10,000,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
151. The composition of any one of claims 135-150, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 1,000,000,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
152. The composition of any one of claims 135-151, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 500,000,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
153. The composition of any one of claims 135-152, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 100,000,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
154. The composition of any one of claims 135-153, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 50,000,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
155. The composition of any one of claims 135-149, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 10,000,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
156. The composition of any one of claims 135-148, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 5,000,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
157. The composition of any one of claims 135-147, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 1,000,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
158. The composition of any one of claims 135-146, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 500,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
159. The composition of any one of claims 135-145, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 100,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
160. The composition of any one of claims 135-144, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 50,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
161. The composition of any one of claims 135-143, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 10,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
162. The composition of any one of claims 135-142, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 5,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
163. The composition of any one of claims 135-141, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 1,000,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
164. The composition of any one of claims 135-140, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 500,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
165. The composition of any one of claims 135-139, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 100,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
166. The composition of any one of claims 135-138, wherein the liquid phase comprises the glycerol and the one or both of 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide at a molar ratio of no greater than 50,000:1 (glycerol: 1,3-dihydroxypropane-2-oxide and 2,3-dihydroxypropane-1-oxide).
167. The composition of any one of claims 1 and 21-166, wherein the solutes of the liquid phase comprise propylene glycol; and the propylene glycol is dissolved in the glycerol of the liquid phase.
168. The composition of claim 167, wherein the concentration of the propylene glycol in the liquid phase is at least 1 percent by mass.
169. The composition of claim 167, wherein the concentration of the propylene glycol in the liquid phase is at least 5 percent by mass.
170. The composition of claim 167, wherein the concentration of the propylene glycol in the liquid phase is at least 10 percent by mass.
171. The composition of claim 167, wherein the concentration of the propylene glycol in the liquid phase is at least 15 percent by mass.
172. The composition of claim 167, wherein the concentration of the propylene glycol in the liquid phase is at least 20 percent by mass.
173. The composition of claim 167, wherein the concentration of the propylene glycol in the liquid phase is at least 25 percent by mass.
174. The composition of claim 167, wherein the concentration of the propylene glycol in the liquid phase is at least 30 percent by mass.
175. The composition of claim 167, wherein the concentration of the propylene glycol in the liquid phase is at least 35 percent by mass.
176. The composition of any one of claims 167-175, wherein the concentration of the propylene glycol in the liquid phase is no greater than 40 percent by mass.
177. The composition of any one of claims 167-174, wherein the concentration of the propylene glycol in the liquid phase is no greater than 35 percent by mass.
178. The composition of any one of claims 167-173, wherein the concentration of the propylene glycol in the liquid phase is no greater than 30 percent by mass.
179. The composition of any one of claims 167-172, wherein the concentration of the propylene glycol in the liquid phase is no greater than 25 percent by mass.
180. The composition of any one of claims 167-171, wherein the concentration of the propylene glycol in the liquid phase is no greater than 20 percent by mass.
181. The composition of any one of claims 167-170, wherein the concentration of the propylene glycol in the liquid phase is no greater than 15 percent by mass.
182. The composition of any one of claims 167-169, wherein the concentration of the propylene glycol in the liquid phase is no greater than 10 percent by mass.
183. The composition of any one of claims 167-168, wherein the concentration of the propylene glycol in the liquid phase is no greater than 5 percent by mass.
184. The composition of any one of claims 1 and 21-167, wherein the liquid phase lacks propylene glycol at a concentration greater than 500 parts per million by mass.
185. The composition of any one of claims 1 and 21-167, wherein the liquid phase lacks propylene glycol at a concentration greater than 100 parts per million by mass.
186. The composition of any one of claims 1 and 21-167, wherein the liquid phase lacks propylene glycol at a concentration greater than 50 parts per million by mass.
187. The composition of any one of claims 1 and 21-167, wherein the liquid phase lacks propylene glycol at a concentration greater than 10 parts per million by mass.
188. The composition of any one of claims 1 and 21-167, wherein the liquid phase lacks propylene glycol at a concentration greater than 5 parts per million by mass.
189. The composition of any one of claims 1 and 21-167, wherein the liquid phase lacks propylene glycol at a concentration greater than 1 part per million by mass.
190. The composition of any one of claims 1 and 21-189, wherein the solutes of the liquid phase comprise one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide, which are dissolved in the glycerol of the liquid phase.
191. The composition of claim 190, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 1,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
192. The composition of claim 190, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 5,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
193. The composition of claim 190, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 10,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
194. The composition of claim 190, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 50,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
195. The composition of claim 190, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 100,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
196. The composition of claim 190, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 500,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
197. The composition of claim 190, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 1,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
198. The composition of claim 190, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 5,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
199. The composition of claim 190, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 10,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
200. The composition of claim 190, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 50,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
201. The composition of claim 190, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 100,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
202. The composition of claim 190, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 500,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
203. The composition of claim 190, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 1,000,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
204. The composition of claim 190, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 5,000,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
205. The composition of claim 190, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of at least 10,000,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
206. The composition of any one of claims 190-205, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 1,000,000,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
207. The composition of any one of claims 190-206, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 500,000,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
208. The composition of any one of claims 190-207, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 100,000,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
209. The composition of any one of claims 190-208, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 50,000,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
210. The composition of any one of claims 190-204, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 10,000,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
211. The composition of any one of claims 190-203, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 5,000,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
212. The composition of any one of claims 190-202, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 1,000,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
213. The composition of any one of claims 190-201, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 500,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
214. The composition of any one of claims 190-200, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 100,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
215. The composition of any one of claims 190-199, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 50,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
216. The composition of any one of claims 190-198, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 10,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
217. The composition of any one of claims 190-197, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 5,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
218. The composition of any one of claims 190-196, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 1,000,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
219. The composition of any one of claims 190-195, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 500,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
220. The composition of any one of claims 190-194, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 100,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
221. The composition of any one of claims 190-193, wherein the liquid phase comprises the propylene glycol and the one or both of 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide at a molar ratio of no greater than 50,000:1 (propylene glycol: 1-hydroxypropane-2-oxide and 2-hydroxypropane-1-oxide).
222. The composition of any one of claims 1 and 21-166, wherein the liquid phase lacks propylene glycol.
223. The composition of any one of claims 1 and 21-222, wherein the solutes of the liquid phase comprise ethanol; and the ethanol is dissolved in the glycerol of the liquid phase.
224. The composition of claim 223, wherein the concentration of the ethanol in the liquid phase is at least 1 percent by mass.
225. The composition of claim 223, wherein the concentration of the ethanol in the liquid phase is at least 5 percent by mass.
226. The composition of claim 223, wherein the concentration of the ethanol in the liquid phase is at least 10 percent by mass.
227. The composition of claim 223, wherein the concentration of the ethanol in the liquid phase is at least 15 percent by mass.
228. The composition of claim 223, wherein the concentration of the ethanol in the liquid phase is at least 20 percent by mass.
229. The composition of claim 223, wherein the concentration of the ethanol in the liquid phase is at least 25 percent by mass.
230. The composition of claim 223, wherein the concentration of the ethanol in the liquid phase is at least 30 percent by mass.
231. The composition of claim 223, wherein the concentration of the ethanol in the liquid phase is at least 35 percent by mass.
232. The composition of any one of claims 223-231, wherein the concentration of the ethanol in the liquid phase is no greater than 40 percent by mass.
233. The composition of any one of claims 223-230, wherein the concentration of the ethanol in the liquid phase is no greater than 35 percent by mass.
234. The composition of any one of claims 223-229, wherein the concentration of the ethanol in the liquid phase is no greater than 30 percent by mass.
235. The composition of any one of claims 223-228, wherein the concentration of the ethanol in the liquid phase is no greater than 25 percent by mass.
236. The composition of any one of claims 223-227, wherein the concentration of the ethanol in the liquid phase is no greater than 20 percent by mass.
237. The composition of any one of claims 223-226, wherein the concentration of the ethanol in the liquid phase is no greater than 15 percent by mass.
238. The composition of any one of claims 223-225, wherein the concentration of the ethanol in the liquid phase is no greater than 10 percent by mass.
239. The composition of any one of claims 223-224, wherein the concentration of the ethanol in the liquid phase is no greater than 5 percent by mass.
240. The composition of any one of claims 1 and 21-223, wherein the liquid phase lacks ethanol at a concentration greater than 500 parts per million by mass.
241. The composition of any one of claims 1 and 21-223, wherein the liquid phase lacks ethanol at a concentration greater than 100 parts per million by mass.
242. The composition of any one of claims 1 and 21-223, wherein the liquid phase lacks ethanol at a concentration greater than 50 parts per million by mass.
243. The composition of any one of claims 1 and 21-223, wherein the liquid phase lacks ethanol at a concentration greater than 10 parts per million by mass.
244. The composition of any one of claims 1 and 21-223, wherein the liquid phase lacks ethanol at a concentration greater than 5 parts per million by mass.
245. The composition of any one of claims 1 and 21-223, wherein the liquid phase lacks ethanol at a concentration greater than 1 part per million by mass.
246. The composition of any one of claims 1 and 21-245, wherein the solutes of the liquid phase comprise ethyl oxonium and ethoxide, which are dissolved in the glycerol of the liquid phase.
247. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:1,000,000.
248. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:500,000.
249. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:100,000.
250. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:50,000.
251. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:10,000.
252. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:5,000.
253. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:1,000.
254. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:500.
255. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:100.
256. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:50.
257. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:10.
258. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:5.
259. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1:1.
260. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 5:1.
261. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 10:1.
262. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 50:1.
263. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 100:1.
264. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 500:1.
265. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 1,000:1.
266. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 5,000:1.
267. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 10,000:1.
268. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 50,000:1.
269. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 100,000:1.
270. The composition of claim 246, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of at least 500,000:1.
271. The composition of any one of claims 246-270, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1,000,000:1.
272. The composition of any one of claims 246-269, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 500,000:1.
273. The composition of any one of claims 246-268, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 100,000:1.
274. The composition of any one of claims 246-267, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 50,000:1.
275. The composition of any one of claims 246-266, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 10,000:1.
276. The composition of any one of claims 246-265, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 5,000:1.
277. The composition of any one of claims 246-264, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1,000:1.
278. The composition of any one of claims 246-263, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 500:1.
279. The composition of any one of claims 246-262, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 100:1.
280. The composition of any one of claims 246-261, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 50:1.
281. The composition of any one of claims 246-260, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 10:1.
282. The composition of any one of claims 246-259, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 5:1.
283. The composition of any one of claims 246-258, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:1.
284. The composition of any one of claims 246-257, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:5.
285. The composition of any one of claims 246-256, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:10.
286. The composition of any one of claims 246-255, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:50.
287. The composition of any one of claims 246-254, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:100.
288. The composition of any one of claims 246-253, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:500.
289. The composition of any one of claims 246-252, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:1,000.
290. The composition of any one of claims 246-251, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:5,000.
291. The composition of any one of claims 246-250, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:10,000.
292. The composition of any one of claims 246-249, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:50,000.
293. The composition of any one of claims 246-248, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:100,000.
294. The composition of any one of claims 246-247, wherein the liquid phase comprises the ethyl oxonium and the ethoxide at a molar ratio of no greater than 1:500,000.
295. The composition of any one of claims 1 and 21-222, wherein the liquid phase lacks ethanol.
296. The composition of any one of claims 1 and 21-245, wherein the solutes of the liquid phase comprise water; and the water is dissolved in the glycerol of the liquid phase.
297. The composition of claim 296, wherein the concentration of the water in the liquid phase is at least 5 parts per million by mass.
298. The composition of claim 296, wherein the concentration of the water in the liquid phase is at least 10 parts per million by mass.
299. The composition of claim 296, wherein the concentration of the water in the liquid phase is at least 50 parts per million by mass.
300. The composition of claim 296, wherein the concentration of the water in the liquid phase is at least 100 parts per million by mass.
301. The composition of claim 296, wherein the concentration of the water in the liquid phase is at least 500 parts per million by mass.
302. The composition of claim 296, wherein the concentration of the water in the liquid phase is at least 0.1 percent by mass.
303. The composition of claim 296, wherein the concentration of the water in the liquid phase is at least 0.5 percent by mass.
304. The composition of claim 296, wherein the concentration of the water in the liquid phase is at least 1 percent by mass.
305. The composition of claim 296, wherein the concentration of the water in the liquid phase is at least 5 percent by mass.
306. The composition of claim 296, wherein the concentration of the water in the liquid phase is at least 10 percent by mass.
307. The composition of claim 296, wherein the concentration of the water in the liquid phase is at least 15 percent by mass.
308. The composition of claim 296, wherein the concentration of the water in the liquid phase is at least 20 percent by mass.
309. The composition of claim 296, wherein the concentration of the water in the liquid phase is at least 25 percent by mass.
310. The composition of claim 296, wherein the concentration of the water in the liquid phase is at least 30 percent by mass.
311. The composition of claim 296, wherein the concentration of the water in the liquid phase is at least 35 percent by mass.
312. The composition of any one of claims 296-311, wherein the concentration of the water in the liquid phase is no greater than 40 percent by mass.
313. The composition of any one of claims 296-310, wherein the concentration of the water in the liquid phase is no greater than 35 percent by mass.
314. The composition of any one of claims 296-309, wherein the concentration of the water in the liquid phase is no greater than 30 percent by mass.
315. The composition of any one of claims 296-308, wherein the concentration of the water in the liquid phase is no greater than 25 percent by mass.
316. The composition of any one of claims 296-307, wherein the concentration of the water in the liquid phase is no greater than 20 percent by mass.
317. The composition of any one of claims 296-306, wherein the concentration of the water in the liquid phase is no greater than 15 percent by mass.
318. The composition of any one of claims 296-305, wherein the concentration of the water in the liquid phase is no greater than 10 percent by mass.
319. The composition of any one of claims 296-304, wherein the concentration of the water in the liquid phase is no greater than 5 percent by mass.
320. The composition of any one of claims 1 and 21-296, wherein the liquid phase lacks water at a concentration greater than 1 percent by mass.
321. The composition of any one of claims 1 and 21-296, wherein the liquid phase lacks water at a concentration greater than 0.5 percent by mass.
322. The composition of any one of claims 1 and 21-296, wherein the liquid phase lacks water at a concentration greater than 0.1 percent by mass.
323. The composition of any one of claims 1 and 21-296, wherein the liquid phase lacks water at a concentration greater than 500 parts per million by mass.
324. The composition of any one of claims 1 and 21-296, wherein the liquid phase lacks water at a concentration greater than 100 parts per million by mass.
325. The composition of any one of claims 1 and 21-296, wherein the liquid phase lacks water at a concentration greater than 50 parts per million by mass.
326. The composition of any one of claims 1 and 21-296, wherein the liquid phase lacks water at a concentration greater than 10 parts per million by mass.
327. The composition of any one of claims 1 and 21-296, wherein the liquid phase lacks water at a concentration greater than 5 parts per million by mass.
328. The composition of any one of claims 1 and 21-296, wherein the liquid phase lacks water at a concentration greater than 1 part per million by mass.
329. The composition of any one of claims 1 and 21-328, wherein the solutes of the liquid phase comprise hydronium and hydroxide, which are dissolved in the glycerol of the liquid phase.
330. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:1,000,000.
331. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:500,000.
332. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:100,000.
333. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:50,000.
334. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:10,000.
335. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:5,000.
336. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:1,000.
337. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:500.
338. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:100.
339. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:50.
340. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:10.
341. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:5.
342. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1:1.
343. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 5:1.
344. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 10:1.
345. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 50:1.
346. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 100:1.
347. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 500:1.
348. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 1,000:1.
349. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 5,000:1.
350. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 10,000:1.
351. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 50,000:1.
352. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 100,000:1.
353. The composition of claim 329, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of at least 500,000:1.
354. The composition of any one of claims 329-353, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1,000,000:1.
355. The composition of any one of claims 329-352, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 500,000:1.
356. The composition of any one of claims 329-351, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 100,000:1.
357. The composition of any one of claims 329-350, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 50,000:1.
358. The composition of any one of claims 329-349, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 10,000:1.
359. The composition of any one of claims 329-348, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 5,000:1.
360. The composition of any one of claims 329-347, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1,000:1.
361. The composition of any one of claims 329-346, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 500:1.
362. The composition of any one of claims 329-345, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 100:1.
363. The composition of any one of claims 329-344, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 50:1.
364. The composition of any one of claims 329-343, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 10:1.
365. The composition of any one of claims 329-342, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 5:1.
366. The composition of any one of claims 329-341, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:1.
367. The composition of any one of claims 329-340, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:5.
368. The composition of any one of claims 329-339, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:10.
369. The composition of any one of claims 329-338, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:50.
370. The composition of any one of claims 329-337, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:100.
371. The composition of any one of claims 329-336, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:500.
372. The composition of any one of claims 329-335, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:1,000.
373. The composition of any one of claims 329-334, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:5,000.
374. The composition of any one of claims 329-333, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:10,000.
375. The composition of any one of claims 329-332, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:50,000.
376. The composition of any one of claims 329-331, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:100,000.
377. The composition of any one of claims 329-330, wherein the liquid phase comprises the hydronium and the hydroxide at a molar ratio of no greater than 1:500,000.
378. The composition of any one of claims 1 and 21-295, wherein the liquid phase lacks water.
379. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 5-alkyl-2-geranylbenzene-1,3-diol.
380. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 5-alkyl-2-(6-isopropenyl-3-methylcyclohex-2-enyl)benzene-1,3-diol.
381. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 5-alkyl-2-(6-isopropenyl-3-methylcyclohex-3-enyl)benzene-1,3-diol.
382. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 3-alkyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene-1-ol.
383. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 3-alkyl-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-1-ol.
384. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 3-alkyl-6,6,9-trimethyl-6H-benzo[c]chromene-1-ol.
385. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is (3-alkyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-yl)-O-acetate.
386. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is (3-alkyl-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-yl)-O-acetate.
387. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is (3-alkyl-6,6,9-trimethyl-6H-benzo[c]chromen-1-yl)-O-acetate.
388. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 3-alkyl-6,6-dimethyl-9-oxo-6,6a,7,8,10,10a-hexahydro-9H-benzo[c]chromene-1-ol.
389. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 3-alkyl-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene-1-ol.
390. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 3-alkyl-9-(hydroxymethyl)-6,6-dimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-1-ol.
391. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 7-alkyl-2-methyl-2-(4-methylpent-3-enyl)-2H-1-benzopyran-5-ol.
392. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 5-alkyl-2-geranyl-3-hydroxyphenolate.
393. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 5-alkyl-3-hydroxy-2-(6-isopropenyl-3-methylcyclohex-2-enyl)phenolate.
394. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 5-alkyl-3-hydroxy-2-(6-isopropenyl-3-methylcyclohex-3-enyl)phenolate.
395. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 3-alkyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene-1-oxide.
396. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 3-alkyl-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-1-oxide.
397. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 3-alkyl-6,6,9-trimethyl-6H-benzo[c]chromene-1-oxide.
398. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 3-alkyl-6,6-dimethyl-9-oxo-6,6a,7,8,10,10a-hexahydro-9H-benzo[c]chromene-1-oxide.
399. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 3-alkyl-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene-1-oxide.
400. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 3-alkyl-9-(hydroxymethyl)-6,6-dimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-1-oxide.
401. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 7-alkyl-2-methyl-2-(4-methylpent-3-enyl)-2H-1-benzopyran-5-oxide.
402. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 3-alkoxy-5-alkyl-2-geranylphenol.
403. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 1,3-dialkoxy-5-alkyl-2-geranylbenzene.
404. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 3-alkoxy-5-alkyl-2-(6-isopropenyl-3-methylcyclohex-2-enyl)phenol.
405. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 1,3-dialkoxy-5-alkyl-2-(6-isopropenyl-3-methylcyclohex-2-enyl)benzene.
406. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 3-alkoxy-5-alkyl-2-(6-isopropenyl-3-methylcyclohex-3-enyl)phenol.
407. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 1,3-dialkoxy-5-alkyl-2-(6-isopropenyl-3-methylcyclohex-3-enyl)phenol.
408. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 1-alkoxy-3-alkyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene.
409. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 1-alkoxy-3-alkyl-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene.
410. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 1-alkoxy-3-alkyl-6,6,9-trimethyl-6H-benzo[c]chromene.
411. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 1-alkoxy-3-alkyl-6,6-dimethyl-9-oxo-6,6a,7,8,10,10a-hexahydro-9H-benzo[c]chromene.
412. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 1-alkoxy-3-alkyl-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene.
413. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 1-alkoxy-3-alkyl-9-(hydroxymethyl)-6,6-dimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene.
414. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is 5-alkoxy-7-alkyl-2-methyl-2-(4-methylpent-3-enyl)-2H-1-benzopyran.
415. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is N-{3-oxo-3-[(3-alkoxy-5-alkyl-2-geranylphenyl)oxy]propyl}morpholinium.
416. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is N-{3-oxo-3-[(3-alkoxy-5-alkyl-2-geranylphenyl)oxy]propyl}morpholine.
417. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is N-(3-oxo-3-{[3-alkoxy-5-alkyl-2-(6-isopropenyl-3-methylcyclohex-2-enyl)phenyl]oxy}propyl)morpholinium.
418. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is N-(3-oxo-3-{[3-alkoxy-5-alkyl-2-(6-isopropenyl-3-methylcyclohex-2-enyl)phenyl]oxy}propyl)morpholine.
419. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is N-(3-oxo-3-{[3-alkoxy-5-alkyl-2-(6-isopropenyl-3-methylcyclohex-3-enyl)phenyl]oxy}propyl)morpholinium.
420. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is N-(3-oxo-3-{[3-alkoxy-5-alkyl-2-(6-isopropenyl-3-methylcyclohex-3-enyl)phenyl]oxy}propyl)morpholine.
421. The composition of any one of claims 402-420, wherein alkoxy is methoxy.
422. The composition of any one of claims 402-420, wherein alkoxy is ethoxy.
423. The composition of any one of claims 402-420, wherein alkoxy is 2-propoxy.
424. The composition of any one of claims 402-420, wherein alkoxy is acetyloxy.
425. The composition of any one of claims 379-424, wherein alkyl is methyl.
426. The composition of any one of claims 379-424, wherein alkyl is ethyl.
427. The composition of any one of claims 379-424, wherein alkyl is propyl.
428. The composition of any one of claims 379-424, wherein alkyl is butyl.
429. The composition of any one of claims 379-424, wherein alkyl is pentyl.
430. The composition of any one of claims 379-424, wherein alkyl is hexyl.
431. The composition of any one of claims 379-424, wherein alkyl is heptyl.
432. The composition of any one of claims 379-424, wherein alkyl is octyl.
433. The composition of any one of claims 379-424, wherein alkyl is nonyl.
434. The composition of any one of claims 379-424, wherein alkyl is decyl.
435. The composition of any one of claims 379-424, wherein alkyl is undecyl.
436. The composition of any one of claims 379-424, wherein alkyl is dodecyl.
437. The composition of any one of claims 379-424, wherein alkyl is prop-2-yl.
438. The composition of any one of claims 379-424, wherein alkyl is but-2-yl.
439. The composition of any one of claims 379-424, wherein alkyl is pent-2-yl.
440. The composition of any one of claims 379-424, wherein alkyl is hex-2-yl.
441. The composition of any one of claims 379-424, wherein alkyl is hept-2-yl.
442. The composition of any one of claims 379-424, wherein alkyl is octan-2-yl.
443. The composition of any one of claims 379-424, wherein alkyl is nonan-2-yl.
444. The composition of any one of claims 379-424, wherein alkyl is dec-2-yl.
445. The composition of any one of claims 379-424, wherein alkyl is undec-2-yl.
446. The composition of any one of claims 379-424, wherein alkyl is dodec-2-yl.
447. The composition of any one of claims 379-424, wherein alkyl is 2-methylpropyl.
448. The composition of any one of claims 379-424, wherein alkyl is 2-methylbutyl.
449. The composition of any one of claims 379-424, wherein alkyl is 2-methylpentyl.
450. The composition of any one of claims 379-424, wherein alkyl is 2-methylhexyl.
451. The composition of any one of claims 379-424, wherein alkyl is 2-methylheptyl.
452. The composition of any one of claims 379-424, wherein alkyl is 2-methyloctyl.
453. The composition of any one of claims 379-424, wherein alkyl is 2-methylnonyl.
454. The composition of any one of claims 379-424, wherein alkyl is 2-methyldecyl.
455. The composition of any one of claims 379-424, wherein alkyl is 2-methylundecyl.
456. The composition of any one of claims 379-424, wherein alkyl is 2-methylprop-2-yl.
457. The composition of any one of claims 379-424, wherein alkyl is 2-methylbut-2-yl.
458. The composition of any one of claims 379-424, wherein alkyl is 2-methylpent-2-yl.
459. The composition of any one of claims 379-424, wherein alkyl is 2-methylhex-2-yl.
460. The composition of any one of claims 379-424, wherein alkyl is 2-methylhept-2-yl.
461. The composition of any one of claims 379-424, wherein alkyl is 2-methyloct-2-yl.
462. The composition of any one of claims 379-424, wherein alkyl is 2-methylnonan-2-yl.
463. The composition of any one of claims 379-424, wherein alkyl is 2-methyldec-2-yl.
464. The composition of any one of claims 379-424, wherein alkyl is 2-methylundec-2-yl.
465. The composition of any one of claims 379-424, wherein alkyl is 3-methylbut-2-yl.
466. The composition of any one of claims 379-424, wherein alkyl is 3-methylpent-2-yl.
467. The composition of any one of claims 379-424, wherein alkyl is 3-methylhex-2-yl.
468. The composition of any one of claims 379-424, wherein alkyl is 3-methylhept-2-yl.
469. The composition of any one of claims 379-424, wherein alkyl is 3-methyloct-2-yl.
470. The composition of any one of claims 379-424, wherein alkyl is 3-methylnonan-2-yl.
471. The composition of any one of claims 379-424, wherein alkyl is 3-methyldec-2-yl.
472. The composition of any one of claims 379-424, wherein alkyl is 3-methylundec-2-yl.
473. The composition of any one of claims 379-424, wherein alkyl is 2,3-dimethylbut-2-yl.
474. The composition of any one of claims 379-424, wherein alkyl is 2,3-dimethylpent-2-yl.
475. The composition of any one of claims 379-424, wherein alkyl is 2,3-dimethylhex-2-yl.
476. The composition of any one of claims 379-424, wherein alkyl is 2,3-dimethylhept-2-yl.
477. The composition of any one of claims 379-424, wherein alkyl is 2,3-dimethyloct-2-yl.
478. The composition of any one of claims 379-424, wherein alkyl is 2,3-dimethylnonan-2-yl.
479. The composition of any one of claims 379-424, wherein alkyl is 2,3-dimethyldec-2-yl.
480. The composition of any one of claims 379-424, wherein alkyl is cyclopropyl.
481. The composition of any one of claims 379-424, wherein alkyl is 1-methylcyclopropyl.
482. The composition of any one of claims 379-424, wherein alkyl is 1-ethylcyclopropyl.
483. The composition of any one of claims 379-424, wherein alkyl is 1-propylcyclopropyl.
484. The composition of any one of claims 379-424, wherein alkyl is 1-butylcyclopropyl.
485. The composition of any one of claims 379-424, wherein alkyl is 1-pentylcyclopropyl.
486. The composition of any one of claims 379-424, wherein alkyl is 1-hexylcyclopropyl.
487. The composition of any one of claims 379-424, wherein alkyl is 1-heptylcyclopropyl.
488. The composition of any one of claims 379-424, wherein alkyl is 1-octylcyclopropyl.
489. The composition of any one of claims 379-424, wherein alkyl is 1-nonylcyclopropyl.
490. The composition of any one of claims 379-424, wherein alkyl is cyclobutyl.
491. The composition of any one of claims 379-424, wherein alkyl is 1-methylcyclobutyl.
492. The composition of any one of claims 379-424, wherein alkyl is 1-ethylcyclobutyl.
493. The composition of any one of claims 379-424, wherein alkyl is 1-propylcyclobutyl.
494. The composition of any one of claims 379-424, wherein alkyl is 1-butylcyclobutyl.
495. The composition of any one of claims 379-424, wherein alkyl is 1-pentylcyclobutyl.
496. The composition of any one of claims 379-424, wherein alkyl is 1-hexylcyclobutyl.
497. The composition of any one of claims 379-424, wherein alkyl is 1-heptylcyclobutyl.
498. The composition of any one of claims 379-424, wherein alkyl is 1-octylcyclobutyl.
499. The composition of any one of claims 379-424, wherein alkyl is cyclopentyl.
500. The composition of any one of claims 379-424, wherein alkyl is 1-methylcyclopentyl.
501. The composition of any one of claims 379-424, wherein alkyl is 1-ethylcyclopentyl.
502. The composition of any one of claims 379-424, wherein alkyl is 1-propylcyclopentyl.
503. The composition of any one of claims 379-424, wherein alkyl is 1-butylcyclopentyl.
504. The composition of any one of claims 379-424, wherein alkyl is 1-pentylcyclopentyl.
505. The composition of any one of claims 379-424, wherein alkyl is 1-hexylcyclopentyl.
506. The composition of any one of claims 379-424, wherein alkyl is 1-heptylcyclopentyl.
507. The composition of any one of claims 379-424, wherein alkyl is cyclohexyl.
508. The composition of any one of claims 379-424, wherein alkyl is 1-methylcyclohexyl.
509. The composition of any one of claims 379-424, wherein alkyl is 1-ethylcyclohexyl.
510. The composition of any one of claims 379-424, wherein alkyl is 1-propylcyclohexyl.
511. The composition of any one of claims 379-424, wherein alkyl is 1-butylcyclohexyl.
512. The composition of any one of claims 379-424, wherein alkyl is 1-pentylcyclohexyl.
513. The composition of any one of claims 379-424, wherein alkyl is 1-hexylcyclohexyl.
514. The composition of any one of claims 379-424, wherein alkyl is ethenyl.
515. The composition of any one of claims 379-424, wherein alkyl is prop-1-enyl.
516. The composition of any one of claims 379-424, wherein alkyl is but-1-enyl.
517. The composition of any one of claims 379-424, wherein alkyl is pent-1-enyl.
518. The composition of any one of claims 379-424, wherein alkyl is hex-1-enyl.
519. The composition of any one of claims 379-424, wherein alkyl is hept-1-enyl.
520. The composition of any one of claims 379-424, wherein alkyl is oct-1-enyl.
521. The composition of any one of claims 379-424, wherein alkyl is nonan-1-enyl.
522. The composition of any one of claims 379-424, wherein alkyl is dec-1-enyl.
523. The composition of any one of claims 379-424, wherein alkyl is undec-1-enyl.
524. The composition of any one of claims 379-424, wherein alkyl is dodec-1-enyl.
525. The composition of any one of claims 379-424, wherein alkyl is ethynyl.
526. The composition of any one of claims 379-424, wherein alkyl is prop-1-ynyl.
527. The composition of any one of claims 379-424, wherein alkyl is but-1-ynyl.
528. The composition of any one of claims 379-424, wherein alkyl is pent-1-ynyl.
529. The composition of any one of claims 379-424, wherein alkyl is hex-1-ynyl.
530. The composition of any one of claims 379-424, wherein alkyl is hept-1-ynyl.
531. The composition of any one of claims 379-424, wherein alkyl is oct-1-ynyl.
532. The composition of any one of claims 379-424, wherein alkyl is nonan-1-ynyl.
533. The composition of any one of claims 379-424, wherein alkyl is dec-1-ynyl.
534. The composition of any one of claims 379-424, wherein alkyl is undec-1-ynyl.
535. The composition of any one of claims 379-424, wherein alkyl is dodec-1-ynyl.
536. The composition of any one of claims 379-424, wherein alkyl is 2-phenylethyl.
537. The composition of any one of claims 379-424, wherein alkyl is 2-phenylprop-2-yl.
538. The composition of any one of claims 379-424, wherein alkyl is adamant-1-yl.
539. The composition of any one of claims 379-424, wherein alkyl is adamant-2-yl.
540. The composition of any one of claims 379-424, wherein alkyl is 6-fluorohex-2-enyl.
541. The composition of any one of claims 379-424, wherein alkyl is 6-fluorohex-2-ynyl.
542. The composition of any one of claims 379-424, wherein alkyl is 2-methyl-6-fluorohex-2-yl.
543. The composition of any one of claims 379-424, wherein alkyl is 6-chlorohex-2-enyl.
544. The composition of any one of claims 379-424, wherein alkyl is 6-chlorohex-2-ynyl.
545. The composition of any one of claims 379-424, wherein alkyl is 2-methyl-6-chlorohex-2-yl.
546. The composition of any one of claims 379-424, wherein alkyl is 6-bromohex-2-enyl.
547. The composition of any one of claims 379-424, wherein alkyl is 6-bromohex-2-ynyl.
548. The composition of any one of claims 379-424, wherein alkyl is 2-methyl-6-bromohex-2-yl.
549. The composition of any one of claims 379-424, wherein alkyl is 6-iodohex-2-enyl.
550. The composition of any one of claims 379-424, wherein alkyl is 6-iodohex-2-ynyl.
551. The composition of any one of claims 379-424, wherein alkyl is 2-methyl-6-iodohex-2-yl.
552. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is cannabidiol.
553. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is tetrahydrocannabinol.
554. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is delta8-tetrahydrocannabinol.
555. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is cannabigerol.
556. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is cannabidivarin.
557. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is tetrahydrocannabivarin.
558. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is delta8-tetrahydrocannabivarin.
559. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is cannabigerovarin.
560. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is cannabichromene.
561. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is cannabinol.
562. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is cannabivarin.
563. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is tetrahydrocannabiphorol.
564. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is perrottetinene.
565. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is nabilone.
566. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is parahexyl.
567. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is HUM-217.
568. The composition of any one of claims 1-10 and 21-378, wherein the cannabinoid is HU-331.
569. A composition, comprising a liquid phase that comprises a cannabinoid
570. The composition of any one of claims 1-15 and 21-569, wherein the liquid phase comprises no greater than 2.0 food calories per milligram of the cannabinoid.
571. The composition of any one of claims 1-15 and 21-570, wherein the liquid phase comprises no greater than 1.9 food calories per milligram of the cannabinoid.
572. The composition of any one of claims 1-15 and 21-571, wherein the liquid phase comprises no greater than 1.8 food calories per milligram of the cannabinoid.
573. The composition of any one of claims 1-15 and 21-572, wherein the liquid phase comprises no greater than 1.7 food calories per milligram of the cannabinoid.
574. The composition of any one of claims 1-15 and 21-573, wherein the liquid phase comprises no greater than 1.6 food calories per milligram of the cannabinoid.
575. The composition of any one of claims 1-15 and 21-574, wherein the liquid phase comprises no greater than 1.5 food calories per milligram of the cannabinoid.
576. The composition of any one of claims 1-15 and 21-575, wherein the liquid phase comprises no greater than 1.4 food calories per milligram of the cannabinoid.
577. The composition of any one of claims 1-15 and 21-576, wherein the liquid phase comprises no greater than 1.3 food calories per milligram of the cannabinoid.
578. The composition of any one of claims 1-15 and 21-577, wherein the liquid phase comprises no greater than 1.2 food calories per milligram of the cannabinoid.
579. The composition of any one of claims 1-15 and 21-578, wherein the liquid phase comprises no greater than 1.1 food calories per milligram of the cannabinoid.
580. The composition of any one of claims 1-15 and 21-579, wherein the liquid phase comprises no greater than 1.0 food calories per milligram of the cannabinoid.
581. The composition of any one of claims 1-15 and 21-580, wherein the liquid phase comprises no greater than 0.9 food calories per milligram of the cannabinoid.
582. The composition of any one of claims 1-15 and 21-581, wherein the liquid phase comprises no greater than 0.8 food calories per milligram of the cannabinoid.
583. The composition of any one of claims 1-15 and 21-582, wherein the liquid phase comprises no greater than 0.7 food calories per milligram of the cannabinoid.
584. The composition of any one of claims 1-15 and 21-583, wherein the liquid phase comprises no greater than 0.6 food calories per milligram of the cannabinoid.
585. The composition of any one of claims 1-15 and 21-584, wherein the liquid phase comprises no greater than 0.5 food calories per milligram of the cannabinoid.
586. The composition of any one of claims 1-15 and 21-585, wherein the liquid phase comprises no greater than 0.4 food calories per milligram of the cannabinoid.
587. The composition of any one of claims 1-15 and 21-586, wherein the liquid phase comprises no greater than 0.3 food calories per milligram of the cannabinoid.
588. The composition of any one of claims 1-15 and 21-587, wherein the liquid phase comprises no greater than 0.2 food calories per milligram of the cannabinoid.
589. The composition of any one of claims 1-15 and 21-588, wherein the liquid phase comprises at least 0.1 food calories per milligram of the cannabinoid.
590. The composition of any one of claims 1-15 and 21-587, wherein the liquid phase comprises at least 0.2 food calories per milligram of the cannabinoid.
591. The composition of any one of claims 1-15 and 21-586, wherein the liquid phase comprises at least 0.3 food calories per milligram of the cannabinoid.
592. The composition of any one of claims 1-15 and 21-585, wherein the liquid phase comprises at least 0.4 food calories per milligram of the cannabinoid.
593. The composition of any one of claims 1-15 and 21-584, wherein the liquid phase comprises at least 0.5 food calories per milligram of the cannabinoid.
594. The composition of any one of claims 1-15 and 21-583, wherein the liquid phase comprises at least 0.6 food calories per milligram of the cannabinoid.
595. The composition of any one of claims 1-15 and 21-582, wherein the liquid phase comprises at least 0.7 food calories per milligram of the cannabinoid.
596. The composition of any one of claims 1-15 and 21-581, wherein the liquid phase comprises at least 0.8 food calories per milligram of the cannabinoid.
597. The composition of any one of claims 1-12 and 21-596, wherein the composition comprises at least 10 milligrams of the liquid phase.
598. The composition of any one of claims 1-12 and 21-597, wherein the composition comprises at least 20 milligrams of the liquid phase.
599. The composition of any one of claims 1-12 and 21-598, wherein the composition comprises at least 40 milligrams of the liquid phase.
600. The composition of any one of claims 1-12 and 21-599, wherein the composition comprises at least 60 milligrams of the liquid phase.
601. The composition of any one of claims 1-12 and 21-600, wherein the composition comprises at least 80 milligrams of the liquid phase.
602. The composition of any one of claims 1-12 and 21-601, wherein the composition comprises at least 100 milligrams of the liquid phase.
603. The composition of any one of claims 1-12 and 21-602, wherein the composition comprises at least 120 milligrams of the liquid phase.
604. The composition of any one of claims 1-12 and 21-603, wherein the composition comprises at least 140 milligrams of the liquid phase.
605. The composition of any one of claims 1-12 and 21-604, wherein the composition comprises at least 160 milligrams of the liquid phase.
606. The composition of any one of claims 1-12 and 21-605, wherein the composition comprises at least 180 milligrams of the liquid phase.
607. The composition of any one of claims 1-12 and 21-606, wherein the composition comprises no greater than 300 milligrams of the liquid phase.
608. The composition of any one of claims 1-12 and 21-607, wherein the composition comprises no greater than 280 milligrams of the liquid phase.
609. The composition of any one of claims 1-12 and 21-608, wherein the composition comprises no greater than 260 milligrams of the liquid phase.
610. The composition of any one of claims 1-12 and 21-609, wherein the composition comprises no greater than 240 milligrams of the liquid phase.
611. The composition of any one of claims 1-12 and 21-610, wherein the composition comprises no greater than 220 milligrams of the liquid phase.
612. The composition of any one of claims 1-12 and 21-611, wherein the composition comprises no greater than 200 milligrams of the liquid phase.
613. The composition of any one of claims 1-12 and 21-605, wherein the composition comprises no greater than 180 milligrams of the liquid phase.
614. The composition of any one of claims 1-12 and 21-604, wherein the composition comprises no greater than 160 milligrams of the liquid phase.
615. The composition of any one of claims 1-12 and 21-603, wherein the composition comprises no greater than 140 milligrams of the liquid phase.
616. The composition of any one of claims 1-12 and 21-602, wherein the composition comprises no greater than 120 milligrams of the liquid phase.
617. The composition of any one of claims 1-12 and 21-616, wherein the composition comprises at least 0.12 food calories.
618. The composition of any one of claims 1-12 and 21-617, wherein the composition comprises at least 0.16 food calories.
619. The composition of any one of claims 1-12 and 21-618, wherein the composition comprises at least 0.20 food calories.
620. The composition of any one of claims 1-12 and 21-619, wherein the composition comprises at least 0.24 food calories.
621. The composition of any one of claims 1-12 and 21-620, wherein the composition comprises at least 0.28 food calories.
622. The composition of any one of claims 1-12 and 21-621, wherein the composition comprises at least 0.32 food calories.
623. The composition of any one of claims 1-12 and 21-622, wherein the composition comprises at least 0.36 food calories.
624. The composition of any one of claims 1-12 and 21-623, wherein the composition comprises at least 0.40 food calories.
625. The composition of any one of claims 1-12 and 21-624, wherein the composition comprises at least 0.44 food calories.
626. The composition of any one of claims 1-12 and 21-625, wherein the composition comprises at least 0.48 food calories.
627. The composition of any one of claims 1-12 and 21-626, wherein the composition comprises at least 0.52 food calories.
628. The composition of any one of claims 1-12 and 21-627, wherein the composition comprises at least 0.56 food calories.
629. The composition of any one of claims 1-12 and 21-628, wherein the composition comprises at least 0.60 food calories.
630. The composition of any one of claims 1-12 and 21-629, wherein the composition comprises at least 0.64 food calories.
631. The composition of any one of claims 1-12 and 21-630, wherein the composition comprises at least 0.68 food calories.
632. The composition of any one of claims 1-12 and 21-631, wherein the composition comprises at least 0.72 food calories.
633. The composition of any one of claims 1-12 and 21-632, wherein the composition comprises at least 0.76 food calories.
634. The composition of any one of claims 1-12 and 21-633, wherein the composition comprises at least 0.80 food calories.
635. The composition of any one of claims 1-12 and 21-634, wherein the composition comprises at least 0.84 food calories.
636. The composition of any one of claims 1-12 and 21-635, wherein the composition comprises no greater than 2.00 food calories.
637. The composition of any one of claims 1-12 and 21-636, wherein the composition comprises no greater than 1.90 food calories.
638. The composition of any one of claims 1-12 and 21-637, wherein the composition comprises no greater than 1.80 food calories.
639. The composition of any one of claims 1-12 and 21-638, wherein the composition comprises no greater than 1.70 food calories.
640. The composition of any one of claims 1-12 and 21-639, wherein the composition comprises no greater than 1.60 food calories.
641. The composition of any one of claims 1-12 and 21-640, wherein the composition comprises no greater than 1.50 food calories.
642. The composition of any one of claims 1-12 and 21-641, wherein the composition comprises no greater than 1.40 food calories.
643. The composition of any one of claims 1-12 and 21-642, wherein the composition comprises no greater than 1.30 food calories.
644. The composition of any one of claims 1-12 and 21-643, wherein the composition comprises no greater than 1.20 food calories.
645. The composition of any one of claims 1-12 and 21-644, wherein the composition comprises no greater than 1.10 food calories.
646. The composition of any one of claims 1-12 and 21-645, wherein the composition comprises no greater than 1.00 food calories.
647. The composition of any one of claims 1-12 and 21-646, wherein the composition comprises no greater than 0.90 food calories.
648. The composition of any one of claims 1-12 and 21-647, wherein the composition comprises no greater than 0.86 food calories.
649. The composition of any one of claims 1-12 and 21-634, wherein the composition comprises no greater than 0.82 food calories.
650. The composition of any one of claims 1-12 and 21-633, wherein the composition comprises no greater than 0.78 food calories.
651. The composition of any one of claims 1-12 and 21-632, wherein the composition comprises no greater than 0.74 food calories.
652. The composition of any one of claims 1-12 and 21-631, wherein the composition comprises no greater than 0.70 food calories.
653. The composition of any one of claims 1-12 and 21-630, wherein the composition comprises no greater than 0.66 food calories.
654. The composition of any one of claims 1-12 and 21-629, wherein the composition comprises no greater than 0.62 food calories.
655. The composition of any one of claims 1-12 and 21-654, wherein the composition comprises at least 1 microgram of the cannabinoid.
656. The composition of any one of claims 1-12 and 21-655, wherein the composition comprises at least 2 micrograms of the cannabinoid.
657. The composition of any one of claims 1-12 and 21-656, wherein the composition comprises at least 4 micrograms of the cannabinoid.
658. The composition of any one of claims 1-12 and 21-657, wherein the composition comprises at least 8 micrograms of the cannabinoid.
659. The composition of any one of claims 1-12 and 21-658, wherein the composition comprises at least 16 micrograms of the cannabinoid.
660. The composition of any one of claims 1-12 and 21-659, wherein the composition comprises at least 32 micrograms of the cannabinoid.
661. The composition of any one of claims 1-12 and 21-660, wherein the composition comprises at least 64 micrograms of the cannabinoid.
662. The composition of any one of claims 1-12 and 21-661, wherein the composition comprises at least 128 micrograms of the cannabinoid.
663. The composition of any one of claims 1-12 and 21-662, wherein the composition comprises at least 256 micrograms of the cannabinoid.
664. The composition of any one of claims 1-12 and 21-663, wherein the composition comprises at least 0.48 milligrams of the cannabinoid.
665. The composition of any one of claims 1-12 and 21-664, wherein the composition comprises at least 0.6 milligrams of the cannabinoid.
666. The composition of any one of claims 1-12 and 21-665, wherein the composition comprises at least 0.7 milligrams of the cannabinoid.
667. The composition of any one of claims 1-12 and 21-666, wherein the composition comprises at least 0.8 milligrams of the cannabinoid.
668. The composition of any one of claims 1-12 and 21-667, wherein the composition comprises at least 0.9 milligrams of the cannabinoid.
669. The composition of any one of claims 1-12 and 21-668, wherein the composition comprises no greater than 2.1 milligrams of the cannabinoid.
670. The composition of any one of claims 1-12 and 21-669, wherein the composition comprises no greater than 2.0 milligrams of the cannabinoid.
671. The composition of any one of claims 1-12 and 21-670, wherein the composition comprises no greater than 1.9 milligrams of the cannabinoid.
672. The composition of any one of claims 1-12 and 21-671, wherein the composition comprises no greater than 1.8 milligrams of the cannabinoid.
673. The composition of any one of claims 1-12 and 21-672, wherein the composition comprises no greater than 1.7 milligrams of the cannabinoid.
674. The composition of any one of claims 1-12 and 21-673, wherein the composition comprises no greater than 1.6 milligrams of the cannabinoid.
675. The composition of any one of claims 1-12 and 21-674, wherein the composition comprises no greater than 1.5 milligrams of the cannabinoid.
676. The composition of any one of claims 1-12 and 21-675, wherein the composition comprises no greater than 1.4 milligrams of the cannabinoid.
677. The composition of any one of claims 1-12 and 21-676, wherein the composition comprises no greater than 1.3 milligrams of the cannabinoid.
678. The composition of any one of claims 1-12 and 21-677, wherein the composition comprises no greater than 1.2 milligrams of the cannabinoid.
679. The composition of any one of claims 1-12 and 21-678, wherein the composition comprises no greater than 1.1 milligrams of the cannabinoid.
680. The composition of any one of claims 1-12 and 21-679, wherein the composition is a spray.
681. The composition of any one of claims 1-12 and 21-680, wherein the composition is an aerosol.
682. The composition of any one of claims 1-12 and 21-681, wherein the composition is an aerosol spray.
683. The composition of any one of claims 1-12 and 21-682, comprising a gas phase, wherein the liquid phase is a dispersed phase; the gas phase is a dispersion medium; and the liquid phase is suspended in the gas phase.
684. The composition of claim 683, wherein the gas phase comprises air.
685. The composition of claim 683 or 684, wherein the gas phase consists essentially of air.
686. The composition of any one of claim 683 or 684, wherein the gas phase comprises a propellant.
687. The composition of claim 686, wherein the gas phase consists essentially of the propellant.
688. The composition of claim 686 or 687, wherein the propellant is nitrous oxide.
689. The composition of claim 686 or 687, wherein the propellant is carbon dioxide.
690. The composition of claim 686 or 687, wherein the propellant is 1,1,1,2-tetrafluorethane.
691. The composition of claim 686 or 687, wherein the propellant is 1,1,1,2,3,3,3-heptafluoropropane.
692. The composition of claim 686 or 687, wherein the propellant is hydrofluoroolefin.
693. The composition of claim 686 or 687, wherein the propellant is dimethyl ether.
694. The composition of claim 686 or 687, wherein the propellant is methyl ethyl ether.
695. A container, configured to dispense a composition according to any one of claims 1-15 and 21-694.
696. A container, comprising a chamber that contains a composition according to any one of claims 1-12 and 21-679.
697. The container of claim 695 or 696, wherein the liquid phase comprises at least 10 micrograms of the cannabinoid.
698. The container of any one of claims 695-697, wherein the liquid phase comprises at least 20 micrograms of the cannabinoid.
699. The container of any one of claims 695-698, wherein the liquid phase comprises at least 40 micrograms of the cannabinoid.
700. The container of any one of claims 695-699, wherein the liquid phase comprises at least 80 micrograms of the cannabinoid.
701. The container of any one of claims 695-700, wherein the liquid phase comprises at least 160 micrograms of the cannabinoid.
702. The container of any one of claims 695-701, wherein the liquid phase comprises at least 320 micrograms of the cannabinoid.
703. The container of any one of claims 695-702, wherein the liquid phase comprises at least 640 micrograms of the cannabinoid.
704. The container of any one of claims 695-703, wherein the liquid phase comprises at least 1 milligram of the cannabinoid
705. The container of any one of claims 695-704, wherein the liquid phase comprises at least 2 milligrams of the cannabinoid.
706. The container of any one of claims 695-705, wherein the liquid phase comprises at least 4 milligrams of the cannabinoid.
707. The container of any one of claims 695-706, wherein the liquid phase comprises at least 8 milligrams of the cannabinoid.
708. The container of any one of claims 695-707, wherein the liquid phase comprises at least 16 milligrams of the cannabinoid.
709. The container of any one of claims 695-708, wherein the liquid phase comprises at least 32 milligrams of the cannabinoid.
710. The container of any one of claims 695-709, wherein the liquid phase comprises at least 64 milligrams of the cannabinoid.
711. The container of any one of claims 695-710, wherein the liquid phase comprises at least 80 milligrams of the cannabinoid.
712. The container of any one of claims 695-711, wherein the liquid phase comprises at least 90 milligrams of the cannabinoid.
713. The container of any one of claims 695-712, wherein the liquid phase comprises at least 99 milligrams of the cannabinoid.
714. The container of any one of claims 695-713, wherein the liquid phase comprises no greater than 120 milligrams of the cannabinoid.
715. The container of any one of claims 695-714, wherein the liquid phase comprises no greater than 110 milligrams of the cannabinoid.
716. The container of any one of claims 695-715, wherein the liquid phase comprises no greater than 101 milligrams of the cannabinoid.
717. The container of any one of claims 695-711, wherein the liquid phase comprises no greater than 90 milligrams of the cannabinoid.
718. The container of any one of claims 695-710, wherein the liquid phase comprises no greater than 80 milligrams of the cannabinoid.
719. The container of any one of claims 695-709, wherein the liquid phase comprises no greater than 64 milligrams of the cannabinoid.
720. The container of any one of claims 695-708, wherein the liquid phase comprises no greater than 32 milligrams of the cannabinoid.
721. The container of any one of claims 695-707, wherein the liquid phase comprises no greater than 16 milligrams of the cannabinoid.
722. The container of any one of claims 695-706, wherein the liquid phase comprises no greater than 8 milligrams of the cannabinoid.
723. The container of any one of claims 695-705, wherein the liquid phase comprises no greater than 4 milligrams of the cannabinoid.
724. The container of any one of claims 695-704, wherein the liquid phase comprises no greater than 2 milligrams of the cannabinoid.
725. The container of any one of claims 695-703, wherein the liquid phase comprises no greater than 1 milligram of the cannabinoid.
726. The container of any one of claims 695-725, wherein the container is configured to dispense at least 1 metered portion of the composition.
727. The container of any one of claims 695-726, wherein the container is configured to dispense at least 2 metered portions of the composition.
728. The container of any one of claims 695-727, wherein the container is configured to dispense at least 3 metered portions of the composition.
729. The container of any one of claims 695-728, wherein the container is configured to dispense at least 4 metered portions of the composition.
730. The container of any one of claims 695-729, wherein the container is configured to dispense at least 6 metered portions of the composition.
731. The container of any one of claims 695-730, wherein the container is configured to dispense at least 8 metered portions of the composition.
732. The container of any one of claims 695-731, wherein the container is configured to dispense at least 12 metered portions of the composition.
733. The container of any one of claims 695-732, wherein the container is configured to dispense at least 16 metered portions of the composition.
734. The container of any one of claims 695-733, wherein the container is configured to dispense at least 24 metered portions of the composition.
735. The container of any one of claims 695-734, wherein the container is configured to dispense at least 32 metered portions of the composition.
736. The container of any one of claims 695-735, wherein the container is configured to dispense at least 48 metered portions of the composition.
737. The container of any one of claims 695-736, wherein the container is configured to dispense at least 64 metered portions of the composition.
738. The container of any one of claims 695-737, wherein the container is configured to dispense at least 96 metered portions of the composition.
739. The container of any one of claims 695-738, wherein the container is configured to dispense no greater than 110 metered portions of the composition.
740. The container of any one of claims 695-737, wherein the container is configured to dispense no greater than 96 metered portions of the composition.
741. The container of any one of claims 695-736, wherein the container is configured to dispense no greater than 48 metered portions of the composition.
742. The container of any one of claims 695-735, wherein the container is configured to dispense no greater than 24 metered portions of the composition.
743. The container of any one of claims 695-734, wherein the container is configured to dispense no greater than 12 metered portions of the composition.
744. The container of any one of claims 726-743, wherein the metered portions have an average mass of at least 10 milligrams of the liquid phase.
745. The container of any one of claims 726-744, wherein the metered portions have an average mass of at least 20 milligrams of the liquid phase.
746. The container of any one of claims 726-745, wherein the metered portions have an average mass of at least 40 milligrams of the liquid phase.
747. The container of any one of claims 726-746, wherein the metered portions have an average mass of at least 60 milligrams of the liquid phase.
748. The container of any one of claims 726-747, wherein the metered portions have an average mass of at least 80 milligrams of the liquid phase.
749. The container of any one of claims 726-748, wherein the metered portions have an average mass of at least 100 milligrams of the liquid phase.
750. The container of any one of claims 726-749, wherein the metered portions have an average mass of at least 120 milligrams of the liquid phase.
751. The container of any one of claims 726-750, wherein the metered portions have an average mass of at least 140 milligrams of the liquid phase.
752. The container of any one of claims 726-751, wherein the metered portions have an average mass of at least 160 milligrams of the liquid phase.
753. The container of any one of claims 726-752, wherein the metered portions have an average mass of at least 180 milligrams of the liquid phase.
754. The container of any one of claims 726-753, wherein the metered portions have an average mass of no greater than 300 milligrams of the liquid phase.
755. The container of any one of claims 726-754, wherein the metered portions have an average mass of no greater than 280 milligrams of the liquid phase.
756. The container of any one of claims 726-755, wherein the metered portions have an average mass of no greater than 260 milligrams of the liquid phase.
757. The container of any one of claims 726-756, wherein the metered portions have an average mass of no greater than 240 milligrams of the liquid phase.
758. The container of any one of claims 726-757, wherein the metered portions have an average mass of no greater than 220 milligrams of the liquid phase.
759. The container of any one of claims 726-758, wherein the metered portions have an average mass of no greater than 200 milligrams of the liquid phase.
760. The container of any one of claims 726-752, wherein the metered portions have an average mass of no greater than 180 milligrams of the liquid phase.
761. The container of any one of claims 726-751, wherein the metered portions have an average mass of no greater than 160 milligrams of the liquid phase.
762. The container of any one of claims 726-750, wherein the metered portions have an average mass of no greater than 140 milligrams of the liquid phase.
763. The container of any one of claims 726-749, wherein the metered portions have an average mass of no greater than 120 milligrams of the liquid phase.
764. The container of any one of claims 726-763, wherein the metered portions have an average amount of food calories of at least 0.12 food calories.
765. The container of any one of claims 726-764, wherein the metered portions have an average amount of food calories of at least 0.16 food calories.
766. The container of any one of claims 726-765, wherein the metered portions have an average amount of food calories of at least 0.20 food calories.
767. The container of any one of claims 726-766, wherein the metered portions have an average amount of food calories of at least 0.24 food calories.
768. The container of any one of claims 726-767, wherein the metered portions have an average amount of food calories of at least 0.28 food calories.
769. The container of any one of claims 726-768, wherein the metered portions have an average amount of food calories of at least 0.32 food calories.
770. The container of any one of claims 726-769, wherein the metered portions have an average amount of food calories of at least 0.36 food calories.
771. The container of any one of claims 726-770, wherein the metered portions have an average amount of food calories of at least 0.40 food calories.
772. The container of any one of claims 726-771, wherein the metered portions have an average amount of food calories of at least 0.44 food calories.
773. The container of any one of claims 726-772, wherein the metered portions have an average amount of food calories of at least 0.48 food calories.
774. The container of any one of claims 726-773, wherein the metered portions have an average amount of food calories of at least 0.52 food calories.
775. The container of any one of claims 726-774, wherein the metered portions have an average amount of food calories of at least 0.56 food calories.
776. The container of any one of claims 726-775, wherein the metered portions have an average amount of food calories of at least 0.60 food calories.
777. The container of any one of claims 726-776, wherein the metered portions have an average amount of food calories of at least 0.64 food calories.
778. The container of any one of claims 726-777, wherein the metered portions have an average amount of food calories of at least 0.68 food calories.
779. The container of any one of claims 726-778, wherein the metered portions have an average amount of food calories of at least 0.72 food calories.
780. The container of any one of claims 726-779, wherein the metered portions have an average amount of food calories of at least 0.76 food calories.
781. The container of any one of claims 726-780, wherein the metered portions have an average amount of food calories of at least 0.80 food calories.
782. The container of any one of claims 726-781, wherein the metered portions have an average amount of food calories of at least 0.84 food calories.
783. The container of any one of claims 726-782, wherein the metered portions have an average amount of food calories of no greater than 2.00 food calories.
784. The container of any one of claims 726-783, wherein the metered portions have an average amount of food calories of no greater than 1.90 food calories.
785. The container of any one of claims 726-784, wherein the metered portions have an average amount of food calories of no greater than 1.80 food calories.
786. The container of any one of claims 726-785, wherein the metered portions have an average amount of food calories of no greater than 1.70 food calories.
787. The container of any one of claims 726-786, wherein the metered portions have an average amount of food calories of no greater than 1.60 food calories.
788. The container of any one of claims 726-787, wherein the metered portions have an average amount of food calories of no greater than 1.50 food calories.
789. The container of any one of claims 726-788, wherein the metered portions have an average amount of food calories of no greater than 1.40 food calories.
790. The container of any one of claims 726-789, wherein the metered portions have an average amount of food calories of no greater than 1.30 food calories.
791. The container of any one of claims 726-790, wherein the metered portions have an average amount of food calories of no greater than 1.20 food calories.
792. The container of any one of claims 726-791, wherein the metered portions have an average amount of food calories of no greater than 1.10 food calories.
793. The container of any one of claims 726-792, wherein the metered portions have an average amount of food calories of no greater than 1.00 food calories.
794. The container of any one of claims 726-793, wherein the metered portions have an average amount of food calories of no greater than 0.90 food calories.
795. The container of any one of claims 726-794, wherein the metered portions have an average amount of food calories of no greater than 0.86 food calories.
796. The container of any one of claims 726-781, wherein the metered portions have an average amount of food calories of no greater than 0.82 food calories.
797. The container of any one of claims 726-780, wherein the metered portions have an average amount of food calories of no greater than 0.78 food calories.
798. The container of any one of claims 726-779, wherein the metered portions have an average amount of food calories of no greater than 0.74 food calories.
799. The container of any one of claims 726-778, wherein the metered portions have an average amount of food calories of no greater than 0.70 food calories.
800. The container of any one of claims 726-777, wherein the metered portions have an average amount of food calories of no greater than 0.66 food calories.
801. The container of any one of claims 726-776, wherein the metered portions have an average amount of food calories of no greater than 0.62 food calories.
802. The container of any one of claims 726-801, wherein the metered portions have an average dose of the cannabinoid of at least 1 microgram.
803. The container of any one of claims 726-802, wherein the metered portions have an average dose of the cannabinoid of at least 2 micrograms.
804. The container of any one of claims 726-803, wherein the metered portions have an average dose of the cannabinoid of at least 4 micrograms.
805. The container of any one of claims 726-804, wherein the metered portions have an average dose of the cannabinoid of at least 8 micrograms.
806. The container of any one of claims 726-805, wherein the metered portions have an average dose of the cannabinoid of at least 16 micrograms.
807. The container of any one of claims 726-806, wherein the metered portions have an average dose of the cannabinoid of at least 32 micrograms.
808. The container of any one of claims 726-807, wherein the metered portions have an average dose of the cannabinoid of at least 64 micrograms.
809. The container of any one of claims 726-808, wherein the metered portions have an average dose of the cannabinoid of at least 128 micrograms.
810. The container of any one of claims 726-809, wherein the metered portions have an average dose of the cannabinoid of at least 256 micrograms.
811. The container of any one of claims 726-810, wherein the metered portions have an average dose of the cannabinoid of at least 0.48 milligrams.
812. The container of any one of claims 726-811, wherein the metered portions have an average dose of the cannabinoid of at least 0.6 milligrams.
813. The container of any one of claims 726-812, wherein the metered portions have an average dose of the cannabinoid of at least 0.7 milligrams.
814. The container of any one of claims 726-813, wherein the metered portions have an average dose of the cannabinoid of at least 0.8 milligrams.
815. The container of any one of claims 726-814, wherein the metered portions have an average dose of the cannabinoid of at least 0.9 milligrams.
816. The container of any one of claims 726-815, wherein the metered portions have an average dose of the cannabinoid of no greater than 2.1 milligrams.
817. The container of any one of claims 726-816, wherein the metered portions have an average dose of the cannabinoid of no greater than 2.0 milligrams.
818. The container of any one of claims 726-817, wherein the metered portions have an average dose of the cannabinoid of no greater than 1.9 milligrams.
819. The container of any one of claims 726-818, wherein the metered portions have an average dose of the cannabinoid of no greater than 1.8 milligrams.
820. The container of any one of claims 726-819, wherein the metered portions have an average dose of the cannabinoid of no greater than 1.7 milligrams.
821. The container of any one of claims 726-820, wherein the metered portions have an average dose of the cannabinoid of no greater than 1.6 milligrams.
822. The container of any one of claims 726-821, wherein the metered portions have an average dose of the cannabinoid of no greater than 1.5 milligrams.
823. The container of any one of claims 726-822, wherein the metered portions have an average dose of the cannabinoid of no greater than 1.4 milligrams.
824. The container of any one of claims 726-823, wherein the metered portions have an average dose of the cannabinoid of no greater than 1.3 milligrams.
825. The container of any one of claims 726-824, wherein the metered portions have an average dose of the cannabinoid of no greater than 1.2 milligrams.
826. The container of any one of claims 726-825, wherein the metered portions have an average dose of the cannabinoid of no greater than 1.1 milligrams.
827. The container of any one of claims 726-826, wherein the metered portions have a standard deviation of no greater than 30 percent of the average mass of the liquid phase.
828. The container of any one of claims 726-827, wherein the metered portions have a standard deviation of no greater than 25 percent of the average mass of the liquid phase.
829. The container of any one of claims 726-828, wherein the metered portions have a standard deviation of no greater than 20 percent of the average mass of the liquid phase.
830. The container of any one of claims 726-829, wherein the metered portions have a standard deviation of no greater than 15 percent of the average mass of the liquid phase.
831. The container of any one of claims 726-830, wherein the metered portions have a standard deviation of no greater than 10 percent of the average mass of the liquid phase.
832. The container of any one of claims 726-831, wherein the metered portions have a standard deviation of no greater than 5 percent of the average mass of the liquid phase.
833. The container of any one of claims 726-832, wherein the metered portions have a standard deviation of no greater than 30 percent of the average amount of food calories.
834. The container of any one of claims 726-833, wherein the metered portions have a standard deviation of no greater than 25 percent of the average amount of food calories.
835. The container of any one of claims 726-834, wherein the metered portions have a standard deviation of no greater than 20 percent of the average amount of food calories.
836. The container of any one of claims 726-835, wherein the metered portions have a standard deviation of no greater than 15 percent of the average amount of food calories.
837. The container of any one of claims 726-836, wherein the metered portions have a standard deviation of no greater than 10 percent of the average amount of food calories.
838. The container of any one of claims 726-837, wherein the metered portions have a standard deviation of no greater than 5 percent of the average amount of food calories.
839. The container of any one of claims 726-838, wherein the metered portions have a standard deviation of no greater than 30 percent of the average dose of the cannabinoid.
840. The container of any one of claims 726-839, wherein the metered portions have a standard deviation of no greater than 25 percent of the average dose of the cannabinoid.
841. The container of any one of claims 726-840, wherein the metered portions have a standard deviation of no greater than 20 percent of the average dose of the cannabinoid.
842. The container of any one of claims 726-841, wherein the metered portions have a standard deviation of no greater than 15 percent of the average dose of the cannabinoid.
843. The container of any one of claims 726-842, wherein the metered portions have a standard deviation of no greater than 10 percent of the average dose of the cannabinoid.
844. The container of any one of claims 726-843, wherein the metered portions have a standard deviation of no greater than 5 percent of the average dose of the cannabinoid.
845. The container of any one of claims 695-844, wherein the container is configured to dispense a spray of the liquid phase.
846. The container of any one of claims 695-845, wherein the container is configured to dispense an aerosol spray of the liquid phase.
847. A method to administer a cannabinoid to a subject, comprising providing a container according to any one of claims 16, 17, and 695-846; spraying a portion of the composition; and then orally consuming the portion of the composition, wherein the subject orally consumes the portion of the composition.
848. A method to administer a cannabinoid to a subject, comprising providing a container according to any one of claims 16, 17, and 695-846; spraying the composition; and then orally consuming the composition, wherein the subject orally consumes the composition.
849. A method to administer a cannabinoid to a subject, comprising providing a container according to any one of claims 16, 17, and 695-846; and spraying a portion of the composition into the mouth of the subject.
850. A method to administer a cannabinoid to a subject, comprising providing a container according to any one of claims 16, 17, and 695-846; and spraying the composition into the mouth of the subject.
851. A method to administer a cannabinoid to a subject, comprising providing a container according to any one of claims 16, 17, and 695-846; and orally administering a portion of the composition to the subject.
852. A method to administer a cannabinoid to a subject, comprising providing a container according to any one of claims 16, 17, and 695-846; and orally administering the composition to the subject.
853. A method to administer a cannabinoid to a subject, comprising providing a composition according to any one of claims 1-15 and 21-694; spraying a portion of the composition; and then orally consuming the portion of the composition, wherein the subject orally consumes the portion of the composition.
854. A method to administer a cannabinoid to a subject, comprising providing a composition according to any one of claims 1-15 and 21-694; spraying the composition; and then orally consuming the composition, wherein the subject orally consumes the composition.
855. A method to administer a cannabinoid to a subject, comprising providing a composition according to any one of claims 1-15 and 21-694; and spraying a portion of the composition into the mouth of the subject.
856. A method to administer a cannabinoid to a subject, comprising providing a composition according to any one of claims 1-15 and 21-694; and spraying the composition into the mouth of the subject.
857. A method to administer a cannabinoid to a subject, comprising providing a composition according to any one of claims 1-15 and 21-694; and orally administering a portion of the composition to the subject.
858. A method to administer a cannabinoid to a subject, comprising providing a composition according to any one of claims 1-15 and 21-694; and orally administering the composition to the subject.
859. A method to treat a health condition in a subject, comprising providing a container according to any one of claims 16, 17, and 695-846; spraying a portion of the composition; and then orally consuming the portion of the composition, wherein the subject orally consumes the portion of the composition.
860. A method to treat a health condition in a subject, comprising providing a container according to any one of claims 16, 17, and 695-846; spraying the composition; and then orally consuming the composition, wherein the subject orally consumes the composition.
861. A method to treat a health condition in a subject, comprising providing a container according to any one of claims 16, 17, and 695-846; and spraying a portion of the composition into the mouth of the subject.
862. A method to treat a health condition in a subject, comprising providing a container according to any one of claims 16, 17, and 695-846; and spraying the composition into the mouth of the subject.
863. A method to treat a health condition in a subject, comprising providing a container according to any one of claims 16, 17, and 695-846; and orally administering a portion of the composition to the subject.
864. A method to treat a health condition in a subject, comprising providing a container according to any one of claims 16, 17, and 695-846; and orally administering the composition to the subject.
865. A method to treat a health condition in a subject, comprising providing a composition according to any one of claims 1-15 and 21-694; spraying a portion of the composition; and then orally consuming the portion of the composition, wherein the subject orally consumes the portion of the composition.
866. A method to treat a health condition in a subject, comprising providing a composition according to any one of claims 1-15 and 21-694; spraying the composition; and then orally consuming the composition, wherein the subject orally consumes the composition.
867. A method to treat a health condition in a subject, comprising providing a composition according to any one of claims 1-15 and 21-694; and spraying a portion of the composition into the mouth of the subject.
868. A method to treat a health condition in a subject, comprising providing a composition according to any one of claims 1-15 and 21-694; and spraying the composition into the mouth of the subject.
869. A method to treat a health condition in a subject, comprising providing a composition according to any one of claims 1-15 and 21-694; and orally administering a portion of the composition to the subject.
870. A method to treat a health condition in a subject, comprising providing a composition according to any one of claims 1-15 and 21-694; and orally administering the composition to the subject.
871. The method of any one of claims 859-870, wherein the health condition is type 2 diabetes mellitus.
872. The method of any one of claims 859-870, wherein the health condition is metabolic syndrome.
873. The method of any one of claims 859-870, wherein the health condition is dyslipidemias.
874. The method of any one of claims 859-870, wherein the health condition is cardiovascular disease.
875. The method of any one of claims 859-870, wherein the health condition is hypertension.
876. The method of any one of claims 859-870, wherein the health condition is pre-hypertension.
877. The method of any one of claims 859-870, wherein the health condition is a neurodegenerative disease or neuropathy.
878. The method of any one of claims 859-870, wherein the health condition is mild cognitive impairment.
879. The method of any one of claims 859-870, wherein the health condition is Alzheimer's Disease.
880. The method of any one of claims 859-870, wherein the health condition is Parkinson's Disease.
881. The method of any one of claims 859-870, wherein the health condition is amyotrophic lateral sclerosis (“ALS”).
882. The method of any one of claims 859-870, wherein the health condition is a motor neuron disease.
883. The method of any one of claims 859-870, wherein the health condition is Huntington's disease.
884. The method of any one of claims 859-870, wherein the health condition is an autoimmune disorder.
885. The method of any one of claims 859-870, wherein the health condition is arthritis.
886. The method of any one of claims 859-870, wherein the health condition is ankylosing spondylitis.
887. The method of any one of claims 859-870, wherein the health condition is an inflammatory autoimmune-mediated arthritis.
888. The method of any one of claims 859-870, wherein the health condition is rheumatoid arthritis.
889. The method of any one of claims 859-870, wherein the health condition is osteoarthritis.
890. The method of any one of claims 859-870, wherein the health condition is psoriatic arthritis.
891. The method of any one of claims 859-870, wherein the health condition is psoriasis.
892. The method of any one of claims 859-870, wherein the health condition is plaque psoriasis.
893. The method of any one of claims 859-870, wherein the health condition is lupus.
894. The method of any one of claims 859-870, wherein the health condition is Sjogren's syndrome.
895. The method of any one of claims 859-870, wherein the health condition is inflammatory bowel disease.
896. The method of any one of claims 859-870, wherein the health condition is Crohn's disease.
897. The method of any one of claims 859-870, wherein the health condition is steroid dependent Crohn's disease.
898. The method of any one of claims 859-870, wherein the health condition is ulcerative colitis.
899. The method of any one of claims 859-870, wherein the health condition is graft-versus-host disease.
900. The method of any one of claims 859-870, wherein the health condition is fibrosis.
901. The method of any one of claims 859-870, wherein the health condition is a localized fibrotic disorder.
902. The method of any one of claims 859-870, wherein the health condition is a fibroproliferative disorder.
903. The method of any one of claims 859-870, wherein the health condition is a systemic fibrotic disorder.
904. The method of any one of claims 859-870, wherein the health condition is frozen shoulder.
905. The method of any one of claims 859-870, wherein the health condition is ocular fibrosis.
906. The method of any one of claims 859-870, wherein the health condition is a headache.
907. The method of any one of claims 859-870, wherein the health condition is a migraine headache.
908. The method of any one of claims 859-870, wherein the health condition is an episodic migraine.
909. The method of any one of claims 859-870, wherein the health condition is pain.
910. The method of any one of claims 859-870, wherein the health condition is nociceptive pain.
911. The method of any one of claims 859-870, wherein the health condition is allodynia.
912. The method of any one of claims 859-870, wherein the health condition is chronic pain.
913. The method of any one of claims 859-870, wherein the health condition is intractable pain.
914. The method of any one of claims 859-870, wherein the health condition is back pain.
915. The method of any one of claims 859-870, wherein the health condition is lower back pain.
916. The method of any one of claims 859-870, wherein the health condition is chronic back pain.
917. The method of any one of claims 859-870, wherein the health condition is sciatica.
918. The method of any one of claims 859-870, wherein the health condition is spinal stenosis.
919. The method of any one of claims 859-870, wherein the health condition is acute radicular back pain.
920. The method of any one of claims 859-870, wherein the health condition is chronic radiculopathy.
921. The method of any one of claims 859-870, wherein the health condition is post laminectomy syndrome.
922. The method of any one of claims 859-870, wherein the health condition is post-operative pain.
923. The method of any one of claims 859-870, wherein the health condition is post-operative cognitive dysfunction.
924. The method of any one of claims 859-870, wherein the health condition is post-operative cognitive deficit.
925. The method of any one of claims 859-870, wherein the health condition is post-operative delerium.
926. The method of any one of claims 859-870, wherein the health condition is stomach pain.
927. The method of any one of claims 859-870, wherein the health condition is endometriosis.
928. The method of any one of claims 859-870, wherein the health condition is dysmenorrhea.
929. The method of any one of claims 859-870, wherein the health condition is pelvic pain.
930. The method of any one of claims 859-870, wherein the health condition is visceral pain.
931. The method of any one of claims 859-870, wherein the health condition is musculoskeletal pain.
932. The method of any one of claims 859-870, wherein the health condition is musculoskeletal joint pain.
933. The method of any one of claims 859-870, wherein the health condition is temporomandibular joint pain.
934. The method of any one of claims 859-870, wherein the health condition is myofascial pain.
935. The method of any one of claims 859-870, wherein the health condition is interstitial cystitis.
936. The method of any one of claims 859-870, wherein the health condition is postherpetic neuralgia.
937. The method of any one of claims 859-870, wherein the health condition is sickle cell anemia.
938. The method of any one of claims 859-870, wherein the health condition is sickle cell disease.
939. The method of any one of claims 859-870, wherein the health condition is cancer pain.
940. The method of any one of claims 859-870, wherein the health condition is intractable cancer pain.
941. The method of any one of claims 859-870, wherein the health condition is fibromyalgia.
942. The method of any one of claims 859-870, wherein the health condition is neurogenic pain.
943. The method of any one of claims 859-870, wherein the health condition is neuropathic pain.
944. The method of any one of claims 859-870, wherein the health condition is peripheral neuropathy.
945. The method of any one of claims 859-870, wherein the health condition is diabetic peripheral neuropathy.
946. The method of any one of claims 859-870, wherein the health condition is chemotherapy-induced peripheral neuropathy.
947. The method of any one of claims 859-870, wherein the health condition is inflammatory demyelinating polyneuropathy.
948. The method of any one of claims 859-870, wherein the health condition is allodynia.
949. The method of any one of claims 859-870, wherein the health condition is peripheral pain.
950. The method of any one of claims 859-870, wherein the health condition is hyperalgesia.
951. The method of any one of claims 859-870, wherein the health condition is opioid-induced hyperalgesia.
952. The method of any one of claims 859-870, wherein the health condition is reflex sympathetic dystrophy.
953. The method of any one of claims 859-870, wherein the health condition is residual limb pain.
954. The method of any one of claims 859-870, wherein the health condition is idiopathic pain.
955. The method of any one of claims 859-870, wherein the health condition is psychogenic pain.
956. The method of any one of claims 859-870, wherein the health condition is causalgia.
957. The method of any one of claims 859-870, wherein the health condition is complex regional pain syndrome.
958. The method of any one of claims 859-870, wherein the health condition is complex regional pain syndrome type I.
959. The method of any one of claims 859-870, wherein the health condition is complex regional pain syndrome type II.
960. The method of any one of claims 859-870, wherein the health condition is arthralgia.
961. The method of any one of claims 859-870, wherein the health condition is fatigue.
962. The method of any one of claims 859-870, wherein the health condition is odontalgia.
963. The method of any one of claims 859-870, wherein the health condition is toothache.
964. The method of any one of claims 859-870, wherein the health condition is Dupuytren's contracture.
965. The method of any one of claims 859-870, wherein the health condition is early stage Dupuytren's contracture.
966. The method of any one of claims 859-870, wherein the health condition is gout.
967. The method of any one of claims 859-870, wherein the health condition is hallux valgus.
968. The method of any one of claims 859-870, wherein the health condition is hallux rigidus.
969. The method of any one of claims 859-870, wherein the health condition is epidermolysis bullosa.
970. The method of any one of claims 859-870, wherein the health condition is hemorrhoids.
971. The method of any one of claims 859-870, wherein the health condition is constipation.
972. The method of any one of claims 859-870, wherein the health condition is a urinary stone.
973. The method of any one of claims 859-870, wherein the health condition is bladder pain syndrome.
974. The method of any one of claims 859-870, wherein the health condition is detrusor overactivity.
975. The method of any one of claims 859-870, wherein the health condition is elevated intraocular pressure.
976. The method of any one of claims 859-870, wherein the health condition is glaucoma.
977. The method of any one of claims 859-870, wherein the health condition is retinitis pigmentosa.
978. The method of any one of claims 859-870, wherein the health condition is retinal degeneration.
979. The method of any one of claims 859-870, wherein the health condition is Sturge-Weber syndrome.
980. The method of any one of claims 859-870, wherein the health condition is heart failure.
981. The method of any one of claims 859-870, wherein the health condition is liver disease.
982. The method of any one of claims 859-870, wherein the health condition is fatty liver.
983. The method of any one of claims 859-870, wherein the health condition is non-alcoholic fatty liver disease (“NAFLD”).
984. The method of any one of claims 859-870, wherein the health condition is non-alcoholic steatohepatitis (“NASH”).
985. The method of any one of claims 859-870, wherein the health condition is liver cirrhosis.
986. The method of any one of claims 859-870, wherein the health condition is decompensated cirrhosis.
987. The method of any one of claims 859-870, wherein the health condition is hepatic encephalopathy.
988. The method of any one of claims 859-870, wherein the health condition is hepatitis.
989. The method of any one of claims 859-870, wherein the health condition is hepatitis C.
990. The method of any one of claims 859-870, wherein the health condition is autoimmune hepatitis.
991. The method of any one of claims 859-870, wherein the health condition is nausea.
992. The method of any one of claims 859-870, wherein the health condition is gastroparesis.
993. The method of any one of claims 859-870, wherein the health condition is dyspepsia.
994. The method of any one of claims 859-870, wherein the health condition is Prader-Willi syndrome.
995. The method of any one of claims 859-870, wherein the health condition is cachexia.
996. The method of any one of claims 859-870, wherein the health condition is anorexia.
997. The method of any one of claims 859-870, wherein the health condition is anorexia nervosa.
998. The method of any one of claims 859-870, wherein the health condition is bulimia.
999. The method of any one of claims 859-870, wherein the health condition is vomiting.
1000. The method of any one of claims 859-870, wherein the health condition is motion sickness.
1001. The method of any one of claims 859-870, wherein the health condition is cancer chemotherapy-induced anorexia.
1002. The method of any one of claims 859-870, wherein the health condition is human deficiency virus (“HIV”) infection related nausea or cachexia.
1003. The method of any one of claims 859-870, wherein the health condition is human deficiency virus (“HIV”).
1004. The method of any one of claims 859-870, wherein the health condition is acquired immune deficiency syndrome (“AIDS”) related nausea or cachexia.
1005. The method of any one of claims 859-870, wherein the health condition is acquired immune deficiency syndrome (“AIDS”).
1006. The method of any one of claims 859-870, wherein the health condition is anxiety.
1007. The method of any one of claims 859-870, wherein the health condition is generalized anxiety disorder.
1008. The method of any one of claims 859-870, wherein the health condition is a specific phobia.
1009. The method of any one of claims 859-870, wherein the health condition is agoraphobia.
1010. The method of any one of claims 859-870, wherein the health condition is social anxiety disorder.
1011. The method of any one of claims 859-870, wherein the health condition is separation anxiety disorder.
1012. The method of any one of claims 859-870, wherein the health condition is panic disorder.
1013. The method of any one of claims 859-870, wherein the health condition is a panic attack.
1014. The method of any one of claims 859-870, wherein the health condition is selective mutism.
1015. The method of any one of claims 859-870, wherein the health condition is obsessive-compulsive disorder.
1016. The method of any one of claims 859-870, wherein the health condition is depression.
1017. The method of any one of claims 859-870, wherein the health condition is treatment resistant depression.
1018. The method of any one of claims 859-870, wherein the health condition is a major depressive disorder with psychotic feature(s).
1019. The method of any one of claims 859-870, wherein the health condition is psychotic depression.
1020. The method of any one of claims 859-870, wherein the health condition is paranoia.
1021. The method of any one of claims 859-870, wherein the health condition is psychosis.
1022. The method of any one of claims 859-870, wherein the health condition is early psychosis.
1023. The method of any one of claims 859-870, wherein the health condition is an unspecified psychosis.
1024. The method of any one of claims 859-870, wherein the health condition is an unspecified reactive psychosis.
1025. The method of any one of claims 859-870, wherein the health condition is a psychotic disorder.
1026. The method of any one of claims 859-870, wherein the health condition is a brief psychotic disorder.
1027. The method of any one of claims 859-870, wherein the health condition is a debilitating psychiatric disorder.
1028. The method of any one of claims 859-870, wherein the health condition is schizophrenia.
1029. The method of any one of claims 859-870, wherein the health condition is schizophreniform disorder.
1030. The method of any one of claims 859-870, wherein the health condition is schizoaffective disorder.
1031. The method of any one of claims 859-870, wherein the health condition is schizophrenia-related psychotic disorder.
1032. The method of any one of claims 859-870, wherein the health condition is dementia.
1033. The method of any one of claims 859-870, wherein the health condition is a major neurocognitive disorder with aggressive behavior.
1034. The method of any one of claims 859-870, wherein the health condition is paranoid personality disorder.
1035. The method of any one of claims 859-870, wherein the health condition is schizoid personality disorder.
1036. The method of any one of claims 859-870, wherein the health condition is schizotypal personality disorder.
1037. The method of any one of claims 859-870, wherein the health condition is a shared psychotic disorder.
1038. The method of any one of claims 859-870, wherein the health condition is a shared paranoia disorder.
1039. The method of any one of claims 859-870, wherein the health condition is a delusional disorder.
1040. The method of any one of claims 859-870, wherein the health condition is bipolar disorder.
1041. The method of any one of claims 859-870, wherein the health condition is bipolar I disorder.
1042. The method of any one of claims 859-870, wherein the health condition is bipolar I disorder.
1043. The method of any one of claims 859-870, wherein the health condition is bipolar depression.
1044. The method of any one of claims 859-870, wherein the health condition is bipolar affective disorder.
1045. The method of any one of claims 859-870, wherein the health condition is mania.
1046. The method of any one of claims 859-870, wherein the health condition is manic disorder.
1047. The method of any one of claims 859-870, wherein the health condition is manic-depressive psychosis.
1048. The method of any one of claims 859-870, wherein the health condition is an addiction.
1049. The method of any one of claims 859-870, wherein the health condition is an addiction to alcohol or an alcohol use disorder.
1050. The method of any one of claims 859-870, wherein the health condition is an addiction to tobacco or a tobacco use disorder.
1051. The method of any one of claims 859-870, wherein the health condition is an addiction to nicotine or a nicotine use disorder.
1052. The method of any one of claims 859-870, wherein the health condition is an addiction to an opioid or an opioid use disorder.
1053. The method of any one of claims 859-870, wherein the health condition is an addiction to a stimulant or a stimulant use disorder.
1054. The method of any one of claims 859-870, wherein the health condition is an addiction to cocaine or a cocaine use disorder.
1055. The method of any one of claims 859-870, wherein the health condition is an addiction to a prescription drug or a prescription drug use disorder.
1056. The method of any one of claims 859-870, wherein the health condition is an addiction to gambling.
1057. The method of any one of claims 859-870, wherein the health condition is an addiction to food.
1058. The method of any one of claims 859-870, wherein the health condition is an addiction to shopping.
1059. The method of any one of claims 859-870, wherein the health condition is an addiction to the internet.
1060. The method of any one of claims 859-870, wherein the health condition is an addiction to sex.
1061. The method of any one of claims 859-870, wherein the health condition is drug withdrawal or a drug use disorder.
1062. The method of any one of claims 859-870, wherein the health condition is alcohol withdrawal syndrome.
1063. The method of any one of claims 859-870, wherein the health condition is nicotine withdrawal.
1064. The method of any one of claims 859-870, wherein the health condition is opioid withdrawal.
1065. The method of any one of claims 859-870, wherein the health condition is cannabis withdrawal.
1066. The method of any one of claims 859-870, wherein the health condition is benzodiazepine withdrawal syndrome.
1067. The method of any one of claims 859-870, wherein the health condition is antidepressant discontinuation syndrome.
1068. The method of any one of claims 859-870, wherein the health condition is antipsychotic withdrawal syndrome.
1069. The method of any one of claims 859-870, wherein the health condition is addictive behavior.
1070. The method of any one of claims 859-870, wherein the health condition is cannabis use disorder.
1071. The method of any one of claims 859-870, wherein the health condition is attention deficit hyperactivity disorder (“ADHD”).
1072. The method of any one of claims 859-870, wherein the health condition is autism or an autism spectrum disorder.
1073. The method of any one of claims 859-870, wherein the health condition is Asperger syndrome.
1074. The method of any one of claims 859-870, wherein the health condition is fragile X syndrome.
1075. The method of any one of claims 859-870, wherein the health condition is a pervasive developmental disorder not otherwise specified (“PDD-NOS”).
1076. The method of any one of claims 859-870, wherein the health condition is a childhood disintegrative disorder.
1077. The method of any one of claims 859-870, wherein the health condition is Tourette's syndrome.
1078. The method of any one of claims 859-870, wherein the health condition is Down syndrome.
1079. The method of any one of claims 859-870, wherein the health condition is post-traumatic stress disorder (“PTSD”).
1080. The method of any one of claims 859-870, wherein the health condition is asthma.
1081. The method of any one of claims 859-870, wherein the health condition is respiratory disease.
1082. The method of any one of claims 859-870, wherein the health condition is chronic lower respiratory disease.
1083. The method of any one of claims 859-870, wherein the health condition is chronic obstructive pulmonary disease (“COPD”).
1084. The method of any one of claims 859-870, wherein the health condition is insomnia.
1085. The method of any one of claims 859-870, wherein the health condition is sleep apnea.
1086. The method of any one of claims 859-870, wherein the health condition is obstructive sleep apnea.
1087. The method of any one of claims 859-870, wherein the health condition is or restless legs syndrome.
1088. The method of any one of claims 859-870, wherein the health condition is cramping.
1089. The method of any one of claims 859-870, wherein the health condition is muscle spasms.
1090. The method of any one of claims 859-870, wherein the health condition is spasticity.
1091. The method of any one of claims 859-870, wherein the health condition is spasmodic torticollis.
1092. The method of any one of claims 859-870, wherein the health condition is a dyskinetic movement disorder.
1093. The method of any one of claims 859-870, wherein the health condition is dystonia.
1094. The method of any one of claims 859-870, wherein the health condition is intractable spasticity.
1095. The method of any one of claims 859-870, wherein the health condition is intractable skeletal muscular spasticity.
1096. The method of any one of claims 859-870, wherein the health condition is inclusion body myositis.
1097. The method of any one of claims 859-870, wherein the health condition is myasthenia gravis.
1098. The method of any one of claims 859-870, wherein the health condition is muscular dystrophy.
1099. The method of any one of claims 859-870, wherein the health condition is Duchenne muscular dystrophy.
1100. The method of any one of claims 859-870, wherein the health condition is muscle tremor.
1101. The method of any one of claims 859-870, wherein the health condition is cerebellar tremor.
1102. The method of any one of claims 859-870, wherein the health condition is dystonic tremor.
1103. The method of any one of claims 859-870, wherein the health condition is essential tremor.
1104. The method of any one of claims 859-870, wherein the health condition is orthostatic tremor.
1105. The method of any one of claims 859-870, wherein the health condition is Parkinsonian tremor.
1106. The method of any one of claims 859-870, wherein the health condition is physiological tremor.
1107. The method of any one of claims 859-870, wherein the health condition is psychogenic tremor.
1108. The method of any one of claims 859-870, wherein the health condition is rubral tremor.
1109. The method of any one of claims 859-870, wherein the health condition is nystagmus.
1110. The method of any one of claims 859-870, wherein the health condition is blepharospasm.
1111. The method of any one of claims 859-870, wherein the health condition is a seizure disorder.
1112. The method of any one of claims 859-870, wherein the health condition is recurrent focal seizures.
1113. The method of any one of claims 859-870, wherein the health condition is recurrent generalized seizures.
1114. The method of any one of claims 859-870, wherein the health condition is recurrent absence seizures.
1115. The method of any one of claims 859-870, wherein the health condition is recurrent myoclonic-absence seizures.
1116. The method of any one of claims 859-870, wherein the health condition is recurrent myoclonus.
1117. The method of any one of claims 859-870, wherein the health condition is recurrent myoclonic seizures.
1118. The method of any one of claims 859-870, wherein the health condition is recurrent tonic seizures.
1119. The method of any one of claims 859-870, wherein the health condition is recurrent tonic-clonic seizures.
1120. The method of any one of claims 859-870, wherein the health condition is recurrent atonic seizures.
1121. The method of any one of claims 859-870, wherein the health condition is recurrent chronic seizures.
1122. The method of any one of claims 859-870, wherein the health condition is epilepsy.
1123. The method of any one of claims 859-870, wherein the health condition is recurrent epileptic spasms.
1124. The method of any one of claims 859-870, wherein the health condition is recurrent infantile spasms.
1125. The method of any one of claims 859-870, wherein the health condition is refractory epilepsy.
1126. The method of any one of claims 859-870, wherein the health condition is refractory childhood epilepsy.
1127. The method of any one of claims 859-870, wherein the health condition is intractable epilepsy.
1128. The method of any one of claims 859-870, wherein the health condition is treatment-resistant epilepsy.
1129. The method of any one of claims 859-870, wherein the health condition is drug resistant epilepsy.
1130. The method of any one of claims 859-870, wherein the health condition is electrical status epilepticus of sleep.
1131. The method of any one of claims 859-870, wherein the health condition is Lennox-Gastaut syndrome.
1132. The method of any one of claims 859-870, wherein the health condition is Dravet syndrome.
1133. The method of any one of claims 859-870, wherein the health condition is febrile infection related epilepsy syndrome (“FIRES”).
1134. The method of any one of claims 859-870, wherein the health condition is juvenile myoclonic epilepsy.
1135. The method of any one of claims 859-870, wherein the health condition is childhood absence epilepsy.
1136. The method of any one of claims 859-870, wherein the health condition is myoclonic absence seizures (“MAS”).
1137. The method of any one of claims 859-870, wherein the health condition is myoclonic astatic epilepsy (“MAE”).
1138. The method of any one of claims 859-870, wherein the health condition is tuberous sclerosis complex (“TSC”).
1139. The method of any one of claims 859-870, wherein the health condition is Rett syndrome.
1140. The method of any one of claims 859-870, wherein the health condition is Angelman syndrome.
1141. The method of any one of claims 859-870, wherein the health condition is a neurological condition.
1142. The method of any one of claims 859-870, wherein the health condition is stroke.
1143. The method of any one of claims 859-870, wherein the health condition is hemorrhagic stroke.
1144. The method of any one of claims 859-870, wherein the health condition is ischemic stroke.
1145. The method of any one of claims 859-870, wherein the health condition is an ischemic reperfusion injury.
1146. The method of any one of claims 859-870, wherein the health condition is epilpetic encephalopathy.
1147. The method of any one of claims 859-870, wherein the health condition is neonatal hypoxic-ischemic encephalopathy (“NHIE”).
1148. The method of any one of claims 859-870, wherein the health condition is hydrocephalus.
1149. The method of any one of claims 859-870, wherein the health condition is hydromyelia.
1150. The method of any one of claims 859-870, wherein the health condition is traumatic brain injury (“TBI”).
1151. The method of any one of claims 859-870, wherein the health condition is post-concussion syndrome.
1152. The method of any one of claims 859-870, wherein the health condition is chronic traumatic encephalopathy.
1153. The method of any one of claims 859-870, wherein the health condition is a spinal cord injury.
1154. The method of any one of claims 859-870, wherein the health condition is a spinal cord disease.
1155. The method of any one of claims 859-870, wherein the health condition is syringomyelia.
1156. The method of any one of claims 859-870, wherein the health condition is Tarlov cysts.
1157. The method of any one of claims 859-870, wherein the health condition is cystic fibrosis.
1158. The method of any one of claims 859-870, wherein the health condition is cerebral palsy.
1159. The method of any one of claims 859-870, wherein the health condition is spinocerebellar ataxia.
1160. The method of any one of claims 859-870, wherein the health condition is a neural-tube defect.
1161. The method of any one of claims 859-870, wherein the health condition is neuropathy.
1162. The method of any one of claims 859-870, wherein the health condition is a brain tumor.
1163. The method of any one of claims 859-870, wherein the health condition is glioblastoma multiforme.
1164. The method of any one of claims 859-870, wherein the health condition is glioblastoma astrocytoma.
1165. The method of any one of claims 859-870, wherein the health condition is neurofibromatosis.
1166. The method of any one of claims 859-870, wherein the health condition is Arnold-Chiari malformation.
1167. The method of any one of claims 859-870, wherein the health condition is multiple sclerosis.
1168. The method of any one of claims 859-870, wherein the health condition is a connective tissue disorder.
1169. The method of any one of claims 859-870, wherein the health condition is Ehlers-Danlos syndrome.
1170. The method of any one of claims 859-870, wherein the health condition is fibrous dysplasia.
1171. The method of any one of claims 859-870, wherein the health condition is osteogenesis imperfecta.
1172. The method of any one of claims 859-870, wherein the health condition is nail-patella syndrome.
1173. The method of any one of claims 859-870, wherein the health condition is idiopathic pulmonary fibrosis.
1174. The method of any one of claims 859-870, wherein the health condition is bone loss.
1175. The method of any one of claims 859-870, wherein the health condition is a bone fracture.
1176. The method of any one of claims 859-870, wherein the health condition is bone loss caused by a bone fracture.
1177. The method of any one of claims 859-870, wherein the health condition is bone loss caused by a surgical procedure.
1178. The method of any one of claims 859-870, wherein the health condition is a periodontal defect.
1179. The method of any one of claims 859-870, wherein the health condition is periodontal disease.
1180. The method of any one of claims 859-870, wherein the health condition is osteopenia.
1181. The method of any one of claims 859-870, wherein the health condition is an osteolytic bone disease.
1182. The method of any one of claims 859-870, wherein the health condition is osteoporosis.
1183. The method of any one of claims 859-870, wherein the health condition is age-related osteoporosis.
1184. The method of any one of claims 859-870, wherein the health condition is hormone-related osteoporosis.
1185. The method of any one of claims 859-870, wherein the health condition is hypogonadism-related osteoporosis.
1186. The method of any one of claims 859-870, wherein the health condition is diabetes-related osteoporosis.
1187. The method of any one of claims 859-870, wherein the health condition is glucocorticoid-related osteoporosis.
1188. The method of any one of claims 859-870, wherein the health condition is or disuse osteoporosis.
1189. The method of any one of claims 859-870, wherein the health condition is a carcinoma.
1190. The method of any one of claims 859-870, wherein the health condition is sarcoma.
1191. The method of any one of claims 859-870, wherein the health condition is lymphoma.
1192. The method of any one of claims 859-870, wherein the health condition is leukemia.
1193. The method of any one of claims 859-870, wherein the health condition is germ cell tumor.
1194. The method of any one of claims 859-870, wherein the health condition is or blastoma.
1195. The method of any one of claims 859-870, wherein the health condition is condition is brain cancer.
1196. The method of any one of claims 859-870, wherein the health condition is ovarian cancer.
1197. The method of any one of claims 859-870, wherein the health condition is breast cancer.
1198. The method of any one of claims 859-870, wherein the health condition is vaginal cancer.
1199. The method of any one of claims 859-870, wherein the health condition is vulvar cancer.
1200. The method of any one of claims 859-870, wherein the health condition is uterine cancer.
1201. The method of any one of claims 859-870, wherein the health condition is cervical cancer.
1202. The method of any one of claims 859-870, wherein the health condition is endometrial cancer.
1203. The method of any one of claims 859-870, wherein the health condition is prostate cancer.
1204. The method of any one of claims 859-870, wherein the health condition is testicular cancer.
1205. The method of any one of claims 859-870, wherein the health condition is penile cancer.
1206. The method of any one of claims 859-870, wherein the health condition is liver cancer.
1207. The method of any one of claims 859-870, wherein the health condition is intrahepatic bile duct cancer.
1208. The method of any one of claims 859-870, wherein the health condition is lung cancer.
1209. The method of any one of claims 859-870, wherein the health condition is small cell lung cancer.
1210. The method of any one of claims 859-870, wherein the health condition is non-small cell lung cancer.
1211. The method of any one of claims 859-870, wherein the health condition is bronchial cancer.
1212. The method of any one of claims 859-870, wherein the health condition is mesothelioma.
1213. The method of any one of claims 859-870, wherein the health condition is pancreatic cancer.
1214. The method of any one of claims 859-870, wherein the health condition is gall bladder cancer.
1215. The method of any one of claims 859-870, wherein the health condition is non-melanoma skin cancer.
1216. The method of any one of claims 859-870, wherein the health condition is melanoma.
1217. The method of any one of claims 859-870, wherein the health condition is Kaposi sarcoma.
1218. The method of any one of claims 859-870, wherein the health condition is thyroid cancer.
1219. The method of any one of claims 859-870, wherein the health condition is head and neck cancer.
1220. The method of any one of claims 859-870, wherein the health condition is nasopharyngeal cancer.
1221. The method of any one of claims 859-870, wherein the health condition is oropharyngeal cancer.
1222. The method of any one of claims 859-870, wherein the health condition is hypopharyngeal cancer.
1223. The method of any one of claims 859-870, wherein the health condition is laryngeal cancer.
1224. The method of any one of claims 859-870, wherein the health condition is oral cavity cancer.
1225. The method of any one of claims 859-870, wherein the health condition is tongue cancer.
1226. The method of any one of claims 859-870, wherein the health condition is mouth cancer.
1227. The method of any one of claims 859-870, wherein the health condition is salivary gland cancer.
1228. The method of any one of claims 859-870, wherein the health condition is esophageal cancer.
1229. The method of any one of claims 859-870, wherein the health condition is gastric cancer.
1230. The method of any one of claims 859-870, wherein the health condition is colorectal cancer.
1231. The method of any one of claims 859-870, wherein the health condition is colon cancer.
1232. The method of any one of claims 859-870, wherein the health condition is rectal cancer.
1233. The method of any one of claims 859-870, wherein the health condition is anal cancer.
1234. The method of any one of claims 859-870, wherein the health condition is kidney cancer.
1235. The method of any one of claims 859-870, wherein the health condition is renal cell cancer.
1236. The method of any one of claims 859-870, wherein the health condition is renal pelvis cancer.
1237. The method of any one of claims 859-870, wherein the health condition is bladder cancer.
1238. The method of any one of claims 859-870, wherein the health condition is urethral cancer.
1239. The method of any one of claims 859-870, wherein the health condition is Hodgkin lymphoma.
1240. The method of any one of claims 859-870, wherein the health condition is non-Hodgkin's lymphoma.
1241. The method of any one of claims 859-870, wherein the health condition is myeloma.
1242. The method of any one of claims 859-870, wherein the health condition is multiple myeloma.
1243. The method of any one of claims 859-870, wherein the health condition is acute lymphocytic leukemia.
1244. The method of any one of claims 859-870, wherein the health condition is chronic lymphocytic leukemia.
1245. The method of any one of claims 859-870, wherein the health condition is acute myeloid leukemia.
1246. The method of any one of claims 859-870, wherein the health condition is chronic myeloid leukemia.
1247. The method of any one of claims 859-870, wherein the health condition is osteosarcoma.
1248. The method of any one of claims 859-870, wherein the health condition is soft tissue cancer.
1249. The method of any one of claims 859-870, wherein the health condition is a severe acute respiratory syndrome coronavirus 2 infection.
1250. The method of any one of claims 859-870, wherein the health condition is long COVID.
1251. The method of any one of claims 859-870, wherein the health condition is hidradenitis suppurativa.
1252. The method of any one of claims 859-870, wherein the health condition is chronic spontaneous urticaria.
1253. The method of any one of claims 859-870, wherein the health condition is atopic dermatitis.
1254. The method of any one of claims 859-870, wherein the health condition is eczema.
1255. The method of any one of claims 859-870, wherein the health condition is acne.
1256. The method of any one of claims 859-870, wherein the health condition is male pattern baldness.
1257. The method of any one of claims 859-870, wherein the health condition is alpoecia.
1258. The method of any one of claims 859-870, wherein the health condition is androgenetic alopecia.
1259. The method of any one of claims 859-1258, wherein at least one symptom of the health condition is pain; and the composition is administered to treat pain.
1260. The method of any one of claims 859-1259, wherein at least one symptom of the health condition is inflammation; and the composition is administered to treat inflammation.
1261. The method of any one of claims 859-1260, wherein at least one symptom of the health condition is anxiety; and the composition is administered to treat anxiety.
1262. The method of any one of claims 859-1261, wherein the subject presents with both the health condition and hypertension; hypertension exacerbates the health condition; and the composition is administered to treat the hypertension.
1263. The method of any one of claims 859-1262, wherein the subject presents with both the health condition and pre-hypertension; either pre-hypertension or hypertension exacerbates the health condition; and the composition is administered to either treat the pre-hypertension or reduce the risk that the subject will develop hypertension.
1264. The method of any one of claims 859-1263, wherein diuretic properties of the cannabinoid treat the health condition.
1265. The method of any one of claims 859-1264, wherein the health condition is an autoimmune disease; and the composition is administered to inhibit aberrant immune response in the subject.
1266. The method of any one of claims 859-1265, wherein aberrant tumor necrosis factor alpha (“TNF-alpha”) signaling either causes or exacerbates the health condition; and the composition is administered to inhibit TNF-alpha-mediated signaling pathways.
1267. The method of any one of claims 859-1266, wherein aberrant interferon gamma (“INF-gamma”) signaling either causes or exacerbates the health condition; and the composition is administered to inhibit INF-gamma-mediated signaling pathways.
1268. The method of any one of claims 859-1267, wherein at least one symptom of the health condition is muscle cramping, spasticity, tremor, or muscle spasms; and the composition is administered to treat the muscle cramping, spasticity, tremor, or muscle spasms.
1269. The method of any one of claims 859-1268, wherein at least one symptom of the health condition is seizures; and the composition is administered to treat seizures.
1270. The method of any one of claims 859-1269, wherein at least one symptom of the health condition is appetite suppression, nausea, or vomiting; and the composition is administered to treat the appetite suppression, nausea, or vomiting.
1271. The method of any one of claims 859-1270, wherein the subject is receiving a primary pharmaceutical agent to treat the health condition; the primary pharmaceutical agent causes appetite suppression, nausea, or vomiting; and the composition is administered to treat the appetite suppression, nausea, or vomiting.
1272. The method of any one of claims 859-1271, wherein at least one symptom of the health condition is decreased bone density; and the composition is administered to treat bone loss.
1273. The method of any one of claims 859-1272, wherein the health condition is a terminal illness; and the composition is administered to provide palliative care.
1274. The method of any one of claims 847-1273, wherein at least 10 milligrams of the liquid phase are administered to the subject.
1275. The method of any one of claims 847-1274, wherein at least 20 milligrams of the liquid phase are administered to the subject.
1276. The method of any one of claims 847-1275, wherein at least 40 milligrams of the liquid phase are administered to the subject.
1277. The method of any one of claims 847-1276, wherein at least 60 milligrams of the liquid phase are administered to the subject.
1278. The method of any one of claims 847-1277, wherein at least 80 milligrams of the liquid phase are administered to the subject.
1279. The method of any one of claims 847-1278, wherein at least 100 milligrams of the liquid phase are administered to the subject.
1280. The method of any one of claims 847-1279, wherein at least 120 milligrams of the liquid phase are administered to the subject.
1281. The method of any one of claims 847-1280, wherein at least 140 milligrams of the liquid phase are administered to the subject.
1282. The method of any one of claims 847-1281, wherein at least 160 milligrams of the liquid phase are administered to the subject.
1283. The method of any one of claims 847-1282, wherein at least 180 milligrams of the liquid phase are administered to the subject.
1284. The method of any one of claims 847-1283, wherein at least 200 milligrams of the liquid phase are administered to the subject.
1285. The method of any one of claims 847-1284, wherein at least 300 milligrams of the liquid phase are administered to the subject.
1286. The method of any one of claims 847-1285, wherein at least 400 milligrams of the liquid phase are administered to the subject.
1287. The method of any one of claims 847-1286, wherein at least 500 milligrams of the liquid phase are administered to the subject.
1288. The method of any one of claims 847-1287, wherein at least 600 milligrams of the liquid phase are administered to the subject.
1289. The method of any one of claims 847-1288, wherein at least 700 milligrams of the liquid phase are administered to the subject.
1290. The method of any one of claims 847-1289, wherein at least 800 milligrams of the liquid phase are administered to the subject.
1291. The method of any one of claims 847-1290, wherein at least 900 milligrams of the liquid phase are administered to the subject.
1292. The method of any one of claims 847-1291, wherein at least 1.0 gram of the liquid phase are administered to the subject.
1293. The method of any one of claims 847-1292, wherein at least 1.2 grams of the liquid phase are administered to the subject.
1294. The method of any one of claims 847-1293, wherein at least 1.4 grams of the liquid phase are administered to the subject.
1295. The method of any one of claims 847-1294, wherein at least 1.6 grams of the liquid phase are administered to the subject.
1296. The method of any one of claims 847-1295, wherein at least 1.8 grams of the liquid phase are administered to the subject.
1297. The method of any one of claims 847-1296, wherein no greater than 5.0 grams of the liquid phase are administered to the subject.
1298. The method of any one of claims 847-1297, wherein no greater than 4.0 grams of the liquid phase are administered to the subject.
1299. The method of any one of claims 847-1298, wherein no greater than 3.0 grams of the liquid phase are administered to the subject.
1300. The method of any one of claims 847-1299, wherein no greater than 2.0 grams of the liquid phase are administered to the subject.
1301. The method of any one of claims 847-1295, wherein no greater than 1.8 grams of the liquid phase are administered to the subject.
1302. The method of any one of claims 847-1294, wherein no greater than 1.6 grams of the liquid phase are administered to the subject.
1303. The method of any one of claims 847-1293, wherein no greater than 1.4 grams of the liquid phase are administered to the subject.
1304. The method of any one of claims 847-1292, wherein no greater than 1.2 grams of the liquid phase are administered to the subject.
1305. The method of any one of claims 847-1291, wherein no greater than 1.0 grams of the liquid phase are administered to the subject.
1306. The method of any one of claims 847-1290, wherein no greater than 900 milligrams of the liquid phase are administered to the subject.
1307. The method of any one of claims 847-1289, wherein no greater than 800 milligrams of the liquid phase are administered to the subject.
1308. The method of any one of claims 847-1288, wherein no greater than 700 milligrams of the liquid phase are administered to the subject.
1309. The method of any one of claims 847-1287, wherein no greater than 600 milligrams of the liquid phase are administered to the subject.
1310. The method of any one of claims 847-1286, wherein no greater than 500 milligrams of the liquid phase are administered to the subject.
1311. The method of any one of claims 847-1285, wherein no greater than 400 milligrams of the liquid phase are administered to the subject.
1312. The method of any one of claims 847-1284, wherein no greater than 300 milligrams of the liquid phase are administered to the subject.
1313. The method of any one of claims 847-1283, wherein no greater than 200 milligrams of the liquid phase are administered to the subject.
1314. The method of any one of claims 847-1313, wherein at least 1 micrograms of the cannabinoid are administered to the subject.
1315. The method of any one of claims 847-1314, wherein at least 2 micrograms of the cannabinoid are administered to the subject.
1316. The method of any one of claims 847-1315, wherein at least 4 micrograms of the cannabinoid are administered to the subject.
1317. The method of any one of claims 847-1316, wherein at least 8 micrograms of the cannabinoid are administered to the subject.
1318. The method of any one of claims 847-1317, wherein at least 16 micrograms of the cannabinoid are administered to the subject.
1319. The method of any one of claims 847-1318, wherein at least 32 micrograms of the cannabinoid are administered to the subject.
1320. The method of any one of claims 847-1319, wherein at least 64 micrograms of the cannabinoid are administered to the subject.
1321. The method of any one of claims 847-1320, wherein at least 128 micrograms of the cannabinoid are administered to the subject.
1322. The method of any one of claims 847-1321, wherein at least 256 micrograms of the cannabinoid are administered to the subject.
1323. The method of any one of claims 847-1322, wherein at least 0.48 milligrams of the cannabinoid are administered to the subject.
1324. The method of any one of claims 847-1323, wherein at least 0.6 milligrams of the cannabinoid are administered to the subject.
1325. The method of any one of claims 847-1324, wherein at least 0.7 milligrams of the cannabinoid are administered to the subject.
1326. The method of any one of claims 847-1325, wherein at least 0.8 milligrams of the cannabinoid are administered to the subject.
1327. The method of any one of claims 847-1326, wherein at least 0.9 milligrams of the cannabinoid are administered to the subject.
1328. The method of any one of claims 847-1327, wherein at least 1 milligrams of the cannabinoid are administered to the subject.
1329. The method of any one of claims 847-1328, wherein at least 2 milligrams of the cannabinoid are administered to the subject.
1330. The method of any one of claims 847-1329, wherein at least 3 milligrams of the cannabinoid are administered to the subject.
1331. The method of any one of claims 847-1330, wherein at least 4 milligrams of the cannabinoid are administered to the subject.
1332. The method of any one of claims 847-1331, wherein at least 5 milligrams of the cannabinoid are administered to the subject.
1333. The method of any one of claims 847-1332, wherein at least 6 milligrams of the cannabinoid are administered to the subject.
1334. The method of any one of claims 847-1333, wherein at least 7 milligrams of the cannabinoid are administered to the subject.
1335. The method of any one of claims 847-1334, wherein at least 8 milligrams of the cannabinoid are administered to the subject.
1336. The method of any one of claims 847-1335, wherein at least 9 milligrams of the cannabinoid are administered to the subject.
1337. The method of any one of claims 847-1336, wherein no greater than 100 milligrams of the cannabinoid are administered to the subject.
1338. The method of any one of claims 847-1337, wherein no greater than 80 milligrams of the cannabinoid are administered to the subject.
1339. The method of any one of claims 847-1338, wherein no greater than 60 milligrams of the cannabinoid are administered to the subject.
1340. The method of any one of claims 847-1339, wherein no greater than 40 milligrams of the cannabinoid are administered to the subject.
1341. The method of any one of claims 847-1340, wherein no greater than 20 milligrams of the cannabinoid are administered to the subject.
1342. The method of any one of claims 847-1341, wherein no greater than 11 milligrams of the cannabinoid are administered to the subject.
1343. The method of any one of claims 847-1335, wherein no greater than 9 milligrams of the cannabinoid are administered to the subject.
1344. The method of any one of claims 847-1334, wherein no greater than 8 milligrams of the cannabinoid are administered to the subject.
1345. The method of any one of claims 847-1333, wherein no greater than 7 milligrams of the cannabinoid are administered to the subject.
1346. The method of any one of claims 847-1332, wherein no greater than 6 milligrams of the cannabinoid are administered to the subject.
1347. The method of any one of claims 847-1331, wherein no greater than 5 milligrams of the cannabinoid are administered to the subject.
1348. The method of any one of claims 847-1330, wherein no greater than 4 milligrams of the cannabinoid are administered to the subject.
1349. The method of any one of claims 847-1329, wherein no greater than 3 milligrams of the cannabinoid are administered to the subject.
1350. The method of any one of claims 847-1328, wherein no greater than 2 milligrams of the cannabinoid are administered to the subject.
1351. The method of any one of claims 847-1328, wherein no greater than 1.2 milligrams of the cannabinoid are administered to the subject.
1352. The method of any one of claims 847-1351, wherein the subject is a mammal.
1353. The method of any one of claims 847-1352, wherein the subject is a rodent.
1354. The method of any one of claims 847-1352, wherein the subject is a lagomorph.
1355. The method of any one of claims 847-1352, wherein the subject is a feline.
1356. The method of any one of claims 847-1352, wherein the subject is a canine.
1357. The method of any one of claims 847-1352, wherein the subject is a porcine.
1358. The method of any one of claims 847-1352, wherein the subject is an ovine.
1359. The method of any one of claims 847-1352, wherein the subject is a caprine.
1360. The method of any one of claims 847-1352, wherein the subject is a vicugna.
1361. The method of any one of claims 847-1352, wherein the subject is a bovine.
1362. The method of any one of claims 847-1352, wherein the subject is an equine.
1363. The method of any one of claims 847-1352, wherein the subject is a primate.
1364. The method of any one of claims 847-1352, wherein the subject is a human.
1365. The method of any one of claims 847-1364, wherein the administering produces a Tmax, which is the time it takes to achieve a maximum blood concentration of the cannabinoid in the subject following the administering; and the Tmax is no greater than 30 minutes.
1366. The method of any one of claims 847-1365, wherein the administering produces a Tmax, which is the time it takes to achieve a maximum blood concentration of the cannabinoid in the subject following the administering; and the Tmax is no greater than 25 minutes.
1367. The method of any one of claims 847-1366, wherein the administering produces a Tmax, which is the time it takes to achieve a maximum blood concentration of the cannabinoid in the subject following the administering; and the Tmax is no greater than 20 minutes.
1368. The method of any one of claims 847-1367, wherein the administering produces a Tmax, which is the time it takes to achieve a maximum blood concentration of the cannabinoid in the subject following the administering; and the Tmax is no greater than 15 minutes.
1369. The method of any one of claims 847-1368, wherein the administering produces a Tmax, which is the time it takes to achieve a maximum blood concentration of the cannabinoid in the subject following the administering; and the Tmax is no greater than 10 minutes.
1370. The method of any one of claims 847-1369, wherein the administering produces a Tmax, which is the time it takes to achieve a maximum blood concentration of the cannabinoid in the subject following the administering; and the Tmax is no greater than 5 minutes.
1371. The method of any one of claims 847-1370, wherein an administered amount of the cannabinoid is administered to the subject during the administering; the subject has blood; a bioavailable amount of the cannabinoid enters the blood of the subject following the administering; the composition has an oral bioavailability, which is equal to the bioavailable amount divided by the administered amount; and the oral bioavailability is at least 5 percent.
1372. The method of any one of claims 847-1371, wherein an administered amount of the cannabinoid is administered to the subject during the administering; the subject has blood; a bioavailable amount of the cannabinoid enters the blood of the subject following the administering; the composition has an oral bioavailability, which is equal to the bioavailable amount divided by the administered amount; and the oral bioavailability is at least 10 percent.
1373. The method of any one of claims 847-1372, wherein an administered amount of the cannabinoid is administered to the subject during the administering; the subject has blood; a bioavailable amount of the cannabinoid enters the blood of the subject following the administering; the composition has an oral bioavailability, which is equal to the bioavailable amount divided by the administered amount; and the oral bioavailability is at least 15 percent.
1374. The method of any one of claims 847-1373, wherein an administered amount of the cannabinoid is administered to the subject during the administering; the subject has blood; a bioavailable amount of the cannabinoid enters the blood of the subject following the administering; the composition has an oral bioavailability, which is equal to the bioavailable amount divided by the administered amount; and the oral bioavailability is at least 20 percent.
1375. The method of any one of claims 847-1374, wherein an administered amount of the cannabinoid is administered to the subject during the administering; the subject has blood; a bioavailable amount of the cannabinoid enters the blood of the subject following the administering; the composition has an oral bioavailability, which is equal to the bioavailable amount divided by the administered amount; and the oral bioavailability is at least 25 percent.
1376. The method of any one of claims 847-1375, wherein an administered amount of the cannabinoid is administered to the subject during the administering; the subject has blood; a bioavailable amount of the cannabinoid enters the blood of the subject following the administering; the composition has an oral bioavailability, which is equal to the bioavailable amount divided by the administered amount; and the oral bioavailability is at least 30 percent.
1377. The method of any one of claims 847-1376, wherein an administered amount of the cannabinoid is administered to the subject during the administering; the subject has blood; a bioavailable amount of the cannabinoid enters the blood of the subject following the administering; the composition has an oral bioavailability, which is equal to the bioavailable amount divided by the administered amount; and the oral bioavailability is at least 35 percent.
1378. The method of any one of claims 847-1377, wherein an administered amount of the cannabinoid is administered to the subject during the administering; the subject has blood; a bioavailable amount of the cannabinoid enters the blood of the subject following the administering; the composition has an oral bioavailability, which is equal to the bioavailable amount divided by the administered amount; and the oral bioavailability is at least 40 percent.
1379. The method of any one of claims 847-1378, wherein an administered amount of the cannabinoid is administered to the subject during the administering; the subject has blood; a bioavailable amount of the cannabinoid enters the blood of the subject following the administering; the composition has an oral bioavailability, which is equal to the bioavailable amount divided by the administered amount; and the oral bioavailability is at least 45 percent.
1380. The method of any one of claims 847-1379, wherein an administered amount of the cannabinoid is administered to the subject during the administering; the subject has blood; a bioavailable amount of the cannabinoid enters the blood of the subject following the administering; the composition has an oral bioavailability, which is equal to the bioavailable amount divided by the administered amount; and the oral bioavailability is at least 50 percent.

CROSS-REFERENCE TO RELATED APPLICATIONS

This patent application claims priority to U.S. Provisional Patent Application No. 63/191,818, filed May 21, 2021; U.S. Provisional Patent Application No. 63/191,836, filed May 21, 2021; U.S. Provisional Patent Application No. 63/191,849, filed May 21, 2021; U.S. Provisional Patent Application No. 63/191,880, filed May 21, 2021; U.S. Provisional Patent Application No. 63/194,815, filed May 28, 2021; U.S. Provisional Patent Application No. 63/254,437, filed Oct. 11, 2021, each of which is incorporated by reference in its entirety.

Provisional Applications (6)

Number	Date	Country
63191818	May 2021	US
63191836	May 2021	US
63191849	May 2021	US
63191880	May 2021	US
63194815	May 2021	US
63254437	Oct 2021	US

COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF CANNABINOIDS

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

International Classifications

Abstract

Description

Claims

CROSS-REFERENCE TO RELATED APPLICATIONS

Provisional Applications (6)